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Respiratory diseases are a major cause of death in South Africa, with TB being one of the 
major respiratory illnesses. The respiratory tract is lined by a layer of mucus which protects 
the airways and lungs against injury by foreign agents. The main constituents of this layer of 
mucus are mucins. MUC5AC and MUC5B are the predominant respiratory tract mucins. 
However, little is known of the association between respiratory mucins and TB. This study 
aimed at describing the types and role of respiratory mucins in TB.  
 
Fifty six sputum samples, 17 tracheal aspirates and 95 bronchoalveolar lavages (BALs) were 
collected in 6M guanidinium hydrochloride and inhibitors. The airway mucus was divided 
into TB and non-TB groups. Mucins were reduced and alkylated with DTT and 
iodoacetamide and purified by density gradient ultracentrifugation in caesium chloride. 
Identification of MUC5AC, MUC5B, MUC2 and MUC7 were determined by western blotting 
and confirmed by immunohistochemistry.  
 
Western blot data proved the dominance of MUC5AC and MUC5B mucins in airway mucus. 
In comparison to the non-TB group, a higher secretion of MUC5AC than MUC5B in patients 
with TB was observed.  MUC5AC also showed distinct behavioural characteristics in its 
fractionation in a caesium gradient compared to MUC5B. The presence of MUC5AC and 
MUC5B in different fractions suggests varying glycosylation of the mucin. Varying 
populations of MUC5B were observed in sputa with 3 new glycoforms shown in TB. A small 
group of TB patients had MUC7 in the sputa (and not in the lavage) and there were varying 
amounts of MUC2 in some TB samples and non-TB mucus. At tissue level, MUC5B was found 
to be the main secreted gel-forming mucin. MUC5B and MUC7 were found to play a role in 
the protection again infection by Mycobacterium tuberculosis in tuberculous granulomas. 
Using proteomics it was demonstrated that respiratory mucus protein expression differs in, 
tracheal aspirates, BALs and sputa. Although inter-individual variations were observed in all 
samples, similar proteins were expressed in relation to the functioning of the lung. O-glycan 
analysis showed that the majority of the O-glycans detected were sialylated and that core 3 
and 4 O-glycan structures diminished in the presence of HIV. 
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Mucus is a slippery secretion that coats the epithelial surfaces of the eyes, middle ear, the 
respiratory, gastrointestinal and urogenital tracts (Linden et al., 2008). It is produced and 
secreted by mucous membranes, typically the mucous glands distributed in the body. 
Mucus serves as a lubricant as it keeps the epithelium hydrated and for the transportation 
and passage of food (Ali and Pearson, 2007). Additionally, it is a permeable gel layer for the 
exchange of gases and nutrients (Almutairi et al., 2016). The mucus is the body’s primary 
barrier against inhaled particles including pathogens and other infectious agents.  
 
In the respiratory tract, the body produces mucus in an attempt to expel the microbes and 
inhaled particles (Bansil and Turner, 2006) The respiratory tract is generally exposed to dust, 
toxic gases and microorganisms through air that has been inhaled.  Injury or damage to the 
respiratory tract as a result of these inhaled particles may result in respiratory infections 
and diseases. The attachment of microbes to the respiratory tract can present the initial 
step in the development of lung infection.  
 
Studying the composition of respiratory mucus in disease will ultimately lead to 
understanding the pathogenesis of diseases. Respiratory diseases are one of the major 
causes of morbidity and mortality in the world with South Africa experiencing a rapid 
increase in tuberculosis epidemic (Mayosi et al., 2009; Nie et al., 2013; van Zyl Smit et al., 
2010). In 2014, South Africa recorded a high incidence rate of TB with 834 cases per 100 000 
population recorded by the World Health Organisation (WHO) (WHO, 2015). In addition, the 
number of deaths attributable to TB among human immunodeficiency virus were 59 per 
100 000 population. The high mortalities related to TB have increased the urgency in the 




1.2 Lower respiratory tract mucus 
 
The lower respiratory tract epithelium extends from the trachea and terminates at the 
bronchioles. It is lined by basal, clara, ciliated, goblet, neuroendocrine (kulchitsky), brush 
and serous cells (Colby et al., 2007). The airway mucus is produced by the goblet cells and 
submucosal glands containing serous and mucous cells.  Furthermore, ciliated cells and 
goblet cells decrease in number as the terminal bronchioles are approached. 
 
The lower airway mucus is continuously secreted, utilized by the body and then discarded or 
recycled. Proposed by Lucas and Douglas in 1934, mucus is composed of two layers. The first 
layer which is approximately 7 m in depth is the periciliary fluid layer (also known as the 
sol phase) that is situated on top of the epithelial cilia (Kim, 1997; Rubin, 2010a; Rubin, 
2010b). The second layer overlies the sol phase and is called the mucus layer, also known as 
the gel phase (Kim et al., 1997; Lai et al., 2009). The mucus gel generally has a neutral pH 
with a thickness varying between 5 m and 50 m (Evans et al., 2009; Lai et al., 2009). The 
function of the periciliary fluid layer is to protect the underlying epithelium and keeps the 
mucus gel hydrated.  
 
The mucus has a short lifespan as it is replaced every 10 to 20 minutes (Lai et al., 2009). The 
lower respiratory mucus is a complex mixture mainly composed of water, approximately 
97% (Lu and Zheng, 2013). The remaining 3% of solids is composed of enzymes, lysozymes, 
defensins, cytokines, inorganic salts, proteins, immunoglobulins, glycoproteins (known as 
mucins), lipids and cellular debris (Bansil and Turner, 2006; Fahy and Dickey, 2010; Vareille 










1.3 Mucus as a barrier 
 
The main and most crucial function of the lower respiratory mucus is to be the first line of 
defense against inhaled particles. In addition to the ciliated cells and goblet cells, the 
respiratory mucus contains lactoferrins, lysozyme, collectins and defensins (Kato et al., 
2015; Vareille et al., 2011). Activation of these proteins upon infection, elicit an innate 
immune response.  
 
Although airway mucus is mainly composed of water, it has viscoelastic and adhesive 
properties. These properties are conferred by the cross-linked and entangled mucus 
glycoproteins (mucins) secreted by goblet cells and submucosal glands (Lai et al., 2009). 
Mucins play a pivotal role in the mucosal defense by trapping inhaled particles and binding 
bacteria through the adhesions on the bacterial membranes (Sonawane et al., 2012; 
Widdicombe, 1995). The trapped particles are cleared from the airways through constant 
coordinated ciliary beating and airflow, a mechanism known as mucociliary clearance, 
towards the larynx (Ali and Pearson, 2007; Curran and Cohn, 2010; Randell and Boucher, 
2006). Mucus clearance is essential for respiratory health as it allows for the expulsion of 
inhaled particles and pathogens from the airways. Healthy mucus has low viscosity and 
elasticity which is essential in mucociliary clearance, which is dependent on the thickness of 
mucus (Ali and Pearson, 2015; Fahy and Dickey, 2010). 
 
1.4 Mucins  
 
1.4.1 Mucin definition and nomenclature 
 
Mucins are the major components of mucus largely responsible for its biological properties 
(Andersch-Bjorkman et al., 2007; Bansil and Turner, 2006; Thornton et al., 1990). They are 
high molecular weight glycoproteins ranging between 2 to 50 MDa and they contain up to 
80% carbohydrate by weight (Bansil and Turner, 2006; Ridley et al., 2014; Thornton et al., 
2008). Mucins, also called MUCs, acquired their name from the gene that encodes their 
protein backbone (apomucin). They are named according to their order of discovery (Ali and 
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Pearson, 2007). According to the HUGO Gene Nomenclature Committee (HGNC) 21 genes 
encoding mucins have been identified through cDNA cloning. Mucin genes have long 
stretches of variable number of tandemly repeated nuclucleotides, a region known as 
variable number of tandem repeats (VNTR) (Rose and Voynow, 2006). Owing to the latter 
characteristic, mucins are highly polymorphic.  
 
Two classes of mucins have thus far been reported based on their chromosomal localization 
and amino acid sequence. The first class is located at the cell surface and is known as 
membrane bound or transmembrane mucins. The other class is secreted and is subdivided 
into gel forming and non-gel forming. The locations of the MUC genes are outlined in Table 
1.1. (HGNC, 2013; Rose and Voynow, 2006). 
 
Table 1.1: Location of the human mucin genes on the chromosome 




























1.4.2 Membrane bound mucins 
 
Membrane bound mucins are intercalated in the plasma membrane through a 
transmembrane domain (Hattrup and Gendler, 2008). This type of mucin is thought to be 
monomeric. They comprise of an extracellular domain mainly composed of glycosylated 
tandem repeat region, a single membrane-spanning domain and a short cytoplasmic tail 
(Hattrup and Gendler, 2008). Furthermore, the cytoplasmic domain is thought to play a role 
as a molecular sensor and is involved in signal transduction pathways (Backstrom et al., 
2013). To date this group consists of MUC1, MUC3A, MUC3B, MUC4, MUC11, MUC12, 
MUC13, MUC15, MUC16, MUC17 and MUC20. 
 
1.4.3 Secreted mucins 
 
This group of mucins is subdivided into two groups, namely, the secreted gel-forming and 
secreted non gel-forming. Eight mucin glycoproteins have been reported to be secreted. 
MUC2, MUC5AC, MUC5B, MUC6 and MUC19 are classified as secreted polymeric gel-
forming mucins rich in cysteine residues (Kreda et al., 2012; Rose and Voynow, 2006). Gel-
forming mucins are vital for the formation of the mucus gel and their main functions are to 
protect and lubricate the epithelium (Backstrom et al., 2013). The other three mucins, 
MUC7, MUC8 and MUC9, are secreted non-gel-forming mucins with no cysteine residues. 
Secreted mucins form major components of salivary, bronchial and cervical mucus 
(Backstrom et al., 2013). 
 
1.4.4 Mucin structure   
 
Mucins are heavily glycosylated molecules with a size between 2 and 50 MDa (Thornton et 
al., 2008). Mucins are also described as polydisperse and heterogeneous in nature. 
Considerable efforts have been devoted to the analysis of the structure of the mucin. 
However its properties such as size, polydispersity, extensive glycosylation, heterogeneity 
and high viscosity have limited these efforts (Harding, 1989; Thornton et al., 1997b). As a 
result there are disagreements in the reporting of conformations of the tertiary structure of 




The first model, the windmill model, was proposed by Allen, Pain and their colleagues 
(Harding, 1989). Their model described four high molecular weight protein subunits linked 
at the naked or non-glycosylated region to a 70 000 molecular weight protein in the centre 
by disulphide bridges, in a shape of a windmill (Harding, 1989; Pearson et al., 1981). On the 
other hand, Carlstedt and Sheehan proposed the second model which was linear, flexible, 
random coil model (Carlstedt et al., 1983; Carlstedt and Sheehan, 1984). Subsequent studies 
have described the gel-forming mucins to behave as random coils in dilute solution and to 
appear linear under the electron microscope (Thornton et al., 1997a). Recently, Ridley and 
coworkers have assessed the intracellular assembly and packaging of MUC5B in secretory 
granules and discovered that the N-terminal domains form dimers through disulfide-linkage 
between D3 domains (Ridley et al., 2014). Their findings thus support a linear model. 
However, these two models had a consensus regarding the molecular weight of the mucin 
which was between 2 and 50 MDa as a result of their polydispersity. Moreover, the random 
coil has been widely described as the structure of the gel-forming respiratory tract mucins 
(Almutairi et al., 2016). 
 
1.4.5 The structure of mucin monomers 
 
Through light scattering Carlstedt and Sheehan, and later using electron microscopy with 
Thornton and their colleagues, have demonstrated that mucins are polydisperse linear 
polymers that are fragmented into monomers upon reduction (Thornton et al., 1997a). The 
reduction process only disrupts the disulphide bonds and has led to the understanding of 
the mucin monomers. These monomers have a molecular weight of 2 – 3 MDa. 
 
The mucins are fragmented into elongated, rod-like molecules with a molecular weight of 2-
3 MDa. The amino (N-) and carboxy (C-) terminal regions of the apomucins are reported to 
be non-glycosylated and rich in cysteine residues. Furthermore, situated at the N-terminal 
regions are D1, D2, D’ and D3 structural domains and situated at the C-terminal regions are 
D4, B, C, CK structural domains which are similar to Von Willebrand Factor (vWF) domains 
(Figure 1.1) (Backstrom et al., 2013; Bansil and Turner, 2006; Ridley et al., 2014). These 
domains are essential for disulphide mediated polymerization. The glycosylated regions are 
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situated at the centre of the apomucins characterized by a high number of serine, threonine 
and proline residues commonly referred to as STP residues. The sequences that encode the 
STP residues are tandemly repetitive and encoded by a single central exon of the MUC gene 
(Rose and Voynow, 2006). However, these repeat units differ from one mucin to another in 
sequence and size. Figure 1.1 illustrates the differences in the organization of the structure 
of mucin monomers. The hydroxyl groups of the serine and threonine residues are linked to 
oligosaccharides through an O-glycosidic bond (Rose and Voynow, 2006; Thornton et al., 




Figure 1.1: A schematic diagram of a gel forming mucin monomer. 
The organization of the mucin monomer into the N- terminal region containing domains similar to von 
Willebrand Factor (vWF) denoted in blue; the central region containing cysteine residues denoted in yellow 
and tandem repeats of serine, threonine and proline residues denoted in green; and the C- terminal region 
containing domains similar to (vWF) denoted in blue. (Adapted from (Backstrom et al., 2013). 
 
1.4.6 Glycosylation of mucin subunits 
 
Mucins from different organs display different patterns of O-glycans. Carbohydrates make 
up 70-80 % of the mucin weight (Sellers et al., 1988). Glycosylation of the mucins is initiated 
in the Golgi apparatus by α-N-acetylgalactosaminyltransferases that facilitate the 
attachment of the N-acetylgalactosamine (GalNAc) to the hydroxyl of the serine and 
threonine residues to form the simplest O-glycan called the Tn antigen (Brockhausen et al., 
2009; Gerken, 2012; Hanisch et al., 2009). Complex core O-glycan structures are achieved by 
elongating the Tn antigen through the addition of galactose, N-acetylglucosamine (GlcNAc), 
fucose and sialic acid.  The structures of the O-glycan cores and antigenic epitopes found in 
mucins are shown in Table 1.2 (Brockhausen et al., 2009). The O-glycans terminate with 
fucose, sialic acid and sulfated GlcNAc or blood group determinants making mucins 





Table 1.2: Structures of O-glycan cores and antigenic epitopes found in mucins 
O-Glycan Structure 
Core  
Tn antigen GalNAcαSer/Thr 
Sialyl-Tn antigen Siaα2-6GalNAcαSer/Thr 
Core 1 or T antigen Galβ1-3GalNAcαSer/Thr 
Core 2 GlcNAcβ1-6(Galβ1-3)GalNAcαSer/Thr 
Core 3 GlcNAcβ1-3GalNAcαSer/Thr 
Core 4 GlcNAcβ1-6(GlcNAcβ1-3)GalNAcαSer/Thr 
Core 5 GalNAcα1-3GalNAcαSer/Thr 
Core 6 GlcNAcβ1-6GalNAcαSer/Thr 
Core 7 GalNAcα1-6GalNAcαSer/Thr 
Core 8 Galα1-3GalNAcαSer/Thr 
Epitope  
Blood groups O, H Fucα1-2Gal- 
Blood group A GalNAcα1-3(Fucα1-2)Gal- 
Blood group B Galα1-3(Fucα1-2)Gal- 
Linear B Galα1-3Gal- 
Blood group i Galβ1-4GlcNAcβ1-3Gal- 
Blood group I Galβ1-4GlcNAcβ1-6(Galβ1-4GlcNAcβ1-3)Gal- 
Blood group Sd(a), Cad GalNAcβ1-4(Siaα2-3)Gal- 
Blood group Lewisa Galβ1-3(Fucα1-4)GlcNAc- 
Blood group Lewisx Galβ1-4(Fucα1-3)GlcNAc- 
Blood group sialyl-Lewisx Siaα2-3Galβ1-4(Fucα1-3)GlcNAc- 
Blood group Lewisy Fucα1-2Galβ1-4(Fucα1-3)GlcNAc- 
 
1.5 Mucin production in the respiratory tract 
 
Studies that led to the characterisation of respiratory mucins have demonstrated that 
MUC1, MUC2, MUC4, MUC5AC, MUC5B, MUC7, MUC8, MUC11, MUC13, MUC15, MUC16, 
MUC18, MUC19, MUC20, MUC21 and MUC22 are expressed in the respiratory tract (Kato et 
al., 2015). Figure 1.2 illustrates some of the membrane bound mucins and the secreted 
mucins in the respiratory tract. Mucin content changes in the respiratory tract under 
different conditions. Using antibodies developed in their laboratories, a number of 
researchers have demonstrated that gel-forming mucins are the main mucins found in the 
airways in order to entrap foreign particles  (Hovenberg et al., 1996; Kirkham et al., 2002; 
Thornton et al., 1996; Wickstrom et al., 1998). They further showed that MUC5AC and 
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MUC5B are the major populations of polymeric mucins secreted in the respiratory airways. 
In addition MUC5AC was shown to be produced in goblet cells and MUC5B to be produced 
in mucous cells in the submucosal glands. However, some evidence suggests that MUC5B is 
also produced in the goblet cell (Rose et al., 2001). 
 
MUC2 has been shown to be expressed in small amounts in the surface epithelium of 
‘irritated’ and diseased airways. It was demonstrated that MUC2 was up-regulated by P. 
aeruginosa, inflammatory mediators and tobacco smoke components (Davies et al., 2002). 
The other secreted mucins are MUC7 and MUC8 which are shown to respectively be 





Figure 1.2: An illustration of some respiratory mucins. 
A: MUC1 and MUC4 membrane bound mucins. B: MUC7 lacking cysteine domains. C: MUC2, MUC5B, and 
MUC5AC mucins. The number of tandem repeats (TR) is indicated as ‘n’ below each MUC. Other domains that 
are shown are the proline, threonine, serine-rich (PTS) domains; an extracellular domain associated with O-




With the membrane-bound mucins identified in the respiratory tract, MUC1 has been 
shown to be produced in the microvilli and MUC4 has been associated with the cilia. MUC13 
on the other hand is expressed on the surface of the trachea. Interestingly, MUC16 has been 
shown to be expressed by the submucosal gland and as a membrane-bound mucin on the 
epithelium of the tracheal surface (Davies et al., 2007). 
 
In addition, glycosylation studies on respiratory mucins have demonstrated that O-glycan 
core 3 and core 4 structures are found in the bronchial epithelium (Hanisch et al., 2009). The 
carbohydrates of the mucin domain attract water creating a hydrophilic environment 
thereby hydrating and lubricating the epithelia.  
 
1.6 Respiratory mucus and mucins in disease 
 
The hypersecretion of mucus is the major cause of morbidity and mortality in respiratory 
tract diseases. Mucus hypersecretion is a prominent feature in asthma, chronic obstructive 
pulmonary disease (COPD) and cystic fibrosis where respiratory mucus and mucins have 
been extensively studied (Fahy and Dickey, 2010). Mucus hypersecretion is a characteristic 
of inflammation and epithelial diseases. Therefore mucociliary clearance plays an important 
role in disease development. Mucus hypersecretion is reported to be caused by the 
expansion of the goblet cells and the increased size of the submucosal glands (Bergeron and 
Boulet, 2006). Studies on the hypersecretion of mucus have shown that mucin content 
increases with increased mucus secretion. This hypersecretion leads to poor mucus 
clearance. Moreover, cough is employed to complement the mucociliary clearance (Rubin, 
2010b). However failure to clear mucus results in mucus retention and colonization by 
microbes (Hauber et al., 2006). 
 
The presence of microbes in the lungs triggers a respiratory defense involving the 
mucociliary clearance, antimicrobial proteins and alveolar macrophages (Mizgerd, 2008). 
Furthermore, the virulent microbes elicit an inflammatory response. However, this 
inflammation may injure the lungs and contribute towards respiratory infections and 
diseases leading to airway obstruction and ultimately leading to the loss of pulmonary 
function. This may be seen in respiratory diseases such as asthma, COPD and cystic fibrosis 
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where mucus accumulates in the airways as a result of poor mucus clearance leading to 
narrow airways, as illustrated in Figure 1.3. The presence of increased inflammatory cells in 
the lumen and airway wall is indicative of airway diseases which can lead to airway 
remodeling. However airway remodeling is mainly observed in asthma. 
 
In addition to mucus hypersecretion, mucins are associated with the regulation of 
inflammation and immune response. Alterations in the sequence of mucin glycosylation, 
and terminal sialylation and sulfation have been found to play a role in the development of 




Figure 1.3: An illustration of the airway mucus in healthy and disease states. 
In a healthy state the airways consist of low levels of mucus. However, disease states are characterised by 
accumulation of mucus in the airways. In asthma, increase number of subepithelial bronchial microvessels can 
be noticed. In both chronic obstructive pulmonary disease (COPD) and cystic fibrosis, increased and prominent 








1.6.1 Asthma  
 
Asthma is a common respiratory disease characterized by inflamed and narrow airways, 
airway hyper-responsiveness and airflow limitation. Affected people are sensitive to 
environmental allergens (Amin et al., 2014). It was estimated that 235 million people 
suffered from asthma in 2013 (WHO, 2013). The extrinsic asthma and intrinsic asthma are 
two forms of asthma that have been identified. Extrinsic asthma presents onset in 
childhood. This type of asthma is episodic and is occasionally caused by an external allergic 
trigger though infections have also been reported as a trigger. The intrinsic asthma presents 
onset in adult life and is commonly caused by an infection. This type of asthma is commonly 
referred to as non-allergic. 
 
Symptoms associated with the disease include coughing, chest tightness, shortness of 
breath, mucus hypersecretion and sputum production (Morcillo and Cortijo, 2006). 
Recurrent episodes of wheezing have also been reported. The narrowing and inflammation 
of the airways increases the susceptibility to allergic reactions as they make the airways 
sensitive to irritations. Airway mucus plugs are an important cause of airway obstruction in 
asthma. In addition, airway remodeling has been considered to be central in mucus 
dysfunction (Fahy and Dickey, 2010; Morcillo and Cortijo, 2006). 
 
The airway mucus in asthma is characterized by high concentrations of mucins, plasma 
proteins that have been leaked from the bronchial blood vessels (Figure 1.3) and 
inflammatory cells (Innes et al., 2009). The high concentration of mucins contributes to the 
elasticity and viscosity of the airway mucus. This thus hampers the clearance of mucus from 
the airways. Groneberg and his colleagues have shown that the expression of MUC5AC and 
MUC5B increased in asthma and that the respective mucins were expressed by different 
types of airway cell (Groneberg et al., 2002). Their results further indicated that changes in 
the level of mucus production in fatal asthmaticus and mild asthma were not as a result of 
metaplasia of the goblet cells and glandular mucous cells. They concluded that the 





Genetic studies on mucins in asthma have shown varying lengths of the MUC5B alleles 
during severe asthma (Vinall et al., 2000). Another study has shown that the short VNTR 
allele of MUC7 (MUC75) was found to be less frequent in asthmatic individuals as compared 
to the non-asthmatic individuals. It was thus deduced that MUC75 plays a role in the 
protection of the respiratory tract of asthmatic individuals (Kirkbride et al., 2001; Rousseau 




COPD is a chronic inflammatory disease characterized by chronic bronchitis, airway 
thickening (Figure 1.3) and emphysema. The World Health Organization estimates that 
COPD will be the third leading cause of death in the world by 2030. COPD is understood to 
be caused by smoking, post-tuberculous lung damage, occupational exposures and domestic 
air pollution (Ehrlich and Jithoo, 2006). It affects the small airways and the alveoli. The 
pathogenesis of COPD is attributed to perpetual inflammation and oxidative stress.  
 
The risk factors of COPD include tobacco smoke, occupational dusts, indoor and outdoor air 
pollution. Inhaled smoke has been reported to lead to the dysfunction of the cilia thus 
resulting in poor mucus clearance. Smoking has also been reported to cause hyperplasia. 
Smoking also leads to the development of emphysema as a result of the expansion of the 
alveoli. The inflammation causes airflow limitations in the bronchioles and reduction in the 
elasticity of the lung tissue thereby entrapping air in the lungs. Brashier and Kodgule (2012) 
have highlighted that TB is increasingly becoming recognized as a risk factor for COPD. 
 
Bacterial and viral infections cause exacerbation of COPD in airway disease (Lu and Zheng, 
2013). The presence of the latter leads to mucin up-regulation in COPD. MUC5AC and 
MUC5B have been shown to be up-regulated in COPD. Caramori et al. (2009) have found 
increased expression of MUC5AC in the submucosal glands of stable COPD patients. Work 
by (Kirkham et al., 2008)has shown MUC5B to be the prominent secreted mucin in COPD. 
MUC16 has been shown to be elevated in the blood of COPD patients (Yilmaz et al., 2011). 
In addition, the increased MUC16 levels have been associated with the right ventricular 
failure in COPD patients. 
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1.6.3 Cystic Fibrosis 
 
Cystic Fibrosis (CF) is a genetic disorder characterized by recurrent airway infections. CF is 
caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance 
regulator (CFTR). The mutation leads to CFTR dysfunction causing events that will ultimately 
result in the deterioration of the lungs. The CFTR failure causes isotonic absorption of 
sodium chloride leading to the dehydration of mucus (Fahy and Dickey, 2010; Perez-Vilar 
and Boucher, 2004). The latter causes mucus retention as a result of poor mucus clearance 
and initiates bacterial colonization. Subsequently, bacterial infections persist, biofilm is 
formed and mucus is overproduced resulting in inflammation and bronchiectasis (Perez-
Vilar and Boucher, 2004)Symptoms include wheezing, phlegm, shortness of breath, 
persistent cough, abdominal pain and greasy stools (Sloane et al., 2005). 
 
Studies on CF have demonstrated that MUC5AC and MUC5B mucin are decreased in the 
disease. However, increased levels of MUC5B were recorded in comparison with the 
MUC5AC mucin levels (Henke et al., 2004; Kirkham et al., 2002). Henke and colleagues 
subsequently showed that MUC5AC and MUC5B mucins increase during pulmonary 
exacerbation (Henke et al., 2007). In another study, small amounts of MUC2 were identified 
in CF (Davies et al., 1999). 
 
Microbes associated in recurrent airway infections mainly present as biofilms on the surface 
of the epithelium. These include P. aeruginosa, Staphylococcus aureus and aspergillus 
species (Fahy and Dickey, 2010). P. aeruginosa is the most common and potent cause of 
airway infection reported in CF. The microbe produces lipopolysaccharide (LPS) which 
initiates the defense response in the respiratory tract (Li et al., 2006). A study by Li et al. 
(2006) examined the expression and regulation of MUC7 gene in the lung and trachea of 
transgenic mice upon stimulation with LPS. MUC7 was shown to be highly expressed in the 
serous cells and within the respiratory epithelium. LPS has also been shown to up-regulate 





1.6.4 Tuberculosis (TB) 
 
TB is a major global health problem that accounted for 1.5 million deaths out of 9.6 million 
new cases in 2014 (WHO, 2015). TB is a disease caused by Mycobacterium tuberculosis 
(M.tb), a pathogenic rod-shaped bacillus that was discovered by Robert Koch in the 
19thcentury. The bacilli are trapped in mucus droplets and transmitted from one person to 
another by inhalation of aerosol from sneezing and coughing into the terminal bronchi and 
pulmonary alveoli (Kruh et al., 2010; Mehta et al., 2012). Pulmonary TB is characterised by a 
productive cough, expectoration of blood, chest pain, loss of appetite, weight loss, night 
sweats, fatigue, chills and fever (Middleton et al., 2004). However, M.tb not only invades 
the pulmonary alveoli, extrapulmonary TB has also been reported in highly vascular areas 
such as lymph nodes, meninges, kidney, spine and growing end of bones (Swaminathan and 
Narendran, 2005) 
 
Upon inhalation, M.tb is transported across the alveolar epithelium into the lung tissue and 
activates innate immune response. Cells of the innate immune response express pattern 
recognition receptors (PRRs), through which they engage the bacteria and secrete host 
defence factors such as cytokines and chemokines (Hazlett and Wu, 2011; Marakalala et al., 
2011). This response then activates phagocyte antimicrobial activities and result in the 
recruitment of additional mononuclear leukocytes into the site of infection forming a 
tuberculous granuloma (Guirado and Schlesinger, 2013). The structure of a tuberculous 
granuloma is illustrated in Figure 1.4. The main function of the granuloma is to contain and 
neutralise M.tb. However, the M.tb pathogen has developed strategies to persist within the 
tuberculous granuloma through the evasion of the host defence. This strategy is achieved by 
subverting the killing effects of macrophages through its ability to block the fusion of 
phagosomes with the lysosome (Bajaj and Batra, 2012; Sonawane et al., 2012). 
Furthermore, the glycan structures in the cell wall of M.tb are reported to play a crucial role 






Figure 1.4: A schematic of the structure of a tuberculous granuloma 
An illustration of the organisation of the granuloma found in tuberculosis which is composed of epitheliod 
cells, macrophages, foam cells, neutrophils, dendritic cells, natural killer (NK) cells,  B and T cells.  The M.tb 
pathogen in shown localised within the tuberculous granuloma. (Adapted from Ramakrishnan, 2012). 
 
Considerable efforts have been taken to control TB. However, in 1993, the high incidence 
rate led WHO to declare TB a ‘global emergency’ (Jordan et al., 2010). Subsequently, in 
2005, the WHO committee for Africa declared TB to be an African regional emergency (Lawn 
et al., 2006). In 2014, South-East Asia and Western Pacific Regions recorded the highest 
number of new TB cases which accounted for 58% of the new cases globally.  Africa had the 
greatest proportion burden with 281 cases per 100 000 people recorded by WHO (WHO, 
2015). In 2014, South Africa had a high incidence of TB with 834 cases per 100 000 people 
(WHO, 2015). The high incidence rate has been attributed to co-infection with human 
immunodeficiency virus (HIV), and the emergence of the drug-resistant strains of TB such as 
the multidrug resistant (MDR-TB) and extensively drug resistant (XDR-TB) have contributed 
to the progression of the TB epidemic (Karim et al., 2009; Streicher et al., 2012).  
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Co-infection with HIV causes susceptibility to opportunistic infections with TB being the 
prominent infection. The presence of HIV has been shown to promote TB by decreasing 
macrophages, activating lymphocytes, increasing tissue destruction and decreasing CD4 
cells (Swaminathan and Narendran, 2005). TB has been shown to enhance HIV replication by 
secreting TNF alpha and through the destruction of CD4 cells (Swaminathan and Narendran, 
2005). 
 
Prolonged periods are required in the treatment of TB as the bacilli differ in metabolic 
activity (Bajaj and Batra, 2012). The recommended TB treatment is isoniazid, rifampicin, 
pyrazinamide and ethambutol for the first 2 months and the continuation of isoniazid and 
rifampicin from months 4 – 6 (WHO, 2009). The bacterium has developed resistance to 
some of the drugs in an attempt to evade the host defence. The resistance to TB drugs is 
caused by genetic mutations (that either occur in the target or the activator of the drug) 
which result in a heritable loss of susceptibility to antibiotics (Sacchettini et al., 2008).  MDR-
TB is the strain of M.tb that is resistant to at least two drugs, isoniazid (INH) and rifampicin. 
XDR-TB refers to the strain of bacteria that is resistant to isoniazid, rifampicin and 
fluoroquinolones (Sacchettini et al., 2008). 
 
1.7 Interaction of TB and the respiratory mucosa 
 
In 2002, Middleton and co-workers initiated a study into the interaction of mycobacteria 
species with the human respiratory mucosa using an organ culture with air interface model 
(Middleton et al., 2002). Their study showed two distinct morphologies of mucus, fibrous 
and globular mucus. In addition, their study showed that mycobacteria species adhered 
specifically to the fibrous mucus matrix and to epithelial cells called M-cells that transport 
particles across the mucosa. The study further showed that M.tb adhered mainly to 
fibronectin in the extracellular matrix in mucosal damage but not to ciliated cells. In their 
subsequent study, still using an organ culture with air interface model, the team illustrated 
the invasion of the human bronchial tissue by M.tb and the increased numbers of 
Mycobacterium avium on the mucosal surfaces (Middleton et al., 2003). 
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These studies led the investigators to hypothesize that the difference between fibrous and 
globular mucus could be attributed to their mucin content. They therefore investigated the 
role of mucins in mycobacterial interactions with the respiratory mucosa (Middleton et al., 
2004). The addition of purified mucins to the organ culture air interface model showed 
increased fibrous mucus. However, this study could not determine whether the presence of 
mycobacteria of the respiratory mucosa stimulated mucus production or not. 
 
1.8 Previous studies in our laboratory 
 
A pilot study by Govender (2006) initiated the investigation into the association between 
respiratory mucins and TB at a biochemical and molecular level. The study involved the 
collection of sputum from healthy individuals, post mortem cadavers and suspected TB 
positive adults and children.  MUC5B was identified in both the healthy controls and TB 
positive adults and children.  In contrast MUC5AC was barely evident in the controls but 
presented in both the TB positive adults and children.  MUC2 barely featured in the control 
group but was identified in the TB positive adults and children.  
 
In addition, genetic investigations were undertaken for the presence of known 
polymorphisms in the mucin genes, MUC2 and MUC5B, in a small number of samples, and 
using a European study as a comparison. Both a MUC2/PvuII polymorphism in exon 11 of 
the MUC2 gene and a VNTR of intron 36 of MUC5B were identified in the study sample. 
Generally the C allele of MUC2/PvuII occurred less frequently than the G allele. 
Categorisation of the sample on the basis of TB status showed a higher C allele frequency in 
TB positive cases and revealed that allele C homozygotes were found only amongst TB 






The MUC5B alleles represented variable numbers of the 59 bp repeat sequence within 
intron 36.  This differed from the European study as a greater number of alleles were 
identified in the Western Cape population. In comparison to the European study of Desseyn 
et al. (1999), it appeared that the frequency of the 8 repeat allele was higher in the Western 
Cape population whereas the 7 repeat allele dominated in the European population. 
Furthermore the 10 and 3 repeat alleles found in this study did not present in the European 
study, and the 4 repeat alleles of the European study was absent in this study group.  The 10 
repeat allele was of interest as it was seen only in a TB negative individual and not in the TB 
positive group.  The 8/8 allele combination common to the study group presented 
predominantly in the TB positive individuals. 
 
1.9 Rationale of the study 
 
The increase in the TB incidence rate has reawakened efforts in identifying biomarkers that 
could serve as targets for drug and vaccine design (Gupta et al., 2012). Furthermore, 
Sonawane et al. (2012) have highlighted that the glycans on the M.tb cell wall could be 
essential in the development of drug targets. In addition, it has been established that the 
respiratory mucus provides the first line of defence by acting as a barrier through adhering 
pathogens through to mucins. However, there is limited information regarding the 
interaction of M.tb with respiratory mucins.  Therefore a need arose in understanding of the 
properties of respiratory mucus in TB. This study thus expanded on the pilot study by 
Govender (2006) to be able to verify its findings and to throw further light on the role of 








1.10 Aims and objectives 
 
Aims: 
Our aim was to isolate and characterise mucins from respiratory mucus in order to elucidate 
the role of the dominant secreted mucins in patients with TB. 
 
Objectives: 
The specific objectives and proposed experiments of the study were to: 
 Determine the respiratory mucins secreted in non-TB and TB mucus and to verify 
their identity using Western blotting. 
 Determine the composition of the respiratory apomucin in non-TB and TB by HPLC 
analysis of amino acid. 
 Release oligosaccharides and determine the alterations in glycosylation. 
 To determine the expression of mucins in lung tissue infected with TB through 
analysis by immunohistochemistry. 
 To generate 2D proteome profile maps of respiratory mucus from non-TB and TB 
mucus. 




CHAPTER 2 : MATERIALS AND METHODS 
 
2.1 Materials and suppliers 
 
The materials used in this study and their sources are tabulated below: 
 
Table 2.1: Chemicals and reagents used for the study 
Materials (Chemical, reagents) Suppliers (company details in 
Appendix)  
Acetone Merck 
Acrylamide (40 % 37.5:1 
acylamide:bisacrylamide) 
BioRad 
AG50WX8 cation-exchange resin  BioRad 
Agarose Sigma 
Agarose (low electrosomotic flow grade) Sigma 
Ampholytes pH 3-10 BioRad 
Ammonium persulfate (APS) Sigma 
AquaStain Vacutec 
Β-Mercaptoethanol BDH 
Bradford Quickstart dye reagent BioRad 
Bromophenol blue sodium salt Merck 
Bovine Serum Albumin (BSA) Sigma 
Caesium Chloride (CsCl) Sigma 
CHAPS Sigma 
Coomassie Brilliant Blue R-250  Sigma 
Dialysis tubing Sigma-Aldrich 
Direct Blue Sigma 
Dithiolthreitol (DTT) Fermentas 
EDTA Merck 
Fat free milk powder Spar brand 





Guanidine Hydrochloride (GuHCl) Sigma 
HRPO-linked goat anti-rabbit Dako 
HRPO-linked rabbit anti-mouse Dako 
Iodoacetamide Sigma-Aldrich 
IPG Strips BioRad 
N-Ethylmaleimide (NEM) Sigma-Aldrich 
Nitrocellulose membrane PALL Corp (Whitehead Scientific) 
PageRulerTM  Prestained Protein Ladder Fermentas (Whitehead Scientific) 
Period acid solution Merck 
PlusOne Drystrip cover fluid GE Healthcare 
PMSF Sigma-Aldrich 
Poly-L-lysine Sigma-Aldrich 
Precast 4-20% gradient gels Vacutec 
Propan-2-ol Merck 
Sodium dodecyl sulfate (SDS) BioRad 



















Table 2.2: Antibodies used in the study for Western Blot analysis 
Antibody Suppliers Mono/Polyclonal Location 
MUC7 Abcam (AB55542) Monoclonal Recombinant fragment: 36-
136 human MUC7  
MUC16 [X325] Abcam (AB10033) Monoclonal  
LUM2-3 (MUC2) EU consortium Polyclonal C-terminus 
MAN5ACI  EU consortium  Polyclonal  
MAN5BI EU consortium Polyclonal N-terminus 
EU-MUC5Bb2-2 EU consortium Monoclonal Cysteine in tandem repeat 
EU-MUC7a EU consortium Monoclonal N-terminus 
HRP-linked goat anti-
rabbit 
Dako(P0488)   
HRP-linked rabbit 
anti-mouse 
Dako(P0260)   
Antibodies from the EU consortium donated by Prof. Dallas Swallow from University College 
London, UK. 
 
2.2 Research ethics and permissions 
 
This study was conducted at the Surgical Research Laboratory, Department of Surgery, 
Groote Schuur Hospital between May 2010 and August 2013. Work done for this project 
was approved by the Ethics Committee of Research at the Health Sciences Faculty of the 
University of Cape Town (UCT). Ethics reference number REC: REF 142/2009. 
 
Further permission was obtained from the Western Cape (Western Cape DoH reference: 
2011 RP 42) and Free State provincial Department of Health (DoH) for the collection of 
sputa at the facilities in the respective provinces. No reference number was supplied by the 






2.3 Sample collection 
 
2.3.1 Healthy or uninfected sample collection (n=17) 
 
Tracheal aspirates were collected from patients with no history of respiratory diseases who 
underwent surgery at Groote Schuur Hospital (Cape Town, Western Cape). Tracheal 
aspirates were collected after induction of anaesthesia and intubation. These samples were 
called uninfected controls. Tracheal aspirates were collected into 6 M GuHCl pH 6.5, 
containing a cocktail of protease inhibitors (10 mM EDTA, 5 mM NEM and 1 mM PMSF). 
Samples were collected and transported on ice and then stored at -20 ˚C until further 
analysis. 
 
2.3.2 Bronchioalveolar lavage (BAL) collection (n=95) 
 
BAL samples were collected from patients who underwent bronchoscopy as part of a 
specific treatment protocol at Groote Schuur Hospital (Cape Town, Western Cape). BAL 
samples were collected in PBS at pH 7.4 and were transported on ice. A protease inhibitor, 1 
mM PMSF, was added to each sample and kept at -80 ˚C in order to be freeze dried. Freeze 
dried BALs were stored at -20 ˚C until further use. 
 
2.3.3 Sputum collection (n=56) 
 
Sputa from TB positive patients were collected from Gugulethu Clinic and DP Marais 
Hospital in the Western Cape and Leseding, Thusanong and Seeisoville Clinics in the Free 
State. Prior to sample collection, patients were encouraged to rinse their mouths with 
water. Sputa were collected into 6M guanidinium hydrochloride (GuHCl) pH 6.5, containing 
a cocktail of protease inhibitors (10 mM EDTA, 5mM NEM and 1 mM PMSF). Samples were 






2.4 Sample preparation 
 
Samples were prepared individually and no samples were pooled. 
 
2.4.1 Mucus sample preparation 
 
Mucus was homogenized with a Junkel and Kunkel Ultra-Turrax at high burst for 30 seconds 
at room temperature to solubilize the sputa in GuHCl. Insoluble debris was separated from 
mucus by centrifugation in a Hitachi HIMAC centrifuge at 3 000 rpm for 30 minutes at 4 ˚C. 
The supernatants were collected into clean tubes. 
 
2.4.2 Preparation of crude mucus  
 
Following mucus sample preparation, the mucus was reduced in 6 M GuHCl and 10 mM DTT 
for 5 hours at 37 ˚C to break the disulphide bonds in the mucus. The thiol groups (-SH) 
resulting from reduction were alkylated with 25 mM iodoacetamide overnight in the dark at 
room temperature. Iodoacetamide binds the sulfhydryl/thiol groups of the cysteine residues 
so that the disulphide bonds cannot be reformed. Samples were then placed in the dialysis 
tubing and dialysed against three changes of distilled water at 4 ˚C with constant stirring. 
Dialysed samples were then freeze dried according to 2.4.6. 
 
2.4.3 Purification of mucins with caesium chloride 
 
Mucins were purified using caesium chloride (CsCl) density gradient ultra-centrifugation 
(Creeth and Denborough, 1970). The density of the mucus was adjusted to 1.39 to 1.40g/ml 
by the addition of CsCl at a final concentration of 3.5M CsCl. Density gradient 
ultracentrifugation was performed using a Beckman ultra-centrifuge at 40 000 rpm for 48 
hours at 4 ˚C. Mucin-rich fractions were identified using a PAS assay to determine the 
glycoprotein and the Bradford assay to determine the concentration of proteins. The 
absorbance of the PAS assay was read at 540 nm and the Bradford assay was read at 595 
nm. The glycoprotein-rich fractions were pooled and subjected to a second CsCl spin at 
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40 000 rpm for 48 hours at 4 ˚C. PAS assay and Bradford assay were performed following 
the second spin. Dialysis tubing was prepared by boiling distilled water with a tinge of EDTA 
and sodium carbonate. The mucin-rich fractions from each patient was pooled and dialysed 
against three changes of 6M GuHCl at 4 ˚C.             
 
2.4.4 Reduction and alkylation of samples 
 
Purified fractions were reduced in 6M GuHCl and 10 mM DTT for 5 hours at 37 ˚C to break 
the disulphide bonds in the mucus. The thiol groups resulting from reduction were alkylated 
with 25 mM iodoacetamide overnight in the dark at room temperature. Iodoacetamide 
binds the sulfhydryl/thiol groups of the cysteine residues so that the disulphide bonds 
cannot be reformed. 
 
2.4.5 Dialysis of samples 
 
It was essential to remove GuHCl from the samples prior to analysis. Samples were placed in 
the dialysis tubing and dialysed against three changes of distilled water at 4 ˚C with constant 
stirring. Dialysed samples were then freeze dried. 
 
2.4.6 Freeze drying 
 
Following dialysis the samples were placed in plastic containers with holes in the lids. 
Samples were frozen in liquid nitrogen and placed in flasks of the freeze dryer (Christ 
ALPHA1-5, Lasec Laboratory). Samples were freeze dried at -80 ˚C until the samples were 
completely lyophilised and stored at -20 ˚C for analysis. 
 
2.5 Amino acid analysis 
 
The amino acid content of respiratory mucins was determined by amino acid analysis. This 
involves four basic steps namely: the hydrolysis of the protein to its individual amino acid 
content, labelling of amino acid with a detectable marker, high pressure liquid 
chromatography (HPLC) separation of mucins and data interpretation. The amino acid 
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content of purified breast milk mucins was analysed using an HPLC system according to the 
methods of Klapper (1982). The samples were vacuum-dried and placed in a hydrolysis 
vessel containing some constantly boiling hydrochloric acid (HCl) and 1% (v/v) phenol. The 
vessel was purged with nitrogen gas and sealed under vacuum. The samples were then 
hydrolyzed in the gas phase at 110 °C for 24 hours. Following hydrolysis, the vessel tip was 
cooled and vacuum dried to remove the residual HCl. The dried samples were re-dissolved 
in citrate buffer pH 2.2 and injected into a high-pressure liquid chromatography column 
packed with a cation exchange resin (sulfonated polystyrene cross-linked with 
divinylbenzene) and eluted with a series of buffers ranging from a low (0.25M trisodium 
citrate, pH 3.05) to high (0.25M sodium nitrate, pH 9.5) pH. Detection was carried out using 
post-column derivatization with o-phthalaldehyde, a fluorescent reagent that reacts with all 
the amino acids except proline. For proline detection, the samples were treated with 
sodium hypochlorite ahead of post column derivatization with OPA. The relative ratios of 
the individual amino acids for each sample were determined and compared. 
 
2.6 Agarose gel electrophoresis  
 
Agarose gel electrophoresis was used to effectively separate proteins larger than 200 kDa. 
To prepare samples for the electrophoresis, 1 mg of the lyophilized sample was weighed out 
and dissolved in 100 µl of sample buffer (2% sodium dodecyl sulfate (SDS), 10% glycerol, 
0.01% bromophenol blue, 5% β-mercaptoethanol). The mixture was boiled in the heating 
block, Dri Block (Stuart Scientifica) at 95 °C for 5 minutes. The samples were cooled at room 
temperature then pulse spun in the microcentrifuge. The samples, 25 µl, were loaded onto 
0.7% (w/v) agarose gels. The proteins were separated by electrophoresis at 65 V and 400 
mA for 2.5 hours in 40mM Tris/acetate and 1mM EDTA at pH 8.0 (1 X TAE) containing 0.1% 
(w/v) SDS.  
 
2.7 Western Blot analysis 
 
Following agarose gel electrophoresis, the gels were soaked in 0.6M sodium chloride/ 60 
mM sodium citrate (4 X SSC) for 3 minutes. Nitrocellulose membrane with a 0.2 µm pore 
size were soaked in running buffer for approximately 5 minutes and subsequently rinsed in  
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4 X SSC. The membrane was placed onto the vacuum blot apparatus (Pharmacia LKB 
Vacugene XL) and 4 X SSC containing 10 % Poly-L-Lysine was vacuum blotted onto the 
membrane. The gels were carefully placed on the membranes, ensuring no air bubbles were 
present between the gels and the membranes. The gels were vacuum blotted for 1 hour at a 
constant pressure of 40 mbars at room temperature. The gels were kept wet with 4 X SSC 
throughout the transfer of proteins. Once the transfer of proteins was complete, the 
membranes were rinsed in water and then incubated in 5% (w/v) low fat milk powder in TBS 
and 0.05% Tween-20 (TBST) for 30 minutes at room temperature on the shaker in order to 
block non-specific binding to antibody. The blocking buffer was discarded and the 
membranes were incubated in primary antibody at 4 ˚C overnight. 
 
Following probing with the primary antibody, the membranes were washed with 1 X TBST 
for 3 x 5 minutes. The membranes were incubated with secondary antibody for 1 hour at 
room temperature on the shaker. The membranes were then washed with 1 X TBST for 3 x 
10 minutes and rinsed with distilled water.  
 
Table 2.3: Concentrations of primary and secondary antibodies used for Western blotting 
Primary antibody Recognition site Secondary antibody 
LUM2-3(MUC2)  (1:2000) C-terminus HRP-linked goat anti-rabbit (1:2000)  
MAN5ACI (1:5000)  HRP-linked goat anti-rabbit (1:2000) 
MAN5BI (1:2000) N-terminus HRP-linked goat anti-rabbit (1:2000) 
EU-MUC7a (1:1000) N-terminus HRP-linked rabbit anti-mouse 
(1:1500) 
 
2.7.1 Mucin detection 
 
Enhanced chemiluminuscence (ECL) solution was prepared according to the manufacturer’s 
instructions. The ECL solution was poured over the membranes and exposed for 30 seconds. 
The ECL solution was removed with filter paper. The membrane was placed in the 





2.7.2 Membrane stripping 
 
After detection the membranes were incubated with stripping buffer (62.5 mM Tris, 0.5 M 
NaCl, 100 mM Mercaptoethanol and 2% SDS) for 1 hour at 37 ˚C. The membranes were 
washed with 1 X TBST for 3 x 15 minutes. Once the membranes were stripped, the 
membranes were incubated in blocking buffer for 30 minutes on the shaker and 




Formalin fixed paraffin wax embedded lung tissue blocks were from post mortem patients. 
Serial sections (2 µm) were cut from the tissue blocks of each patient and heat fixed at 60 ˚C 
for 1 hour. The sections were dewaxed in xylol for 15 minutes with 3 changes, rehydrated 
through graded alcohols (absolute and 96% two changes) at 2 minutes intervals and rinsed 
with water. The sections were then divided for Histochemical staining: haematoxylin and 
eosin (H & E) staining for diagnosis, high iron diamante (HID) to identify sulfomucins and 
sialomucins, periodic acid Schiff/alcian blue (PAS/AB) staining to identify neutral mucins and 
sialomucins, and Immunohistochemistry: MUC2,MUC5AC,MUC5B,MUC7,MUC16 and MUC7 
to identify the mucins expressed in the lungs. 
 
2.8.1 H & E Staining 
 
The tissue sections were dewaxed and rehydrated through the alcohols to water and 
stained with haematoxylin for 9 minutes. The tissue was rinsed for 3 minutes under running 
tap water, blued in Scott’s Tap Water Substitute (a blueing reagent designed for minimising 
loss of tissue sections) for 3 minutes and rinsed again with water for 3 minutes. The tissue 
was stained with 1% eosin for 3 minutes followed by a quick rinse under running tap water. 






2.8.2 HID Staining 
 
Following dewaxing and rehydration through the alcohols to distilled water, the tissue was 
treated with HID solution for 18 hours. The sections were rinsed in distilled water and 
stained with 1% Alcian blue. Once stained, the sections were rinsed under running water for 
5 minutes, dehydrated through the alcohols to xylol cover slipped and mounted using 
entellan. 
 
2.8.3 PAS/AB Staining 
 
The sections were dewaxed and rehydrated through the alcohols to tap water, then treated 
with Alcian blue solution for 5 minutes. The sections were rinsed in 3 changes of distilled 
water and treated with periodic acid solution for 2 minutes. The sections were rinsed again 
with 3 changes in distilled water followed by staining with Schiff reagent for 8 minutes and 
then rinsed in running tap water for 10 minutes. The nuclei were stained with Mayers 
haematoxylin for 35 seconds then rinsed under tap water, blued in Scott’s  Tap Water 
Substitute for 2 minutes, rinsed again under running water for 5 minutes, dehydrated 
through the alcohols to xylol, cover slipped and mounted using entellan. 
 
2.8.4 Mucins detection  
 
The sections were dewaxed in xylol, rehydrated through graded alcohols to tap water. 
Endogenous peroxidase was blocked with 1% hydrogen peroxide in distilled water for 15 
minutes followed by rinsing under tap water. Antigens were retrieved with 0.01M citrate 
buffer for 2 minutes in a pressure cooker on full pressure. The sections were cooled under 
running water for 15 minutes and then rinsed with 1 X PBST. Non-specific binding sites were 
blocked with normal goat serum (1:20 in 1 X PBS) for 10 minutes. The normal goat serum 
was drained off the slides (not rinsed) and then probed with primary antibodies according to 
Table 2 below. The sections were rinsed twice with 1 X PBST at 5 minutes intervals followed 
by incubation with the secondary antibody (Envision Monoclonal goat anti Mouse). The 
secondary antibody was rinsed off with 1 X PBST and the colour developed with 
diaminobenzidine (DAB) substrate chromogen system for 8 minutes. The DAB was rinsed off 
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with 1 X PBS and then water. The colour was enhanced by incubating the tissue in 1% 
Copper Sulfate for 10 minutes. The tissue was counterstained with haematoxylin for 2 
minutes followed by a quick rinse under running tap water, blued in Scott’s water for 2 
minutes and rinsed in running tap water for 10 minutes. The tissue was dehydrated through 




Table 2.4: Concentrations of primary antibodies for immunohistochemistry for detecting 
mucin expression in lung tissue 
Antibody Supplier Dilution Incubation time 
MUC2 Leica (NL-MUC2) 1:100 in 1 X PBS 1 hour 
MUC5AC Leica (NL-MUC5AC) 1:100 in 1 X PBS 30 minutes 
MUC5Bb2-2 EU Consortium 1:100 in 1 X PBS 1 hour 
MUC7 Abcam (AB55542) 1:100 in 1 X PBS 1 hour 
MUC16 [X325]  Abcam (AB10033) 1:100 in 1 X PBS 30 minutes 
* Antibodies from the EU consortium donated by Prof. Dallas Swallow from University 
College London, UK. 
 
2.9 Proteomic analysis 
 
2.9.1 Sample preparation 
 
5mg of each sample was weighed out and dissolved in 2 ml of 1 X PBS. Precipitation of 
respiratory mucus proteins with acetone was carried out as described by Khan and Packer 
(Khan and Packer, 2006). 
 
To prepare the samples for acetone precipitation, a 1:5 mucus-to-acetone ratio was used to 
precipitate respiratory mucus proteins according to Khan and Packer, 2006. The mucus 
proteins were precipitated overnight at -20 ˚C.  Following overnight precipitation, the 
samples were centrifuged at 13 200 rpm for 15 minutes at 4 ˚C. The supernatants were 
stored at -20 ˚C for later use and the pellets were resuspended in 1 ml of solubilisation 
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buffer. Protein concentrations were determined using the BioRad assay according to the 
manufacturer’s instructions. Protein quantification was done in triplicate using bovine 
serum albumin (BSA) as a standard. 
 
 
2.9.2 One dimensional (1D) SDS Polyacrylamide Gel Electrophoresis (PAGE) 
analysis 
 
Equal volumes of the samples prepared in section 2.9.1 and the sample buffer were mixed 
and boiled in the heating block at 95 °C for 5 minutes. The samples were cooled at room 
temperature then pulse spun in the microcentrifuge. The samples were loaded on 12% and 
4-20% gradient gels respectively. The proteins were separated by electrophoresis at 100 V 
for 2 hours. The gels were stained with a protein stain, AquaStain (Vacutec) for 10 minutes. 
 
2.9.3 Two dimension (2D) SDS PAGE analysis 
 
2.9.3.1  Sample solubilisation 
 
A 100 g of each sample was added to 1.25 l of ampholytes, 2 l of 50% DTT and 8 M urea 
solubilisation buffer to the final volume of 125 l. 
 
2.9.3.2 In-gel rehydration 
 
The samples were loaded in the grooves of the rehydration tray (GE Healthcare). The gel 
sides of the 7 cm long IPG strips pH 4-7 (BioRad) were immersed in the prepared samples in 
the rehydration tray and the IPG strips were covered with mineral oil (GE Healthcare). The 
respective IPG strips were re-hydrated overnight at room temperature.  
 
2.9.3.3 Isoelectric focusing (IEF) 
 
Following the overnight rehydration of IPG strips, the strips were loaded on the Ettan 
IPGphorII
 
IEF machine (GE Healthcare), aligned and overlaid with mineral oil. The IEF 
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machine was programmed for a three-step long run. For the first step, 250 V were applied 
for 10 minutes. For the second step, 4 000 V were applied for an hour. For the final step, 4 
000 V were applied until 12 000 V-hours were reached. The IEF was carried out at 20 ˚C. 
 
2.9.3.4 Equilibration of the IPG strips  
 
Equilibration buffers 1 and 2 were prepared fresh by adding 2% (w/v) DTT (buffer 1) and 
2.5% (w/v) iodoacetamide (buffer 2) to equilibration base buffer (6M Urea, 2% SDS, 0.05 M 
Tris-HCl and 20% glycerol at pH 8.8) respectively. Buffer 1 containing DTT reduces disulphide 
bonds and maintains monothiols in the reduced state. Buffer 2 contains iodoacetamide 
which covalently binds cysteines so that the protein cannot form disulphide bonds.  
 
Following the IEF, the strips were rinsed with water and placed in each channel of the 
rehydration/equilibration tray. Each channel was filled with 2.5ml of equilibration buffer 1 
and incubated with gentle agitation for 15 minutes. After 15 minutes, the equilibration 
buffer 1 was decanted and each channel was refilled with 2.5 ml of equilibration buffer 2. 
The strips were then incubated with gentle agitation for 15 minutes. The strips were rinsed 
with 1 X SDS buffer in preparation for the second dimension. 
 
2.9.3.5 Second dimension of 2D PAGEs 
 
Following equilibration, the strips were placed on top of 12% SDS PAGE gels. The gels were 
assembled using the Mini-Protean III Cell (BioRad).   To secure the strips, 1% low melting 
agarose gel was overlaid on top of the strips. The gels were run at 100 V for 1.5 hours.  
 
2.9.3.6 SDS PAGE Staining 
 
Following electrophoresis, the gels were stained using the three-step Coomassie staining. 
The gels were first placed in the Coomassie I stain solution (10% glacial acetic acid, 0.025% 
(w/v) Coomassie Brilliant blue R-250 and 25% propan-2-ol dissolved in distilled water) then 
heated in a microwave for 1 minute and incubated overnight at room temperature with 
agitation. The stain was decanted, replaced with Coomassie II stain solution (10% glacial 
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acetic acid and 0.003125% (w/v) Coomassie Brilliant blue R-250 dissolved in distilled water) 
and heated in a microwave for 1 minute. The gels were incubated with the stain for 30 
minutes with agitation. Following staining with Coomassie II staining solution, the stain was 
decanted, replaced with Coomassie III staining solution (10% glacial acetic acid and 
0.003125% (w/v) Coomassie Brilliant blue R-250 dissolved in distilled water) then heated in 
a microwave for about 1 minute. The gels were incubated with the stain for 30 minutes with 
agitation. The stain was decanted and the gels were destained with the destaining solution 
(10% glacial acetic acid and 1% glycerol dissolved in distilled water) until the desired protein 
bands or spots were achieved. The images were taken with the Molecular Imager PharoxFS 
Plus System (BioRad). 
 
2.9.4 Comparative analysis of 2D gel images 
 
Comparative analysis of 2D SDS-PAGE gels within defined experiments was done using the 
BioRad PDQuest Advanced 2D Analysis Software version 8.0.1. Background was subtracted 
and peaks were located. Quantification of resolved proteins was normalized according to 
the total density of the valid spots. 
 
2.9.5 In gel trypsin digestion 
 
All gel pieces were cut into smaller cubes and washed twice with water followed by 50% 
(v/v) acetonitrile for 10 minutes. The acetonitrile was replaced with 50 mM ammonium 
bicarbonate and incubated for 10 minutes, and repeated two more times. All the gel pieces 
were then incubated in 100% acetonitrile until they turned white, after which the gel pieces 
were dried in the speedivac. Proteins were reduced with 10 mM DTT for 1 hour at 57 °C. 
This was followed by brief washing steps of ammonium bicarbonate followed by 50% 
acetonitrile before proteins were alkylated with 55 mM iodoacetamide for 1 hour in the 
dark. Following alkylation the gel pieces were washed with ammonium bicarbonate for 10 
minutes followed by 50% acetonitrile for 20 minutes, before being dried in vacuo. The gel 
pieces were digested with 20 µl of a 10 ng/µl trypsin solution at 37 °C overnight. The 
resulting peptides were extracted twice with 70% acetonitrile in 0.1% formic acid for 30 
minutes, and then dried and stored at -20 °C. All peptides were cleaned using stage tips 
35 
 
before injection. Dried peptides were dissolved in 5% acetonitrile in 0.1% formic acid and 10 
µl injections were made for nano-LC chromatography. Mass spectrometry was carried out as 
in section 2.9.7. 
 
 
2.9.6 Filter-aided sample preparation (FASP)  
 
Samples were mixed 40 µl sample with 40 µl SDT lysis buffer (4% SDS, 100 mM Tris-HCl pH 
7.6, 0.1 M DTT that was added freshly just before use). The 80 µl sample was then mixed 
with 100 µl UA buffer (8 M urea, 100 mM Tris-HCl, pH 8.5) and placed on the filter (Amicon 
ultra 0.5 centrifugal filter, 10 kDa, Millipore). The device was centrifuged for 40 minutes at 
14 000 ×g. This was followed by the addition of 200 µl UA and centrifugation at 14 000 ×g 
for 40 minutes. The proteins were then alkylated by the addition of 100 µl of 0.05 M 
iodoacetamide UA buffer. This was then mixed and incubated for 5 minutes before 
centrifugation at 14 000 ×g for 30 minutes. This was followed by the addition of 100 µl of UB 
(8 M urea, 0.1 M Tris-HCl pH 8.0), centrifuged for 30 minutes at 14 000 ×g and repeated 
once more. After centrifugation 100 µl of a 50 mM ammonium bicarbonate solution was 
added, centrifuged at 14 000 ×g for 30 minutes and repeated once more. This was followed 
by the addition of 40 µl trypsin and then incubated at 37 °C for 17 hours in a wet chamber. 
Following incubation, the filter was placed in a clean eppendorf tube and centrifuged for 40 
minutes at 14 000 ×g, followed by the addition of 40 µl of a 0.5 M sodium chloride solution 
and centrifuged for 20 minutes at 14 000 ×g. Finally, the solution was acidified by the 
addition of 4 µl FA. The filtrate was then desalted using C18 StageTips. The desalted solution 
was dried in the speedivac and stored at -20 °C. Dried peptides were dissolved in 5% 
acetonitrile in 0.1% formic acid and 10 µl injections were made for nano-LC 
chromatography. 
 
2.9.7 Mass spectrometry 
 
All experiments were performed on a Thermo Scientific EASY-nLC II connected to a LTQ  
Orbitrap Velos mass spectrometer (Thermo Scientific, Bremen, Germany) equipped with a 
nano-electropsray source. For liquid chromatography, separation was performed on an 
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EASY-Column (2 cm, ID 100 µm, 5 µm, C18) pre-column followed by an XBridge BEH130 
NanoEase column (15 cm, ID 75 µm, 3.5 µm, C18) column with a flow rate of 300 
nl/minutes. The gradient used was from 5-40 % B in 20 minutes, 40-80% B in 5 minutes and 
kept at 80% B for 10 minutes. Solvent A was 100% water in 0.1 % formic acid, and solvent B 
was 90% acetonitrile in 0.1% formic acid. For 120 minutes gradient: The gradient used was 
from 5-17% B in 5 minutes, 17-25% B in 90 minutes, 25-60% B in 10 minutes, 60-80% B in 5 
minutes and kept at 80% B for 10 minutes. Solvent A was 100% water in 0.1 % formic acid, 
and solvent B was 90% acetonitrile in 0.1% formic acid. 
 
The mass spectrometer was operated in data-dependent mode to automatically switch 
between Orbitrap-MS and LTQ-MS/MS acquisition. Data were acquired using the Xcaliber 
software package. The precursor ion scan MS spectra (m/z 400 – 2000) were acquired in the 
Orbitrap with resolution R = 60000 with the number of accumulated ions being 1 x 106. The 
20 most intense ions were isolated and fragmented in linear ion trap (number of 
accumulated ions 1.5 x 104) using collision induced dissociation. The lock mass option 
(polydimethylcyclosiloxane; m/z 445.120025) enabled accurate mass measurement in both 
the MS and MS/MS modes. In data-dependent LC-MS/MS experiments, dynamic exclusion 
was used with 60 seconds exclusion duration. Mass spectrometry conditions were 1.5 kV, 
capillary temperature of 200 °C, with no sheath and auxiliary gas flow. The ion selection 
threshold was 500 counts for MS/MS and an activation Q-value of 0.25 and activation time 
of 10 ms were also applied for MS/MS. 
 
2.9.8 Data analysis 
 
Thermo Proteome Discoverer 1.3 (Thermo Scientific, Bremen, Germany) was used to 
identify proteins via automated database searching (Mascot, Matrix Science, London, UK 
and Sequest) of all tandem mass spectra against the UNIPROT Homo Sapiens database. 
Carbamidomethyl cysteine was set as fixed modification, and oxidized methionine, N-
acetylation and deamidation (NQ) was used as variable modifications. The precursor mass 
tolerance was set to 10 ppm, and fragment mass tolerance set to 0.8 Da. Two missed tryptic 
cleavages were allowed. Proteins were considered positively identified when they were 
identified with at least 2 tryptic peptides per protein, a Mascot or Sequest score of more 
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than p<0.05 as determined by Proteome Discoverer 1.3. Percolator was also used for 
validation of search results. In Percolator a decoy database was searched with a false 
discovery rate (FDR) (strict) of 0.02 and FDR (relaxed) of 0.05 with validation based on the q-
value. 
 
2.10 Oligosaccharide analysis 
 
This section of the work was conducted by Dr. Chunsheng Jin and Dr. Niclas Karlsson at 
Medicinaregatan, University of Gothenburg in Sweden. 
 
Liquid-chromatography-Mass spectrometry was performed to analyse the O-linked 
oligosaccharides from the mucin glycoproteins separated by gel electrophoresis. Freeze 
dried mucus was separated on composite gel for AgPAGE with a gradient of 0-6% 
polyacrylamide, 0.5%-1% agarose (low electrosomotic flow grade)  and 0-10% glycerol 
within the gel, made up in a 0.375 M Tris-HCl buffer, pH 8.1., 40% ammonium persulfate and 
TEMED. The gel was poured using a BioRad miniprotein system at 50 °C and allowed to set 
for 30minutes at this temperature followed by additional time at room temperature. 
Sample buffer was made up 2X at a concentration of 0.75M Tris-HCl pH 8.1, 20% glycerol, 
bromophenol blue, 2% SDS. Unreduced sample was placed in the reducing sample buffer 
and boiled for 20 minutes. Iodoacetamide is added in excess (25 mM) and the solution was 
incubated in the dark at room temperature for 20 minutes. Running buffer was 192 mM 
borate, 1mM EDTA, 0.1% SDS and Tris, pH 7.6. Gel electrophoresis was at 40mAmp for 2-3 
hours. A Kaleidoscope prestained marker was used. These enable observation of problems 
with polymerisation as high molecular weight standards will not separate. The 
electrophoresis was followed by electro-blotting of the glycoproteins to PVDF using a semi-
dry method and staining with Direct Blue (DB71) for the glycoprotein bands. The gel was 
also stained with Coomassie Brilliant Blue. The identified bands were then removed.  
The bands were wetted with methanol.  
 
Oligosaccharide side-chains were separated by reductive alkaline β-elimination of sugar 
side-chains from the mucin glycoprotein. Samples from gel electrophoresis or purified 
sample (100 µl at a concentration of 1mg/ml in ddH20), were incubated in eppendorfs, and 
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sealed to prevent evaporation, at 50˚C for 16h in 20 µl of 50 mM NaOH and 1.5 M NaBH4. 
The resulting solutions were neutralized by the addition of 1ul of glacial acetic acid, before 
being desalted with 25 µl of AG50WX8 cation-exchange resin laid on top of a reversed-
phase u-C18 ZipTip (Millipore), and dried in a Savant SpeedVac. Borate was then removed 
by repeated (5 times) addition and evaporation of 50ul of 1% acetic acid in methanol. The 
samples were resuspended in 10 µl of MilliQ water for liquid chromatography coupled to 
electrospray mass spectrometry (LC/ESI-MS) analysis.  
 
The desalted oligosaccharide alditols were then analysed by liquid chromatography coupled 
to electrospray tandem mass spectrometry (LC/ESI-MS/MS) on a graphitized carbon column 
(7-ím Hypercarb particles (Thermo-Hypersil) in a 100 × 0.25mm column) or a 150 × 0.32mm 
Hypercarb column (Thermo-Hypersil). A solvent rate through the column of 5ul/minutes was 
provided by a Surveyor LC pump (ThermoFinnigan) with flow splitting from 100 µl/minutes. 
Oligosaccharides were eluted with an H2O/acetonitrile gradient (0-40% acetonitrile in 30 
minutes, followed by a 3 minutes wash with 90% acetonitrile) containing 10 mM NH4HCO3. 
Mass spectrometry was performed using an LCQ Deca (ThermoFinnigan) in negative ion 
mode, with three scan events: full scan with mass range 320-2000 m/z, dependent zoom 
scan of the most intense ions in each scan, and dependent MS/MS scan after collision-
induced fragmentation. The capillary temperature was 180 ˚C, the capillary voltage was 
32.0V, and the electrospray voltage was 2.5kV. Dynamic exclusion of ions for zoom scan for 
30 seconds was introduced after three selections within 30 seconds. For MS/MS, the 
normalized collision energy was 35%, with an activation time of 30 minutes. Oligosaccharide 
structure and linkage were determined using a combination of analysis of LC/ESI-MS/MS 
data and the GlycoSuiteDB sugar database (http://www.glycosuite.com). 
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CHAPTER 3 : CLINICAL DATA AND SAMPLE COLLECTION 
 
3.1 Clinical recruitment 
 
A total of 168 adults were recruited from primary health clinics in suburban Kroonstad in the 
Free State Province and suburban Cape Town in the Western Cape Province. In addition to 
the primary health clinics, adults were also recruited from the Respiratory Clinic at Groote 
Schuur Hospital and at the DP Marais Hospital in the Western Cape Province.  DP Marais 
Hospital is a TB/HIV hospital in the Western Cape.  
 
Of the 168 recruited for the study, 64 were definite tuberculosis (TB) and 104 adults without 
TB. Table 3.1 demonstrates the breakdown of the diagnoses from patients without TB 
within the non-TB group and the uninfected controls for the study. Both males and females 
were recruited.  The ages of the recruited patients ranged for 21 to 75 years. The recruited 
patients presented with wheezing, weight loss, coughing and/or a productive cough, chest 
pains, and shortness of breath.   
 
3.2 Diagnostic classification 
 
Uninfected controls  –  This group was composed of patients who underwent surgery 
for various reasons besides lung disease. An exclusion criterion was set to exclude patients 
with prior history of TB. 
 
Non-TB  – This group was composed of patients with other respiratory infections 
and diseases and patients with no evidence of active TB based on direct sputum smear 
microscopy and radiology.  
 
TB   – Patients positively diagnosed with active pulmonary TB by either x-ray 
showing abnormalities consistent with active TB or 2 sputum smears positive for acid-fast 
bacilli (AFB). This group also included drug resistant TB strains such as multidrug-resistant 
(MDR)-TB patients and extensive drug-resistant (XDR)-TB. 
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Table 3.1: Diagnoses of patients without TB 
Diagnosis  Number of patients 
Uninfected controls 17 
Sarcoidosis 53 
Lung Cancer 4 











3.3 Co-infection with HIV 
 
It was difficult to recruit patients who were infected with TB only, since the incidence of TB 
is strongly associated with HIV infection in this region. Of the 104 patients without TB, 47 
were infected with HIV. Out of the 63 TB patients 56 were co-infected with HIV. 
 
3.4 Choice of samples 
 
Initially the project was aimed at analysing respiratory mucus in bronchoalveolar lavage 
(BAL) samples obtained by bronchoscopy from patients who routinely underwent the 
procedure for diagnostic and therapeutic purposes. The BALs are usually assessed for the 
composition of the extracellular luminar spaces of airways during respiratory diseases 
(Plymoth et al., 2003). The BALs were chosen as a sample of choice to limit the possibility of 
contamination of respiratory mucus by salivary secretions during expectoration. However, 




In addition to the BALs, sputum was thus selected as the second sample of choice for TB 
positive mucus. Patients were encouraged to rinse their mouths in order to limit 
contamination of the respiratory mucus by salivary secretions during expectoration.  All of 
the sputa collected (n=56) were from TB positive patients with a productive cough as it 
proved difficult to get sufficient sample from those who did not. The TB positive patients 
were all on medication. 
 
In an attempt to collect sputum from recruits without TB and other respiratory diseases, 
sputum was induced with 5% saline. However there was no sputum production from these 
individuals. Therefore tracheal aspirates were collected from patients who underwent 




Significant research has been done to find quicker and reliable techniques for diagnosing TB. 
However, direct sputum smear microscopy is the most common and widely used technique 
in diagnosing TB. Recently, a confirmed diagnosis of TB is given upon isolating M.tb or upon 
identifying the specific DNA sequence of the bacteria from the sputum or BAL mucus 
(Majeed and Bukhari, 2011). 
 
The collection of mucus from the recruited patients proved to be a huge limitation to the 
study. Firstly individuals without respiratory diseases did not produce mucus even after 
sputum induction. Secondly, individuals without respiratory diseases do not undergo 
bronchoscopy as it is an invasive procedure. Thirdly, with the complication of HIV, some 
definite TB positive patients were sputum-scarce as they did not have a productive cough 
(Peter et al., 2014). This factor decreased the collection of sputum from patients with 
definite TB. Another limiting factor was the inadequate amount of mucus extracted from 
the sputa and tracheal aspirates for analyses.   
 
Collection of mucus from individuals without respiratory diseases was very difficult. 
Therefore better methods are necessary for inducing sputum from these individuals.
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CHAPTER 4 : PROTEIN ANALYSIS OF RESPIRATORY SECRETIONS IN 




Proteomics is a tool used to study proteins in a biological sample. As the proteome differs 
from cell to cell, expression proteomics was introduced to compare proteins expressed 
under certain conditions. To date, expression proteomics remains the most used 
methodology to compare proteins in the diseased and healthy state. The lung proteome has 
been widely studied to give information towards understanding the mechanisms leading to 
lung dysfunction, and to finding biomarkers for diagnostic and prognostic purposes (Lindahl 
et al., 2001; Wattiez et al., 1999). Knowledge of the lung proteome has been acquired 
through the analysis of samples such as the epithelial lining fluid, sputum, plasma/serum, 
lung tissue and the bronchoalveolar lavage fluid (BALF) (Kriegova et al., 2006; Magi et al., 
2006). 
 
Owing to its ability to separate hundreds of proteins at a time, the two-dimensional (2D) 
SDS-PAGE technique remains the method of choice in expression proteomics for separating 
proteins in complex mixtures (Gorg et al., 2000). The principle of 2D electrophoresis is based 
on separating the extracted proteins firstly according to their isoelectricpoint (pI) followed 
by the second dimension where proteins are separated according to their relative molecular 
mass (Scott et al., 2005).  
 
Gel-based and shotgun proteomic techniques have been employed in the development of 
the lung proteome (Issa et al., 2011; Plymoth et al., 2003; Wattiez et al., 2007). The 2D 
technique is widely used as it allows for the separation and visualisation of the lung proteins 
under various physiological conditions. However, the separation of mucins and 
glycoconjugates using the gel-based techniques is limited due to their large size (Kesimer 
and Sheehan, 2012). Recent advances in shotgun proteomics by (Kesimer et al., 2009), has 
led to the identification of mucins using a high performance liquid chromatography coupled 




The aim of this chapter was to identify protein expressed in uninfected controls and TB 
respiratory mucus. To identify the proteins expressed in the respiratory mucus, proteins 
were reduced with DTT and alkylated with iodoacetamide. The resulting proteins were 
precipitated with acetone and their concentrations determined using the Bradford assay. 
The results were divided into uninfected controls which were collected from healthy 
tracheal aspirates, TB BALs and TB sputum. The TB group was divided into 2 groups (BALs 




4.2.1 Separation of respiratory mucus proteins by 1D SDS PAGE 
 
The 1D SDS PAGE was carried out to evaluate the abundance of extracted proteins, the 
quality of the extracted proteins and their loading quantities prior to separation using the 
2D technique. The staining of proteins at the top of the wells was observed in all samples. 
The detection of these proteins indicated the presence of high molecular weight proteins 
that could not penetrate the 4% polyacrylamide gel. The protein band intensities varied 
between samples indicating inter-individual variations as equal amounts of protein were 
loaded.  
 
Multiple protein bands were observed in the uninfected controls group (Figure 4.1). 
Similarities in the pattern of the expressed proteins were observed in the biological 
replicates within the group. Proteins were highly expressed at approximately 72 kDa, above 
55 kDa, between 34 kDa and 26 kDa, and at approximately 17 kDa. 
 
Similar protein expression patterns between samples in the TB BALs group in lanes 1 – 4 
(Figure 4.2) were noticed. Moreover, more proteins were expressed in lanes 3 and 4 (Figure 
4.2) in comparison to lanes 1 and 2. These proteins were highly expressed between 72 kDa 
and 55 kDa, between 34 kDa and 26 kDa, and at approximately 17 kDa. Interestingly, 2 




Lanes 5 – 9 (Figure 4.2) illustrate protein expression patterns in the TB sputum group. One 
case of MDR-TB was included in the TB sputum group, lane 9 (Figure 4.2).  Protein 
expression varied between samples indicating inter-individual variation. Highly expressed 
proteins were noted in lanes 6 and 8. These highly expressed proteins were noted between 
95 and 55 kDa, between 34 kDa and 26 kDa, and at approximately 17 kDa. A protein band 
was observed at approximately 17 kDa in sputa in comparison to TB BALs. Interestingly, the 




Figure 4.1: A 1D SDS PAGE analysis of proteins from the uninfected controls group. 
Approximately 15 µg of protein from healthy tracheal aspirates (uninfected controls) was loaded onto 4-20% 
SDS polyacrylamide gels. MW is the molecular weight marker lane. Lanes 1-4 represent biological replicates of 











Figure 4.2: A comparative 1D SDS PAGE analysis of proteins from TB BALs and TB sputum 
groups. 
Approximately 15 µg of protein respectively from BAL and sputa of patients with TB was loaded onto 4-20% 
SDS polyacrylamide gels. MW is the molecular weight marker lane. Lanes 1-4 represent biological replicates of 
proteins extracted from BALs.  Lanes 5-8 represent biological replicates of proteins extracted from sputa. Lane 














4.2.2 Protein identification using mass spectrometry 
 
Proteins were identified from 1D SDS polyacrylamide gels. Gel pieces from 1D SDS 
polyacrylamide gels were trypsinised and the peptide digests were analysed with mass 
spectrometry. The mass spectrometer was operated in data-dependent mode to 
automatically switch between Orbitrap-MS and LTQ-MS/MS acquisition. Proteins were 
considered positively identified with at least 2 tryptic peptides per protein. A Mascot or 
Sequest score of more than p<0.05 as determined by Proteome Discoverer 1.3 Percolator 
was also used for validation of the search results. 
 
The names of the proteins from the uninfected controls group, the TB sputum group and TB 
BALs group are listed as assigned on the database. Proteins with a mascot score above 24 
were usually considered significant. Proteins with sequence coverage of 5% were 
considered good. The total number of peptides detected for each protein and those that 
were unique to the protein were assigned by the databases. The tables below give a 
summary of the identified proteins, their score, the number of unique peptides identified, 
the number of peptides identified, the number of amino acids of the identified proteins, 
their molecular weight and calculated isoelectric points (pI) as assigned by the databases. A 
total of 122 proteins were identified from the uninfected controls group (Table 4.1), 79 
proteins (Table 4.2) and 74 proteins (Table 4.3) were identified from the TB BALs and TB 














Table 4.1: Proteins identified using mass spectrometry from the uninfected controls group 
following separation by 1D SDS PAGE 
Accession 
No. 












P63104 14-3-3 protein zeta/delta  26.86 1 1 245 27.7 4.79 
P11021 78 kDa glucose-regulated protein  38.80 2 2 654 72.3 5.16 
P60709 Actin, cytoplasmic 1  121.12 5 5 375 41.7 5.48 
P40394 Alcohol dehydrogenase class 4 
mu/sigma chain  
36.73 1 1 386 41.5 7.85 
P30838 Aldehyde dehydrogenase, dimeric 
NADP-preferring  
42.59 2 2 453 50.4 6.54 
P01023 Alpha-2-macroglobulin  120.57 7 7 1474 163.2 6.46 
P01019 Angiotensinogen  51.41 1 1 485 53.1 6.32 
P04083 Annexin A1  64.83 1 1 346 38.7 7.02 
P03973 Antileukoproteinase  47.88 2 2 132 14.3 8.75 
P01008 Antithrombin-III  41.03 1 1 464 52.6 6.71 
P02730 Band 3 anion transport protein  38.03 2 2 911 101.7 5.19 
Q8TDL5 BPI fold-containing family B member 1  122.01 3 3 484 52.4 7.23 
P04003 C4b-binding protein alpha chain  64.83 2 2 597 67.0 7.30 
Q9NZT1 Calmodulin-like protein 5  39.24 1 1 146 15.9 4.44 
P04040 Catalase  218.64 5 5 527 59.7 7.39 
P49913 Cathelicidin antimicrobial peptide  50.68 2 2 170 19.3 9.41 
O43866 CD5 antigen-like  31.37 1 1 347 38.1 5.47 
P00450 Ceruloplasmin  35.91 2 2 1065 122.1 5.72 
P02452 Collagen alpha-1(I) chain  41.14 1 1 1464 138.9 5.80 
P01024 Complement C3  138.94 6 6 1663 187.0 6.40 
P08603 Complement factor H  104.89 3 3 1231 139.0 6.61 
P31146 Coronin-1A  29.76 1 1 461 51.0 6.68 
P81605 Dermcidin  73.36 2 2 110 11.3 6.54 
Q02413 Desmoglein-1  74.58 1 1 1049 113.7 5.03 
P13639 Elongation factor 2  35.12 1 1 858 95.3 6.83 
P14625 Endoplasmin  27.80 1 1 803 92.4 4.84 
Q96HE7 ERO1-like protein alpha 65.83 1 1 468 54.4 5.68 
P02675 Fibrinogen beta chain  197.77 6 6 491 55.9 8.27 
Q5D862 Filaggrin-2  59.77 1 1 2391 247.9 8.31 
P04075 Fructose-bisphosphate aldolase A  31.66 2 2 364 39.4 8.09 
P00738 Haptoglobin  75.67 3 3 406 45.2 6.58 
P00739 Haptoglobin-related protein  80.98 1 1 348 39.0 7.09 
P69905 Hemoglobin subunit alpha  83.60 2 2 142 15.2 8.68 
P68871 Hemoglobin subunit beta  230.48 6 6 147 16.0 7.28 
P69891 Hemoglobin subunit gamma-1 31.08 1 1 147 16.1 7.20 
P22492 Histone H1t  34.01 1 1 207 22.0 11.71 
O60814 Histone H2B type 1-K  40.07 1 1 126 13.9 10.32 
P68431 Histone H3.1  50.53 2 2 136 15.4 11.12 
P62805 Histone H4  30.63 1 1 103 11.4 11.36 
Q86YZ3 Hornerin  38.47 3 3 2850 282.2 10.04 
P01876 Ig alpha-1 chain C region  156.19 2 6 353 37.6 6.51 
P01877 Ig alpha-2 chain C region ] 145.50 1 5 340 36.5 6.10 
P01880 
P01857 
Ig delta chain C region 













P01859 Ig gamma-2 chain C region  126.02 1 4 326 35.9 7.59 
P01860 Ig gamma-3 chain C region  88.02 1 5 377 41.3 7.90 
P01742 Ig heavy chain V-I region EU  40.96 1 1 117 12.5 6.57 
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P01743 Ig heavy chain V-I region HG3  30.08 1 1 117 12.9 8.92 
P01765 Ig heavy chain V-III region TIL  61.48 1 1 115 12.3 9.13 
P01834 Ig kappa chain C region  169.49 2 2 106 11.6 5.87 
P01616 Ig kappa chain V-II region MIL  38.40 1 2 112 12.0 9.29 
P0CG05 Ig lambda-2 chain C regions  80.08 1 1 106 11.3 7.24 
P0CF74 Ig lambda-6 chain C region  32.05 1 1 106 11.3 7.24 
P01871 Ig mu chain C region  145.01 5 5 452 49.3 6.77 
Q9Y6R7 IgGFc-binding protein  212.75 12 12 5405 571.6 5.34 
P01591 Immunoglobulin J chain  48.05 1 1 159 18.1 5.24 
P19827 Inter-alpha-trypsin inhibitor heavy 
chain H1  
24.93 1 1 911 101.3 6.79 
Q13835-2 Isoform 1 of Plakophilin-1  74.12 1 1 726 80.4 8.97 
P02751-
10 
Isoform 10 of Fibronectin  87.37 2 2 2176 239.5 5.88 
P01009-2 Isoform 2 of Alpha-1-antitrypsin  103.67 2 2 359 40.2 5.47 
P12814-2 Isoform 2 of Alpha-actinin-1 40.07 2 2 887 102.6 5.50 
P35222-2 Isoform 2 of Catenin beta-1  59.67 1 1 88 9.5 4.92 
Q00610-2 Isoform 2 of Clathrin heavy chain 1  49.53 3 3 1639 187.8 5.69 
P0C0L4-2 Isoform 2 of Complement C4-A 124.44 1 1 1698 187.6 7.12 
P0C0L4-2 Isoform 2 of Complement C4-A  41.96 1 1 1698 187.6 7.12 
Q96KP4-2 Isoform 2 of Cytosolic non-specific 
dipeptidase  
36.82 1 1 391 43.8 6.48 
P02671-2 Isoform 2 of Fibrinogen alpha chain  31.90 1 1 644 69.7 8.06 
P06396-2 Isoform 2 of Gelsolin  33.38 1 1 731 80.6 5.85 
P14314-2 Isoform 2 of Glucosidase 2 subunit beta  41.06 2 2 525 59.1 4.42 
P04406-2 Isoform 2 of Glyceraldehyde-3-
phosphate dehydrogenase  
51.78 1 1 293 31.5 7.61 
Q8TC59-2 Isoform 2 of Piwi-like protein 2  24.03 1 1 937 105.7 9.04 
P10909-3 Isoform 3 of Clusterin  47.83 1 1 274 32.3 6.65 
P11277-3 Isoform 3 of Spectrin beta chain, 
erythrocytic 
50.63 1 1 2106 242.7 5.35 
Q9UGM3-
7 
Isoform 7 of Deleted in malignant brain 
tumors 1 protein 
164.94 4 4 2532 273.3 5.44 
Q15149-7 Isoform 7 of Plectin  36.58 1 1 4515 512.3 5.77 
P15924-2 Isoform DPII of Desmoplakin  102.62 4 4 2272 260.0 6.96 
P02679-2 Isoform Gamma-A of Fibrinogen 
gamma chain  
39.53 3 3 437 49.5 6.09 
P05164-2 Isoform H14 of Myeloperoxidase  150.81 7 7 650 73.8 9.11 
P01042-2 Isoform LMW of Kininogen-1  34.10 1 1 427 47.9 6.65 
P14923 Junction plakoglobin 68.09 1 1 745 81.7 6.14 
P13645 Keratin, type I cytoskeletal 10 599.09 10 12 584 58.8 5.21 
P13646 Keratin, type I cytoskeletal 13 423.63 6 10 458 49.6 4.96 
P02533 Keratin, type I cytoskeletal 14  170.14 3 7 472 51.5 5.16 
P08779 Keratin, type I cytoskeletal 16  179.14 2 6 473 51.2 5.05 
Q04695 Keratin, type I cytoskeletal 17  61.30 2 4 432 48.1 5.02 
P08727 Keratin, type I cytoskeletal 19  73.15 3 4 400 44.1 5.14 
P04264 Keratin, type II cytoskeletal 1  496.40 12 13 644 66.0 8.12 
P13647 Keratin, type II cytoskeletal 5  233.87 6 9 590 62.3 7.74 
P02538 Keratin, type II cytoskeletal 6A  329.08 7 12 564 60.0 8.00 
P02788 Lactotransferrin  328.50 15 15 710 78.1 8.12 
P30740 Leukocyte elastase inhibitor  62.54 3 3 379 42.7 6.28 
P23490 Loricrin  46.13 1 1 312 25.7 8.09 
P61626 Lysozyme C  89.36 2 2 148 16.5 9.16 
P14780 Matrix metalloproteinase-9  40.46 2 2 707 78.4 6.06 
P26038 Moesin  72.88 2 2 577 67.8 6.40 
P98088 Mucin-5AC (Fragments)  233.53 13 14 5030 526.3 6.90 
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Q9HC84 Mucin-5B  163.74 10 10 5762 596.0 6.64 
P59665 Neutrophil defensin 1  61.82 2 2 94 10.2 6.99 
Q06830 Peroxiredoxin-1  31.13 1 1 199 22.1 8.13 
P03952 Plasma kallikrein  25.28 1 1 638 71.3 8.22 
P00747 Plasminogen  52.89 1 1 810 90.5 7.24 
P13796 Plastin-2  50.55 1 1 627 70.2 5.43 
P01833 Polymeric immunoglobulin receptor  138.30 6 6 764 83.2 5.74 
Q99623 Prohibitin-2  42.94 1 1 299 33.3 9.83 
P12273 Prolactin-inducible protein  63.61 1 1 146 16.6 8.05 
P02760 Protein AMBP  29.17 1 1 352 39.0 6.25 
P05109 Protein S100-A8  60.41 1 1 93 10.8 7.03 
Q08188 Protein-glutamine gamma-
glutamyltransferase E  
57.27 1 1 693 76.6 5.86 
Q8IWL1 Pulmonary surfactant-associated 
protein A2  
43.56 1 1 248 26.2 5.17 
A6NMY6 Putative annexin A2-like protein  75.10 4 4 339 38.6 6.95 
Q58FF6 Putative heat shock protein HSP 90-
beta 4  
35.69 2 2 505 58.2 4.73 
P46940 Ras GTPase-activating-like protein 
IQGAP1  
36.89 1 1 1657 189.1 6.48 
P13489 Ribonuclease inhibitor  42.40 1 1 461 49.9 4.82 
P02787 Serotransferrin  273.26 12 12 698 77.0 7.12 
P02768 Serum albumin 1097.25 23 23 609 69.3 6.28 
P22531 Small proline-rich protein 2E  22.45 1 1 72 7.8 8.31 
Q9Y6N5 Sulfide:quinone oxidoreductase, 
mitochondrial  
31.35 1 1 450 49.9 9.11 
P08670 Vimentin  74.79 3 3 466 53.6 5.12 
P02774 Vitamin D-binding protein  140.11 2 2 474 52.9 5.54 
P04004 Vitronectin  34.09 1 1 478 54.3 5.80 
P25311 Zinc-alpha-2-glycoprotein 32.60 2 2 298 34.2 6.05 

















Table 4.2: Proteins identified using mass spectrometry from the TB bronchoalveolar 
lavages group following separation by 1D SDS PAGE 
Accession 
No. 












P63104 14-3-3 protein zeta/delta  101.81 2 2 245 27.7 4.79 
P52209 6-phosphogluconate dehydrogenase, 
decarboxylating  
47.12 1 1 483 53.1 7.23 
P60709 Actin, cytoplasmic 1  39.74 2 2 375 41.7 5.48 
P01011 Alpha-1-antichymotrypsin  74.83 1 1 423 47.6 5.52 
P01023 Alpha-2-macroglobulin 26.63 1 1 1474 163.2 6.46 
P09525 Annexin A4  24.86 1 1 319 35.9 6.13 
P02647 Apolipoprotein A-I  40.36 1 1 267 30.8 5.76 
P02730 Band 3 anion transport protein 75.31 1 1 911 101.7 5.19 
P04003 C4b-binding protein alpha chain 63.38 1 1 597 67.0 7.30 
P04040 Catalase  153.38 3 3 527 59.7 7.39 
P07339 Cathepsin D  53.26 1 1 412 44.5 6.54 
P23528 Cofilin-1 53.30 1 1 166 18.5 8.09 
P02745 Complement C1q subcomponent 
subunit A  
29.45 1 1 245 26.0 9.11 
P01024 Complement C3  109.15 2 2 1663 187.0 6.40 
P01040 Cystatin-A  39.22 1 1 98 11.0 5.50 
P81605 Dermcidin  69.12 2 2 110 11.3 6.54 
P02675 Fibrinogen beta chain 33.48 1 1 491 55.9 8.27 
Q5D862 Filaggrin-2  40.11 1 1 2391 247.9 8.31 
P69905 Hemoglobin subunit alpha 106.51 1 1 142 15.2 8.68 
P68871 Hemoglobin subunit beta  161.79 3 3 147 16.0 7.28 
P02042 Hemoglobin subunit delta  41.50 1 2 147 16.0 8.05 
P02790 Hemopexin  34.78 1 1 462 51.6 7.02 
P62805 Histone H4  32.65 1 1 103 11.4 11.36 
Q86YZ3 Hornerin  73.92 3 3 2850 282.2 10.04 
P01876 Ig alpha-1 chain C region 99.38 2 2 353 37.6 6.51 
P01877 Ig alpha-2 chain C region  47.48 1 1 340 36.5 6.10 
P01857 Ig gamma-1 chain C region 99.58 3 6 330 36.1 8.19 
P01859 Ig gamma-2 chain C region  82.95 1 3 326 35.9 7.59 
P01860 Ig gamma-3 chain C region  132.88 2 5 377 41.3 7.90 
P01768 Ig heavy chain V-III region CAM  65.11 1 2 122 13.7 9.63 
P01781 Ig heavy chain V-III region GAL  43.85 1 1 116 12.7 8.48 
P01771 Ig heavy chain V-III region HIL  60.55 1 1 121 13.6 9.36 
P01834 Ig kappa chain C region  210.49 3 3 106 11.6 5.87 
P01598 Ig kappa chain V-I region EU  39.54 1 1 108 11.8 8.44 
P01616 Ig kappa chain V-II region MIL  75.74 1 2 112 12.0 9.29 
P01620 Ig kappa chain V-III region SIE 105.90 1 1 109 11.8 8.48 
P04433 Ig kappa chain V-III region VG 
(Fragment)  
30.87 1 1 115 12.6 4.96 
P01703 Ig lambda chain V-I region NEWM  73.79 1 1 103 10.9 9.29 
P0CG05 Ig lambda-2 chain C regions  74.83 1 1 106 11.3 7.24 
P01871 Ig mu chain C region  65.46 1 1 452 49.3 6.77 
P01591 Immunoglobulin J chain  51.68 1 1 159 18.1 5.24 
P02751-10 Isoform 10 of Fibronectin 56.59 2 2 2176 239.5 5.88 
Q08554-2 Isoform 1B of Desmocollin-1  36.46 1 1 840 93.8 5.53 
P35222-2 Isoform 2 of Catenin beta-1  61.57 1 1 88 9.5 4.92 
P53675-2 Isoform 2 of Clathrin heavy chain 2 50.52 1 1 1583 180.2 5.78 





Isoform 2 of Complement factor B 













P35579-2 Isoform 2 of Myosin-9  89.25 1 1 1382 159.8 5.97 
P02549-2 Isoform 2 of Spectrin alpha chain, 
erythrocytic 1 
24.31 1 1 2416 279.5 5.05 
P60174-1 Isoform 2 of Triosephosphate 
isomerase  
40.17 1 1 249 26.7 6.90 
Q9Y3Z3-3 Isoform 3 of Deoxynucleoside 
triphosphate triphosphohydrolase 
SAMHD1  
31.60 1 1 556 63.6 6.77 
P55058-3 Isoform 3 of Phospholipid transfer 
protein  
29.59 1 1 398 44.1 6.55 
P11277-3 Isoform 3 of Spectrin beta chain, 
erythrocytic 
188.21 5 5 2106 242.7 5.35 
P02788-2 Isoform DeltaLf of Lactotransferrin  37.94 2 2 666 73.1 7.85 
P02679-2 Isoform Gamma-A of Fibrinogen 
gamma chain  
72.13 1 1 437 49.5 6.09 
P05164-2 Isoform H14 of Myeloperoxidase  53.91 1 1 650 73.8 9.11 
P14923 Junction plakoglobin  62.42 1 1 745 81.7 6.14 
P13645 Keratin, type I cytoskeletal 10  374.91 10 11 584 58.8 5.21 
P02533 Keratin, type I cytoskeletal 14  114.38 1 5 472 51.5 5.16 
P08779 Keratin, type I cytoskeletal 16  108.59 3 4 473 51.2 5.05 
P04264 Keratin, type II cytoskeletal 1  307.66 6 8 644 66.0 8.12 
P13647 Keratin, type II cytoskeletal 5  169.18 4 6 590 62.3 7.74 
P61626 Lysozyme C  29.34 1 1 148 16.5 9.16 
P98088 Mucin-5AC (Fragments)  79.42 4 4 5030 526.3 6.90 
Q9HC84 Mucin-5B  223.29 12 12 5762 596.0 6.64 
P30041 Peroxiredoxin-6  54.48 1 1 224 25.0 6.38 
P13796 Plastin-2  42.81 1 1 627 70.2 5.43 
P01833 Polymeric immunoglobulin receptor  43.77 2 2 764 83.2 5.74 
P05109 Protein S100-A8  55.61 1 1 93 10.8 7.03 
Q08188 Protein-glutamine gamma-
glutamyltransferase E  
37.90 1 1 693 76.6 5.86 
Q8IWL1 Pulmonary surfactant-associated 
protein A2  
81.12 1 1 248 26.2 5.17 
A6NMY6 Putative annexin A2-like protein 69.69 1 1 339 38.6 6.95 
Q58FF6 Putative heat shock protein HSP 90-
beta 4  
46.02 1 1 505 58.2 4.73 
P02787 Serotransferrin  139.57 5 5 698 77.0 7.12 
P02768 Serum albumin 497.07 15 15 609 69.3 6.28 
P11166 Solute carrier family 2, facilitated 
glucose transporter member 1  
33.86 1 1 492 54.0 8.72 
Q9Y6N5 Sulfide:quinone oxidoreductase, 
mitochondrial  
38.65 2 2 450 49.9 9.11 










Table 4.3: Proteins identified using mass spectrometry from the TB sputum group 
following separation by 1D SDS PAGE 
Accession 
No. 












P52209 6-phosphogluconate dehydrogenase, 
decarboxylating  
34.07 1 1 483 53.1 7.23 
P60709 Actin, cytoplasmic 1  99.96 3 3 375 41.7 5.48 
P01023 Alpha-2-macroglobulin  121.75 4 4 1474 163.2 6.46 
P04083 Annexin A1  126.97 1 1 346 38.7 7.02 
P03973 Antileukoproteinase  58.33 3 3 132 14.3 8.75 
P05090 Apolipoprotein D  44.09 1 1 189 21.3 5.15 
P06731 Carcinoembryonic antigen-related cell 
adhesion molecule 5  
65.33 1 1 702 76.7 5.92 
P04040 Catalase  49.89 1 1 527 59.7 7.39 
P49913 Cathelicidin antimicrobial peptide 28.36 1 1 170 19.3 9.41 
P23528 Cofilin-1  47.78 1 1 166 18.5 8.09 
P01024 Complement C3  91.91 2 2 1663 187.0 6.40 
P81605 Dermcidin  54.57 1 1 110 11.3 6.54 
Q92817 Envoplakin  48.37 1 1 2033 231.5 6.96 
Q01469 Fatty acid-binding protein, epidermal  36.64 2 2 135 15.2 7.01 
P02675 Fibrinogen beta chain  139.41 3 3 491 55.9 8.27 
Q5D862 Filaggrin-2  63.11 1 1 2391 247.9 8.31 
Q08380 Galectin-3-binding protein  37.30 1 1 585 65.3 5.27 
P00738 Haptoglobin  67.70 2 2 406 45.2 6.58 
P69905 Hemoglobin subunit alpha 34.20 1 1 142 15.2 8.68 
P68871 Hemoglobin subunit beta 76.96 1 1 147 16.0 7.28 
O60814 Histone H2B type 1-K  50.55 2 2 126 13.9 10.32 
Q6NXT2 Histone H3.3C  46.40 1 1 135 15.2 11.11 
Q86YZ3 Hornerin  58.11 3 3 2850 282.2 10.04 
P01876 Ig alpha-1 chain C region  68.12 1 3 353 37.6 6.51 
P01877 Ig alpha-2 chain C region  89.47 1 3 340 36.5 6.10 
P01857 Ig gamma-1 chain C region  105.64 2 3 330 36.1 8.19 
P01859 Ig gamma-2 chain C region  113.20 1 2 326 35.9 7.59 
P01860 Ig gamma-3 chain C region 80.25 1 3 377 41.3 7.90 
P01742 Ig heavy chain V-I region EU  68.29 1 1 117 12.5 6.57 
P01768 Ig heavy chain V-III region CAM  67.52 1 1 122 13.7 9.63 
P01772 Ig heavy chain V-III region KOL  48.63 1 1 126 13.7 5.87 
P01834 Ig kappa chain C region  206.07 2 2 106 11.6 5.87 
P01616 Ig kappa chain V-II region MIL 74.87 1 2 112 12.0 9.29 
P0CG05 Ig lambda-2 chain C regions  111.59 2 2 106 11.3 7.24 
P01871 Ig mu chain C region 83.50 2 2 452 49.3 6.77 
P01591 Immunoglobulin J chain  48.26 1 1 159 18.1 5.24 
Q13835-2 Isoform 1 of Plakophilin-1  96.89 1 1 726 80.4 8.97 
Q8TDL5-2 Isoform 2 of BPI fold-containing family B 
member 1  
49.99 1 1 160 17.7 9.72 
P0C0L4-2 Isoform 2 of Complement C4-A  131.37 1 1 1698 187.6 7.12 
P35579-2 Isoform 2 of Myosin-9  85.09 1 1 1382 159.8 5.97 
P01009-3 Isoform 3 of Alpha-1-antitrypsin  46.22 1 1 306 34.7 5.19 
Q9UGM3-
4 
Isoform 4 of Deleted in malignant brain 
tumors 1 protein  
40.03 1 1 1527 166.4 5.43 
P35241-4 Isoform 4 of Radixin  62.30 1 1 447 52.6 6.16 
Q9UGM3-
7 
Isoform 7 of Deleted in malignant brain 
tumors 1 protein  
136.03 1 1 2532 273.3 5.44 
P02788-2 Isoform DeltaLf of Lactotransferrin  267.62 6 6 666 73.1 7.85 
P15924-2 Isoform DPII of Desmoplakin  46.35 1 1 2272 260.0 6.96 
53 
 
P02679-2 Isoform Gamma-A of Fibrinogen gamma 
chain  
59.79 1 1 437 49.5 6.09 
P05164-2 Isoform H14 of Myeloperoxidase  56.09 3 3 650 73.8 9.11 
P13645 Keratin, type I cytoskeletal 10  258.73 5 6 584 58.8 5.21 
P13646 Keratin, type I cytoskeletal 13  525.97 5 7 458 49.6 4.96 
P02533 Keratin, type I cytoskeletal 14  168.35 1 7 472 51.5 5.16 
P08779 Keratin, type I cytoskeletal 16  171.70 1 7 473 51.2 5.05 
Q7Z3Y8 Keratin, type I cytoskeletal 27  128.06 2 4 459 49.8 5.05 
P04264 Keratin, type II cytoskeletal 1  211.20 3 4 644 66.0 8.12 
P30740 Leukocyte elastase inhibitor  71.62 1 1 379 42.7 6.28 
P61626 Lysozyme C  130.93 4 4 148 16.5 9.16 
P98088 Mucin-5AC (Fragments)  272.16 11 12 5030 526.3 6.90 
Q9HC84 Mucin-5B  190.68 6 7 5762 596.0 6.64 
P59665 Neutrophil defensin 1  36.23 1 1 94 10.2 6.99 
P80188 Neutrophil gelatinase-associated lipocalin  35.31 1 1 198 22.6 8.91 
Q8WUA2 Peptidyl-prolyl cis-trans isomerase-like 4  36.45 1 1 492 57.2 5.92 
P36955 Pigment epithelium-derived factor  51.92 1 1 418 46.3 6.38 
P01833 Polymeric immunoglobulin receptor  197.34 3 3 764 83.2 5.74 
P12273 Prolactin-inducible protein  61.96 1 1 146 16.6 8.05 
P05109 Protein S100-A8  64.37 1 1 93 10.8 7.03 
A6NMY6 Putative annexin A2-like protein  65.08 1 1 339 38.6 6.95 
O95968 Secretoglobin family 1D member 1  35.20 1 1 90 9.9 9.25 
P02787 Serotransferrin  182.03 6 6 698 77.0 7.12 
P02768 Serum albumin  509.34 11 11 609 69.3 6.28 
Q5T750 Skin-specific protein 32  34.01 1 1 250 26.2 7.97 
P22531 Small proline-rich protein 2E  42.22 2 2 72 7.8 8.31 
P02774 Vitamin D-binding protein  36.28 1 1 474 52.9 5.54 
P25311 Zinc-alpha-2-glycoprotein  55.34 1 1 298 34.2 6.05 

















4.2.3 Classification of the functions of identified proteins 
 
The functions of the identified proteins were classified using the Panther Classification 
System (http://www.pantherdb.org/). Panther is an acronym for protein analysis through 
evolutionary relationships. The functions of the proteins were first separated according to 
their protein classes then according to their family/subfamily that demonstrated similar 
functions. Figure 4.3 illustrates the classes of proteins identified from the uninfected 
controls group in a form of a pie chart. The classes of proteins found from the TB BALs group 
and the TB sputum group are represented in Figure 4.4 and Figure 4.5 respectively.  
 
The figures show that more structural and cytoskeletal proteins were present in all three 
groups. Higher percentages of hydrolases, extracellular matrix, receptor proteins and 
proteins belonging to the protease family were noticed in the uninfected controls group 
when compared to the TB groups analysed from BALs and sputa. Defence proteins displayed 
similar percentages between the uninfected controls, the TB BALs and TB sputum groups. 
More calcium binding proteins were observed in uninfected controls and TB sputum groups 
than in TB BALs. 
 
The protein classes could further be subdivided into 2 groups namely the molecular function 
(Table 4.4) and biological processes (Table 4.5) they are involved in. The molecular function 
also confirmed that more calcium binding proteins were observed in uninfected controls 
and TB sputum groups than in TB BALs. A higher number of proteins involved in antioxidant 





Figure 4.3: Proteins of the uninfected controls group classified according to their protein class. 




Figure 4.4: Proteins of the TB BALs group classified according to their protein class. 




Figure 4.5: Proteins of the TB sputum group classified according to their protein class. 





Table 4.4: Classification of proteins according to their molecular function using the 
Panther Classification System 
Molecular Function Uninfected 
controls (%) 




Antioxidant activity 2.1 4.3 2.7 
Binding 30.7 26.1 48.6 
Catalytic activity 22 19.6 21.6 
Enzyme regulator activity 12.1 8.7 16.3 
Receptor activity 6.6 4.3 0 
Structural molecule activity 20 28.3 8.1 
Translation regulator activity 1 0 0 





Table 4.5: Classification of proteins according to their biological process using the Panther 
Classification System 






Apoptosis 0.9 0 0.8 
Cell adhesion 4.5 3.3 3.8 
Cell communication 7.1 6.6 6.9 
Cell cycle 3.1 2.5 1.5 
Cellular component organisation 9.4 11.6 9.8 
Cellular process 17.4 16.5 17.4 
Developmental process 8.5 10.7 9.8 
Generation of precursor metabolites and energy 0.9 0.9 0.8 
Homeostasis process 0.9 0.9 0 
Immune system process 9.8 9.1 9.8 
Localization 0.4 0 15.9 
Metabolic process 17 16.5 0 
Reproduction 2.2 0 2.3 
Response to stimuli 7.6 6.6 7.6 
System process 3.6 4.1 4.5 










Proteins play crucial roles in the body with functions such as enzymes, transporters, 
structure creators, receptors, growth factors and antibodies among many others (Garrett 
and Grisham, 2005). The use of proteomics in the identification of proteins in the diseased 
and healthy state has been carried out for more than a decade. In 2005, Sloane and 
colleagues examined the expression of proteins during pulmonary exacerbations in cystic 
fibrosis (Sloane et al., 2005). Similarly proteomic techniques were applied in other studies to 
determine proteins in diseases such as asthma (Haenena et al., 2014), pulmonary 
sarcoidosis (Kriegova et al., 2006) and tumor-associated glycoproteins (Li et al., 2013). 
Recently, (Fu et al., 2012) initiated an investigation into the expression of proteins in TB. 
However, the knowledge is far from complete and more information is required regarding 
TB. These studies have highlighted the importance of the extraction of the proteins from the 
sample and the reproducibility of the experiment.  
 
Mucins are large polydisperse glycoproteins with molecular weights ranging between 200 
kDa and 2 MDa (Issa et al., 2011). It was thus essential to determine proteomic techniques 
that would lead to the identification of large proteins such as mucins. The protein extraction 
from the various sources of mucus was optimised using the acetone method. In an attempt 
to identify proteins using non gel-based techniques, the filter-aided sample preparation 
(FASP) method was employed. Using this technique, the samples were lysed, filtered with 10 
kDa filter, detergents were removed with repeated washes and trypsinised in preparation 
for mass spectrometry. However, there was a limitation identifying proteins above 180 kDa. 
Therefore, this technique could not be used in the identification of proteins between the 
uninfected controls and TB groups, as large proteins, mucins in particular, could not be 
identified.  
 
Gel-based techniques (1D SDS and 2D SDS polyacrylamide gels) were thus used in the 
identification of large proteins including mucins. However, proteins above 170 kDa we 
confined to the IPG strip and could not be resolved into the gel. Therefore these proteins 
could not be identified. The 1D protein profiles showed that the extracted proteins were of 




concentrations in different samples indicative of inter-individual variations.  The biological 
replicates from each group (uninfected controls, TB BALs and TB sputum) demonstrated 
high similarities in the protein expression pattern within each group. The consistency in the 
expression pattern across the replicates indicated the validity/reproducibility of the 
technique in separating mucus proteins.  
 
The limitations of the 2D technique and the FASP technique led to the identification of 
proteins from the combination of 1D SDS polyacrylamide gels and mass spectrometry 
techniques. More proteins were identified from the uninfected controls group (122 
proteins) in comparison to the TB BALs (79 proteins) and TB sputum groups (74 proteins).  
Although the Orbitrap mass spectrometry managed to identify the proteins, the identified 
proteins could not be quantified using this technique. Following protein identification, 
proteins were classified according to their protein classes, molecular function and biological 
processes using the Panther Classification System. 
 
The most abundant protein class was cytoskeletal proteins which were higher in TB (BALs 
and sputum) when compared to uninfected controls. A similar phenomenon was observed 
with structural proteins, which were represented in higher proportions in the TB groups 
than in the uninfected controls group. Cytoskeletal and structural proteins are important for 
cell movement and provide extracellular proteins which form structures thus providing 
strength and protection to cells and tissue (Fu et al., 2012; Garrett and Grisham, 2005). 
Higher cytoskeletal and structural proteins in TB may be due to lung tissue remodelling that 
takes place during disease progression. It was also not surprising to find these proteins in 
abundance in all samples tested as they are constantly required to maintain their function in 
the presence or absence of the disease. Similarly, high cytoskeletal proteins were identified 
by Fu and colleagues (Fu et al., 2012). However, they found that the cytoskeletal proteins 
were downregulated following TB infection except for ARP2 actin-related protein 2 homolog 
and tropomyosin isoform which were upregulated.  
 
Defence and immunity proteins were higher in the TB groups compared to the uninfected 
controls group. However, the difference was not highly significant. The innate immunity is 




express pattern recognition receptors (PRRs), through which they engage the bacteria and 
secrete host defence factors such as cytokines and chemokines (Hazlett and Wu, 2011; 
Marakalala et al., 2011); Therefore the results indicate that the defence proteins 
continuously fight off inhaled particles in an attempt to protect the lungs against infections. 
 
Another class of proteins present in higher percentages are the hydrolase proteins. 
Increased hydrolases were noticed in the uninfected controls group compared to the TB 
groups. As part of the innate immunity response, macrophages are involved in the capture 
of M.tb.  These macrophages reside in the alveolar surfactant film. Hydrolases are present in 
both the alveolar surfactant film and macrophages (Arcos et al., 2011; Torrelles, 2012). 
However, hydrolases that are secreted into the surfactant film are different from lysosomal 
hydrolases, with the latter proteins known to degrade bacteria upon phagolysosome fusion. 
The hydrolases that were detected in the TB BAL group are likely to be from the alveolar 
surfactant film rather than the lysosomes within macrophages. Arcos et al. (2011) showed 
that hydrolases present in the alveolar lining fluid can modify the mycobacterial cell 
envelope resulting in altered intracellular trafficking. Moreover, exposure of M.tb to the 
hydrolases led to the induction of protective effects characterized by pro-inflammatory 
cytokine production and reduced bacterial survival within macrophages (Arcos et al., 2011). 
Thus, surfactant hydrolases have potential in mediating host defence against TB 
progression.  
 
Also found in the alveolar surfactant protein (SP) fraction are four surfactant apoproteins 
called SP-A, -B, -C, and –D (Torrelles, 2012). Interestingly, through PANTHER, the surfactant 
protein was assigned its own protein class. This group consisted of SP-A2. This protein is an 
isoform of the SP-A family. The SP-A is a lipoprotein synthesized and secreted by the type II 
epithelial cells of the lung and Clara cells of the terminal bronchioles (Hu et al., 2012; 
Kishore et al., 2006). This surfactant protein plays a role in the reduction of surface tension 
at the air-liquid interface in the lung during gas-exchange, maintaining the integrity of the 
alveoli, and in the modulation of inflammatory and immunological responses (Silveyra and 
Floros, 2013; Wang et al., 2009). The surfactant protein A2 was found in both uninfected 
controls and TB BALs. The uninfected controls’ samples were tracheal aspirates that were 




that SP-A2 was identified in the tracheal aspirates of healthy individuals and not in TB 
sputum. Sputum proteins are representative of alveolar cells (Nicholas et al., 2006). The 
mechanism behind this alveolar surface protein in tracheal aspirates is not yet understood.  
 
As part of the innate immunity, alveolar macrophages would express PRRs which would 
result in a cascade of immune responses including phagocytosis, signal transduction and the 
induction of T-cell mediated immunity (Marakalala et al., 2011; Torrelles, 2012). M.tb has 
been shown to trigger host immune responses through specific molecules signaling 
downstream receptors such as Toll-like receptors (TLRs), nucleotide-binding oligomerization 
domain-like (NODs) receptors and C-type lectin-like receptors (CLRs) (Marakalala et al., 
2011). The results showed a higher percentage of proteins associated with signaling 
molecules in the TB group than uninfected controls. The higher signaling molecules in the TB 
group may be attributed to active signaling events induced upon the recognition of the 
bacteria. 
 
A higher percentage of extracellular matrix (ECM) was observed in uninfected controls than 
in the TB group. The ECM is crucial in maintaining normal lung function, ventilation and gas 
exchange (Pelosi et al., 2007). In order to maintain the physiological balance of the lung 
ECM, regulatory mechanisms such as the degradation of the ECM by matrix 
metalloproteinases (MMPs) are employed to maintain a balance between synthesis and 
degradation of the ECM. MMPs also play a role in tissue remodeling and cellular recruitment 
(Ong et al., 2014). The decrease in ECM in the TB group may be attributed to tissue 
remodelling and possibly the destruction of the ECM due to the spread of the bacteria in the 
TB group. The proliferation of M.tb in the lungs may lead to TB-mediated necrosis and 
cavitation of granulomas as a result of hyper-inflammation (Elkington et al., 2011; Ong et al., 
2014). A higher percentage of the ECM protein would be expected in uninfected controls as 
they would be maintaining the normal functioning of the lungs. 
 
The proteomic analysis revealed other protein classes whose differential expression was 
interesting but their relationship to TB is poorly understood. For instance transfer/carrier 
proteins were two-fold higher in TB group than in the uninfected controls group. This 




understood proteins is a class of chaperones, which were higher in uninfected 
controlscompared to the TB BALs. These proteins can mediate a form of autophagy, in 
which some cytosolic proteins are targeted for degradation in the lysosomes (Kaushik and 
Cuervo, 2012). Autophagy is an important response in TB in that stimuli enabling cells that 
induce autophagy may kill intracellular M.tb (Bradfute et al., 2013). Hence detailed 
understanding of its relationship with chaperones in the context of the disease will likely 
yield exciting outcomes. 
 
The current study utilized a combination of proteomics and mass spectrometry to identify 
classes of proteins that can potentially be used as bio-signatures in TB. With a dire need for 
alternative diagnostics, expression trends of specific host proteins could be exploited into 





CHAPTER 5 : ISOLATION AND PURIFICATION OF MUCINS BY WESTERN 
BLOTTING 
 
5.1  Introduction  
 
In order to study the mechanism and ultimately the structure of proteins, the proteins must be 
purified (Berg et al., 2002; Garrett and Grisham, 2005). There is however no single universal 
method to isolate and purify all proteins as they vary in water solubility, size and charge. 
Mucins are high molecular weight glycoproteins that are large in size and mass. Additionally, 
mucins are polydisperse, extensively glycosylated, heterogeneous and have high viscosity in 
solution (Harding, 1989; Thornton et al., 1997). These characteristics are a limiting factor in the 
analysis of mucins as the majority of mucin subunits range between 200 kDa and 10 MDa (Issa 
et al., 2011). Holden et al., in 1971, reported that the tendency of mucins to form gels at 
moderate concentrations and their ability to adhere to supporting media suggests that they are 
held together by strong intermolecular forces (Holden et al., 1971). 
 
Over the past years considerable efforts have been made in developing techniques to separate 
and identify mucins in accordance with their large size and polydispersity. Sheehan et al. (1991) 
have shown that in order to study respiratory mucins, the integrity of the core protein must be 
maintained throughout the process of purification through the addition of denaturants and 
protease inhibitors to eliminate endogenous proteolytic activity.  Therefore mucous gels are 
extracted in 6M guanidinium hydrochloride (GuHCl) containing EDTA to limit 
metalloproteinases and NEM to suppress degradation by thiol proteinases (Carlstedt and 
Sheehan, 1984). 
 
(Creeth and Denborough, 1970) demonstrated the success of the use of a technique involving 
sedimentation equilibrium in a caesium chloride gradient when working with high molecular 
weight glycoproteins. Their findings were later supported by (Bhaskar and Reid, 1981) and 
(Woodward et al., 1982). The success of this technique has been crucial in the isolation and 





A few reports appear in the literature on the investigation of mucins by SDS polyacrylamide gel 
electrophoresis (PAGE) (Mall et al., 1999; Pearson et al., 1981). However purified mucins do not 
penetrate the acrylamide gels because of their large size and extensive glycosylation. In 1971, 
Holden et al. reported the use of agarose to facilitate the entry and migration of mucins in the 
gel. Agarose gel electrophoresis followed by Western blotting has thus, in more recent times, 
become the standard technique to investigate purified mucins after they have been reduced 
(Sheehan et al., 2004; Thornton et al., 1996). 
 
This chapter therefore aimed at evaluating the types of mucins secreted in TB and non-TB 
respiratory mucus. The specific objectives were to identify mucins by Western blotting firstly in 
crude material, namely tracheal aspirates from patients with non-lung disease, BALs with a 
variety of diseases, and TB sputa with the TB group HIV negative and positive and 2 cases of 
MDR-TB. The second approach was to identify mucins in the groups described after purification 
by CsCl density gradient ultracentrifugation. Mucins were subjected to Western blotting from 
individual fractions of the second density gradient ultra-centrifugation at a density of 1.39-1.40 
g/ml. 
 
5.2  Results  
 
5.2.1 Identification of respiratory mucins from crude samples  
 
Mucins were investigated in tracheal aspirates of patients undergoing surgery for non-
respiratory conditions, BALs (for various diseases, see methods section 2.3.1) and sputa 
collected from the patients without and with a diagnosis of TB. Crude mucus was reduced, 
alkylated, dialysed against water and lyophilised and subjected to electrophoresis on agarose 
gel (See methods section 2.6). Following electrophoresis the gels were transferred to 
nitrocellulose membranes and probed with anti-secretory mucin antibodies, namely, anti (-






5.2.1.1 Identification of mucins in crude tracheal aspirates of patients undergoing 
surgery for non-lung diseases controls/normal? 
 
Tracheal aspirates were collected by an anaesthetist from patients undergoing surgery for 
various reasons besides lung disease. These aspirates were designated uninfected controls. 
Mucins identified from tracheal aspirates from patients undergoing surgical procedures of non-
lung diseases are illustrated in Figure 5.1 (lanes 1-4). Distinct MUC5AC bands with similar 
electrophoretic mobility and intensity were observed from the normal tracheal aspirates. The 
MUC5AC band in lane 4 was larger and brighter than the bands in lanes 1-3. MUC5B appeared 
as a smear with varying electrophoretic mobility. MUC5B had migrated further down the gel in 
comparison to MUC5AC. Single distinct bands of MUC2 with similar electrophoretic mobility 
were observed whilst MUC7 migrated further into the gel, with each sample varying in mobility. 
 
 
Figure 5.1:  Agarose gel electrophoresis of reduced crude uninfected mucus from tracheal 
aspirates undergoing surgical procedures for non-lung diseases. 
Reduced and alkylated crude tracheal aspirate mucus was electrophoresed on a 0.7% agarose gel and subsequently 











5.2.1.2 Identification of mucins in crude bronchoalveolar lavage (BALs) from 
patients with a variety of lung diseases. 
 
Bronchoalveolar lavages were obtained from patients with suspected lung disease and 
underwent bronchoscopy. Notable differences were seen in the band intensities. Brighter 
MUC5AC bands were seen in samples from patients with and without TB indicating higher 
levels of MUC5AC in BALs (Figure 5.2). MUC5AC migrated to a similar position on the gel. 
Sarcoidosis comprised the largest group of the non-TB group. Despite similar electrophoretic 
mobility of MUC5AC within the sarcoidosis group, inter-individual variations were observed for 
equal loadings. One sarcoidosis patient had a very intense and widespread smear which 
suggested a wide range of charge for the MUC5AC population in this case (Figure 5.2). A similar 
observation was made for MUC5AC in alveolar proteinosis whilst pneumonia showed a clear 
single band. A single band of MUC5AC was seen in TB alone whilst the material from a patient 
with TB and HIV was a large bright smear, again suggesting the presence of more than one 
population of MUC5AC of varying charges.  
 
MUC5B appeared as a smear over a large area (Figure 5.2). This suggested the presence of 
different populations of MUC5B suggesting a heterogeneous distribution of this mucin. When 
compared to MUC5AC, the MUC5B material was less intense with hardly a band for TB and TB 
with HIV. MUC2 bands appeared to have similar electrophoretic mobility to MUC5AC (Figure 
5.3). When compared to MUC5AC, the MUC2 bands were fainter except one sarcoidosis 
patient. There is a more intense band for TB/HIV in MUC2 than in MUC5B. MUC7 was not 
detected in the BALs. The analysed BALs gave similar patterns in the migration of mucin bands 
for MUC5AC, MUC5B and MUC2 between the patients with and without TB. In all cases for 





Figure 5.2: Identification of reduced crude non-TB and TB mucus from crude bronchoalveolar 
lavages. 
Reduced and alkylated crude TB and non-TB BAL mucus was electrophoresed on a 0.7% agarose gel and 




5.2.1.3 Identification of mucins in crude sputa 
 
Sputa were obtained by expectoration from patients diagnosed with TB (see methods section 
2.3.3). Varying populations of MUC5AC and MUC5B mucins were observed in TB sputa as 
compared to the BALs in Figure 5.2. These populations are illustrated in Figure 5.3 (lanes 1-17). 
MUC5AC presented largely as a single band with similar electrophoretic mobility appearing as a 
smear with inter-individual variation. In some cases, MUC5AC was barely visible (Figure 5.4 
lanes 7 and 12). Figure 5.4 lane 15 had the brightest band with a much wider smear. Higher 






Figure 5.3: Identification of MUC5AC and MUC5B following agarose gel electrophoresis of 
reduced crude TB sputa. 
Reduced and alkylated crude TB sputa were electrophoresed on a 0.7% agarose gel and subsequently blotted onto 
nitrocellulose membrane. The blot was probed with anti (-MUC5AC and -MUC5B) antibodies. 
 
Interesting observations were made upon closer examination of the MUC5B from patients with 
TB. Two forms of MUC5B charges were observed from the samples loaded in lanes 8, 10, 15 
and 17 (Figure 5.3). The migration of MUC5B on the gel was similar in the samples of patients in 
lanes 10 and 15. On the contrary, the migration of MUC5B in samples of the patient in lane 8 
was lower on the gel compared to those in lanes 10 and 15. Three bands of MUC5B charges 
were observed from the samples in lanes 1 and 16 (Figure 5.3). The presence and appearance 
of the three MUC5B bands is a novel phenomenon in TB, of which the one with the highest 
mobility could be a protein (A Mall in personal communication with the late John Sheehan). 
Notable differences were seen in the migration of the three MUC5B bands on the gel from 
samples in lanes 1 and 16. The migration of MUC5B appeared higher in lane 1 indicative of high 
density population while a lower density population was observed in lane 16, lower on the gel.  
 
No MUC2 was present in the TB sputa. MUC7 bands appeared as a smear over a large area 
suggesting the presence of different populations of MUC7 (Figure 5.4). The material in lanes 12 
and 15 displayed the greatest heterogeneity. The MUC7 bands migrated further down the gel 
when compared to MUC5AC and MUC5B as depicted in Figure 5.3. There was much inter-





Figure 5.4: Identification of MUC2 and MUC7 following agarose gel electrophoresis of 
reduced crude TB sputa. 
Reduced and alkylated crude TB sputa were electrophoresed on a 0.7% agarose gel and subsequently blotted onto 
nitrocellulose membrane. The blot was probed with anti (-MUC2 and -MUC7) antibodies. 
 
In summary, in crude samples, all the mucins examined (MUC5AC, MUC5B, MUC2 and MUC7) 
were identified in uninfected controls. No MUC7 was found in BALs and no MUC2 was found in 
sputa. 
 
5.2.1.4 The presence of mucins in TB patients co-infected with HIV 
 
The reduced crude sputa were further assessed to determine whether there were differences 
between TB and TB co-infected with HIV. Tracheal aspirates from uninfected controls were 
compared to TB sputa. Very little variation in the intensities of the MUC5AC bands were 
observed between the samples from TB group and samples from the TB group co-infected with 
HIV (Figure 5.5). Slight variations in the migration of MUC5AC were observed between the TB 
group (TB group and TB group co-infected with HIV) and the uninfected controls.  There was 
very little variation in MUC5B band intensities between the samples within the TB group. 
MUC5B bands appeared as a smear suggesting the presence of more than one population of 
the mucin with varying charges (Figure 5.5). Generally, MUC5AC was higher in the TB group 
than that in uninfected controls. No MUC2 was detected in the TB group whilst a single band 






Figure 5.5: Comparison of MUC5AC and MUC5B in TB, TB/HIV and uninfected reduced crude 
respiratory mucus. 
Reduced and alkylated mucus was electrophoresed on a 0.7% agarose gel and subsequently blotted onto 




Figure 5.6: Comparison of MUC2 in TB, TB/HIV and uninfected reduced crude respiratory 
mucus. 
Reduced and alkylated mucus was electrophoresed on a 0.7% agarose gel and subsequently blotted onto 






5.2.1.5 Identification of respiratory mucins in Multi Drug Resistant (MDR)-TB 
 
Of the 63 patients with TB only 2 cases presented with MDR-TB. Following western blotting, no 
mucins were identified in MDR patients compared to the TB patients. A dot blot was thus 
conducted to validate the Western blot results. No mucins were detected in one of the MDR-TB 
cases. The second case showed higher levels of MUC5AC. MUC7 mucins were secreted in the 
MDR patient whilst traces of MUC5B and MUC2 were observed in uninfected controls (Figure 
5.7). The reduction and absence of secreted gel-forming mucins in MDR-TB prompted the 
investigation into determining whether reported membrane-bound mucins in the respiratory 
tract were present in this type of TB. A dot blot analysis of the membrane-bound mucins 
showed traces of MUC16 and the absence of MUC1 and MUC4 (Figure 5.8) in MDR-TB when 
compared to uninfected controls. 
 
 
Figure 5.7:Dot blot analysis of secreted mucins of MDR-TB sputum in comparison to tracheal 
aspirate of an uninfected control. 
Reduce and alkylated mucus from MDR-TB sputum and uninfected tracheal aspirate were dot blotted onto 








Figure 5.8: Dot blot analysis of membrane-bound mucins of MDR-TB sputum in comparison to 
tracheal aspirate of an uninfected control. 
Reduced and alkylated mucus from MDR-TB sputum and uninfected tracheal aspirate were dot blotted onto 
















5.2.2 Identification of respiratory mucins from purified samples  
 
5.2.2.1 Caesium chloride density gradient ultracentrifugation 
 
Mucus from patients with and without respiratory infections and diseases were collected in 
denaturing media (6M GuHCl and a cocktail of protease inhibitors; 10 mM EDTA, 5 mM NEM 
and 1 mM PMSF). The mucins were extracted by a two-step caesium chloride isopycnic density 
gradient ultra-centrifugation to remove protein and DNA contamination. Subsequently purified 
mucin fractions were desalted by dialysis, lyophilized and their masses determined and 
recorded. 
 
Through this technique, a clear separation of protein and mucins of the TB and non-TB mucus 
occurs as shown in Figure 5.9. Mucins fractionated at a density between 1.39 and 1.40 g/ml 





Figure 5.9:  Caesium chloride density-gradient ultra-centrifugation profiles of respiratory 
mucins. 
Freeze dried mucus was dissolved in 4M GuHCl containing protease inhibitors, and the density adjusted to 1.39 to 
1.40g/ml with solid CsCl. Density-gradient ultra-centrifugation was performed in a Beckman L45 ultracentrifuge for 
48h at 40 000 rpm (105 000 x g) at 4˚C, twice. Fractions from (A) sputa, (B) tracheal aspirates and (C) 
bronchoalveolar lavages were tested for PAS reactivity (absorbance at 540 nm) ( ), protein content using 










5.2.2.2 Identification of mucins from purified tracheal aspirates from uninfected 
controls  
 
The presence of mucins was investigated in each fraction collected after the second CsCl spin. 
Figure 5.10 illustrates the CsCl density gradient profile following the second spin. The mucin-
rich fractions were observed between fractions 5 and 7 with the mucin peak observed in 
fraction 6 (Figure 5.10). Figure 5.11 shows the different charge densities of MUC5AC and 
MUC5B following Western blotting. MUC5AC bands were observed in the middle of the gel. 
MUC5AC bands were observed in fraction 4 and traces were observed in fraction 8, which fell 
outside the mucin-rich fractions (fractions 5–7) as shown in Figure 5.11. The MUC5AC band in 
fraction 5 appeared as a smear in comparison to the other MUC5AC bands. MUC5AC bands 
appeared smaller than the MUC5B bands. MUC5B bands were observed in mucin-rich fractions 
and also in fractions 4 and 8. The bands appeared as large smears suggesting varying 
populations of MUC5B. MUC5B bands were observed higher on the gel in comparison to the 
MUC5AC bands. Furthermore, the size of the MUC5B smear appeared to increase with the 
density within the mucin-rich fractions (Figure 5.11). 
 
Increased band intensities of MUC2 were observed from the mucin-rich fractions Figure 5.12 
fractions 5-7). Traces of MUC2 were observed in Figure 5.12 fraction 4. The MUC5B band in 
fraction 5 appeared as a smear. MUC2 bands were observed lower on the gel compared to 
MUC5AC and MUC5B bands. No MUC7 mucins were detected from the purified mucin 
fractions. Varying levels of MUC5AC, MUC5B and MUC2 mucins were identified in the 
respiratory mucus of patients without TB. There were increased levels of MUC5B compared to 

















Figure 5.10: Caesium chloride density gradient ultra-centrifugation profile of purified tracheal 
aspirates of uninfected controls. 
Reduced tracheal aspirates was dissolved in 4M GuHCl containing protease inhibitors, and the density adjusted to 
1.39 to 1.40g/ml with solid CsCl. Density-gradient ultra-centrifugation was performed in a Beckman L45 
ultracentrifuge for 48h at 40 000 rpm (105 000 x g) at 4˚C, twice. Each fraction was tested for PAS reactivity 
(absorbance at 540 nm) ( ), protein content using Bradford assay (absorbance at 595 nm) ( ) and the 

















Figure 5.11: Identification of MUC5AC and MUC5B in purified fractions after second caesium 
gradient spin from tracheal aspirates of uninfected controls following agarose gel 
electrophoresis. 
Reduced and alkylated purified non-TB tracheal aspirate fractions were electrophoresed on a 0.7% agarose gel and 
subsequently blotted onto a nitrocellulose membrane. The blot was probed with anti-(MUC5AC and MUC5B) 
antibodies. C1 denotes positive control and C2 negative control. For MUC5AC, C1 = gastric mucus (MUC5AC) and 
C2 = colon mucus (MUC2). For MUC5B, C1 = saliva (MUC5B) and C2 = colon mucus (MUC2). 
 
 
Figure 5.12: Identification of MUC2 and MUC7 in purified fractions after second caesium 
gradient spin from tracheal aspirates of uninfected controls following agarose gel 
electrophoresis. 
Reduced and alkylated purified non-TB tracheal aspirate fractions after the second caesium gradient spin were 
electrophoresed on a 0.7% agarose gel and subsequently blotted onto a nitrocellulose membrane. The blot was 
probed with anti (-MUC2 and -MUC7) antibodies. C1 denotes positive control:  and C2 negative control. For MUC2, 







5.2.2.3 Identification of mucins from purified sputum from patients with TB 
 
The presence of mucins in sputum from patients with TB was investigated in each fraction 
collected after the second CsCl density-gradient ultra-centrifugation. Figure 5.13 shows the CsCl 
density-gradient profile following the second spin. The mucin-rich fractions were observed 
between fractions 5 and 7 with the mucin peak observed in fraction 6 densities (Figure 5.13). 
Following Western blotting, a single MUC5AC band was observed in all fractions and showed 
similar electrophoretic mobility in the gel (Figure 5.14). Traces of MUC5AC were observed in 
fractions 1, 2 and 9. Brighter bands were observed between fractions 3 and 8. There seemed to 
be a greater charge variation of the mucins in fractions 4 and 6 than in other fractions as the 
bands appeared as large smears (Figure 5.14). MUC5B was mainly observed in the late fractions 
(fractions 6 – 9 in Figure 5.14) at higher densities. Traces of MUC5B were noticed in fraction 4. 
MUC5B had similar charge migration on the gel except for fraction 6 which migrated less than 
the other fractions (Figure 5.14). 
 
 MUC2 was observed in the late fractions (fractions 6 – 9). Differing electrophoretic mobility of 
MUC2 populations were observed in fractions 6 and 8 (Figure 5.15). A single band of MUC7 
with low intensity was observed in fraction 6 within the mucin-rich fractions illustrated in figure 
5.15. The MUC7 band had migrated further than the other mucin bands. 
 
It was noteworthy that MUC5AC had brighter bands compared to MUC5B, MUC2 and MUC7 
mucin fractions. This indicated that there were higher levels of MUC5AC compared to MUC5B, 
MUC2 and MUC7 in the TB samples. Interestingly, MUC5AC and MUC5B mucin subunits 







Figure 5.13: Caesium chloride density gradient ultra-centrifugation profile of TB samples. 
Reduced sputum was dissolved in 4M GuHCl containing protease inhibitors and the density adjusted to 1.39 to 
1.40g/ml with solid CsCl. Density-gradient ultra-centrifugation was performed in a Beckman L45 ultracentrifuge for 
48h at 40 000 rpm (105 000 x g) at 4˚C, twice. Teach fraction was tested for PAS reactivity (absorbance at 540 nm) 
( ), protein content using Bradford assay (absorbance at 595 nm) ( ) and the density of each fraction was 
















Figure 5.14: Agarose gel electrophoresis of purified and reduced TB mucin fractions. 
Reduced and alkylated purified TB fractions were electrophoresed on a 0.7% agarose gel and subsequently blotted 





Figure 5.15: Agarose gel electrophoresis of purified and reduced TB mucins. 
Reduced and alkylated purified TB fractions were electrophoresed on a 0.7% agarose gel and subsequently blotted 
onto nitrocellulose membrane. The blot was probed with anti-(MUC7 and MUC2) antibodies. 
 
In summary, in purified samples, no MUC7 was identified in uninfected controls. In BALs, small 
yields of purified fractions were found following lyophilising. However, these small fractions 
were insufficient for Western blot analyses.  In sputa, all the mucins examined (MUC5AC, 
MUC5B, MUC2 and MUC7) were identified in uninfected controls. Table 5.1 below summarises 





Table 5.1: A summary of the secreted mucins in TB and non-TB mucus 
Diagnosis  Number of 
patients recruited 
MUC5AC MUC5B MUC2 MUC7 
Uninfected controls 17 17 17 4 12 
Definite TB - BALs 8 4 4 3 0 
Sarcoidosis 53 47 47 12 0 
Lung Cancer 4 4 3 1 0 
Pulmonary Alveolar Proteinosis 4 3 3 0 0 
Asthma 1 1 1 0 0 
Bronchiectasis 6 4 4 0 0 
Pneumonitis 5 5 5 2 0 
COPD 1 1 1 0 0 
Asbestosis 1 1 1 1 0 
Silicosis 2 1 1 1 0 
Interstitial Lung Disease 7 7 7 2 0 
LIP 3 1 1 1 0 














5.3 Discussion  
 
Initially, mucins were purified according to the CsCl density-gradient ultra-centrifugation as 
previously described by Creeth et al. (1977) and in later years by (Hovenberg et al., 1996; 
Thornton et al., 1996; Wickstrom et al., 1998). Following CsCl density-gradient 
ultracentrifugation, effective separation of mucins was assessed by PAS assay, protein 
determination and measuring the density of fractions from the isolation process.  However, 
using this technique, the yield of lyophilised material from each fraction was too small and in 
some cases resulted in loss of mucins. These losses and small yields of purified fractions 
hampered further analyses of the resulting mucin-rich fractions. It was thus decided to analyse 
crude reduced, alkylated and dialysed respiratory mucus as this resulted in higher yields of 
lyophilised material. Regardless of the small yield of mucins, purification by CsCl density-
gradient was successful as it showed clear separation of mucins from the proteins. However it 
did not indicate the inter-individual variations.  
 
In order to overcome the obstacle experienced by Thornton et al. (1995) where mucins did not 
readily enter the SDS PAGE, an agarose gel electrophoresis technique was employed according 
to (Tytgat et al., 1995). This technique separated mucins according to their charge instead of 
size. Once the mucins were separated by agarose gel electrophoresis the gel was vacuum 
blotted onto a nitrocellulose membrane for Western Blot analysis. 
 
Analysis by Western blot showed inter-individual variations in both the quantity (observed 
through intensities) and charge of the mucins in specimens from TB and uninfected controls. 
Upon examination, mucins were observed in non-mucin rich fractions (as seen in Figures 5.14 
and 5.15) with varying densities in the purified samples. This indicated broad mucin 
populations in TB. Broad mucin populations have been previously observed in the sputum of a 
chronic-bronchitic patient (Wickstrom et al., 1998). Mucins in both Figures 5.14 and 5.15 were 
examined in individual fractions following the second density gradient ultracentrifugation. This 
was carried out to examine the populations of mucins in each fraction. The use of this 
technique was inspired by Thornton et al. (1996) where they used the technique to analyse 





The overall electrophoretic mobility of MUC5AC on a gel is consistent in the TB and non-TB 
respiratory mucus from the tracheal aspirates, BALs and sputa. Therefore MUC5AC appears to 
be consistent with charge density. A phenomenon also observed by Thornton et al. (1996) that 
despite the variations in the level of MUC5AC mucin between respiratory samples, the 
electrophoretic mobility and charge density remains similar. In contrast, the electrophoretic 
mobility of MUC5B varied between individuals. This indicated the heterogeneous nature of 
MUC5B previously reported by (Wickstrom et al., 1998). The previous separation of MUC5B by 
Mono-Q chromatography indicated 2 differently charged states of the mucin (Thornton and 
Sheehan, 2004). In this study 3 glycoforms of MUC5B were observed in TB, the one with the 
greatest mobility possibly a protein (A. Mall in conversation with the late John Sheehan). 
 
In general, more MUC5AC than MUC5B was observed in both the TB and non-TB groups. 
Reports in literature have indicated that both MUC5AC and MUC5B are present in healthy 
individuals (Henke et al., 2004; Kirkham et al., 2002; Rose and Voynow, 2006). When comparing 
the TB group to the non-TB group higher levels of MUC5AC and MUC5B were observed in the 
TB group. These increased levels of MUC5AC and MUC5B might possibly indicate a defence 
mechanism employed in the fight against infection by Mycobacterium tuberculosis.  
 
MUC2 was mainly present in uninfected controls with only 2 cases in the TB group. A 
preliminary study on mucins in TB in our laboratory indicated the presence of MUC2 in adults 
with TB (Govender, 2006)The Govender study further demonstrated a pronounced doublet of 
MUC2 in TB. However, this study only found a single band of MUC2. Reports on MUC2 mucin in 
the respiratory tract indicate the presence of MUC2 in nasal epithelial cells, in the case of 
allergic rhinitis and laryngeal cancer respectively (Voynow et al., 1998).  MUC2 was further 
reported by (Vinall et al., 2000), to be associated with the protection of atopic individuals 
preventing them from developing asthma. The inconsistencies in the expression of MUC2 in 
this study might be as a result of the association of the MUC2 mucin with allergies (Takeuchi et 
al., 1995). 
 
No MUC7 mucins were detected from BALs. However, it was detected in sputa suggesting that 




respiratory mucus in order to limit contamination by salivary mucins. The rinsing of the mouth 
with water was encouraged before the expulsion of sputum. 
 
Two patients were found to be infected with MDR-TB within the TB group. Western blot 
analysis was carried out to identify the secreted mucins in MDR-TB. However, the experiments 
yielded negative results. It was thus decided to analyse the mucus on dot blots as the 
concentration of the mucins can be increased without using more sample. The dot blot analysis 
showed no detection of mucins in one case, while the other case mainly showed mucin 
depletion and traces of MUC5AC, MUC7 and MUC16. Upon further examination of the latter 
case, the MDR-TB patient was found to have Pseudomonasaeruginosa infection with resistance 
to the antibiotics administered. 
 
P. aeruginosa is an opportunistic pathogen. It is associated with both acute and chronic lung 
infections especially in people with Cystic Fibrosis (da Silva et al., 2013; Landry et al., 2006). A 
few reports on the interaction of P. aeruginosa and mucins have demonstrated that P. 
aeruginosa stimulated the production of MUC2 and MUC7 respectively (Li et al., 2006). The 
depletion of mucins in MDR-TB mucus suggested that there was mucin degradation by P. 
aeruginosa. Work by Aristoteli and Willcox (2003), on microbial keratitis in corneal ulceration 
demonstrated that mucin-depleting Pseudomonas strains have a long-term growth advantage 
implying that mucins were used as nutrient source in the progression of the infection. The 
MDR-TB patient produced high viscosity mucus although the depletion of mucins was noticed 
from the patient. The production of the high quantity of mucus was probably as a result of the 
presence of P. aeruginosa.   
 
This chapter of the study has demonstrated that both MUC5AC and MUC5B are the major 
secreted mucins in both TB and non-TB respiratory mucus. The secretion of MUC2 seems to be 
influenced by allergies. No MUC7 was found in BALs, indicating that mucins from the 












As mentioned in previous chapters, mucin apoproteins are rich in repetitive serine, 
threonine and proline amino acid residues often referred to as the STP-rich domain. As 
amino acids are the monomers of proteins, their analysis contributes towards the 
understanding of the structure of mucins and apomucins. Amino acid analysis is performed 
to estimate the quantitative amounts of amino acids present in a sample (Yan and Packer, 
2000). 
 
Once the respiratory mucins were isolated and purified as described in chapter 5, their 
amino acid composition was determined through amino acid analysis. Amino acid analysis is 
a valuable technique used to quantitatively estimate amino acids in a given sample (Yan and 
Packer, 2000). The technique involves the acid hydrolysis of amino acid peptide bonds, 
separation, derivatization and their detection (Dołowy and Pyka, 2014; Yan and Packer, 
2000). 
 
The aim of this chapter was to determine amino acid content of mucins by HPLC from 





The carbohydrate side chains were hydrolysed from the purified mucins to yield 
polysaccharide-free polypeptide chains. The amino acid composition of the purified mucins 
was determined by HPLC analysis employing a polystyrene-divinylbenzene cross-linked 
cation-exchange resin with post-column orthophthalaldehyde (OPA) fluorescence detection. 
In order to determine proline residues, a sodium hypochlorite reagent was allowed to react 
with proline on the column in order to convert it into an OPA-detectable derivative.   The 
respiratory mucins were found to contain high amounts of threonine, serine and glutamic 




glutamic acid was observed in patients co-infected with HIV. The identified amino acids are 
presented in Table 6.1. The threonine, serine and proline amino acids which are the 
distinguishing characteristic in mucins were 28.9% in non-TB, 28.7 % in non-TB/HIV, 26.7 % 
in TB and 28.0 % in TB/HIV.  
 
 
Table 6.1: Amino acid composition of purified mucins in TB and non-TB 








Aspartic acid 8.4 8.6 8.9 8.4 
Threonine  10.1 10.8 10.3 10.3 
Serine  9.9 10.2 8.8 9.0 
Glutamic acid 10.4 10.8 10.3 11.0 
Proline 8.9 7.7 7.6 8.7 
Glycine 7.0 6.8 7.0 7.4 
Alanine  6.9 6.6 7.5 7.9 
Valine  7.0 7.6 8.1 7.0 
Methionine  0.9 0.7 0.8 0.9 
Isoleucine  3.3 2.8 3.0 3.2 
Leucine 8.4 8.6 8.5 8.2 
Tyrosine 3.6 4.6 4.2 3.1 
Phenylalanine  3.7 3.8 4.0 3.8 
Histidine 3.6 3.4 3.5 3.8 
Lysine 3.6 3.4 3.6 3.2 
Arginine  4.3 3.6 3.9 4.1 












There were no significant differences in the amino acid composition between the TB and 
non-TB groups. No significant differences were observed in the percentage of the STP amino 
acid residue. Increased amounts were noted in glutamic acid, leucine, aspartic acid, valine, 
glycine and alanine amino acids. The significance in the increase of these amino acids is 
unknown. Following the analysis of amino acids, the mucus was further analysed to 













Mucins as glycoproteins form part of proteins that are post-translationally modified. The 
most common modifications widely described in proteins are glycosylation, hydroxylation, 
acetylation phosphorylation and ubiquitation (Karve and Cheema, 2011). Glycosylation 
influences protein conformation, flexibility, charge and hydrophobicity (Blixt and 
Westerlind, 2014; Takahashi et al., 2009). Mucins are characterized by extensive stretches 
of O-glycosylation. O-glycosylation is the most abundant form of glycosylation that plays a 
role in cell adhesion (Fukuda, 2002). This most common type of glycosylation is 
characterised by the addition of N-acetylgalactosamine (GalNAc) to the hydroxyl group of 
either serine or threonine residues (Brockhausen et al., 2009; Tian and Ten Hagen, 2009). 
This is the simplest O-glycan and it is called the Tn antigen. The Tn antigen can be extended 
to form eight different inner core structures; with core 1 through 4 being the most common 
O-glycan core structures (Brockhausen et al., 2009; Cherian et al., 2015). Furthermore the 
latter core structures have been shown to occur as extended, complex O-glycans that carry 
antigens for ABO blood group and Lewis type. 
 
Short O-GalNAc glycans can be further elongated to form complex O-glycans that terminate 
in sialic acid, fucose, sulfate, antigens for ABO and Lewis blood group determinants. The 
function of the O-linked glycans includes protection against pathogens, i.e. reports on sialic 
acid have shown that it serves as a binding site for various pathogens and toxins (Schauer, 
2009, 2004; Varki, 2008). Mucins play a pivotal role in the mucosal defence by binding 
bacteria through the adhesions on the bacterial membranes (Sonawane et al., 2012; 
Widdicombe, 1995). However, the specificity is dependent on the types of sialic acid, 
modifications and linkages to the oligosaccharide side chains (3 or 6-linked sialic acid). 
 
The aim of this chapter was to determine and describe the O-glycans found in respiratory 
mucus. The specific objectives were to identify oligosaccharides from proteins of the mucus 




elimination.  Crude mucus was reduced, alkylated, dialysed against water, lyophilised and 
then separated on a composite gel (AgPAGE) and 3-8% SDS-NuPAGE by electrophoresis. 
Separated proteins were then blotted on PVDF membrane and subsequently stained with 
Alcian Blue to visualise the glycoproteins bands. The mucin bands were excised and 
subjected to reducative β-elimination (Schulz et al., 2002). Released O-glycans were 
analysed by LC-MS/MS in negative-ion mode as described previously (Schulz et al., 2002). 
Three samples were analysed from the uninfected controls group, BALs group and Sputa 




7.2.1. SDS PAGE analysis 
 
Oligosaccharides were investigated in TB and non-TB. Non-TB mucus samples were collected 
from tracheal aspirates of patients undergoing surgery for non-respiratory conditions (see 
methods section 2.3.1). The samples are the uninfected controls. TB mucus samples were 
collected from bronchoalveolar lavages (BALs) and sputa. Three samples were analysed 
from each group. 
 
In the uninfected controls, all glycoprotein bands were seen above 250 kDa. Two 
glycoprotein bands were observed from one uninfected control (sample 1). Only one 
glycoprotein band was observed from the remaining two samples (uninfected control 2 and 
3) in the group (Figure 7.1). One glycoprotein band was also observed in all the BAL 1-3 
samples (Figure 7.1). Again, the observed glycoprotein bands were above 250 kDa. In sputa, 
glycoproteins with varying molecular weights between the 150 kDa mark and above were 
observed in lanes 8 and 10 (Figure 7.1). The remaining sample only had one band above 250 
kDa. The MDR sample showed a similar pattern to sputa of varying molecular weights 
between the 150 kDa mark and above. When comparing samples, the glycoprotein bands 
from the uninfected controls’ samples, sputa samples and the MDR sample were brighter 
than the bands from the BAL samples. BAL 1-2 samples appeared fainter than the BAL 3 







Figure 7.1: A 3-8% SDS-NuPAGE analysis of oligosaccharides in respiratory mucus from 
uninfected controls and in TB. 
Respiratory mucus was reduced and alkylated, separated by 3-8% Tris-acetate NuPAGE, blotted onto 
polyvinylidene fluoride (PVDF) membrane and stained with Alcian Blue. Oligosaccharide bands (indicated with 
black arrows). MW is the molecular weight marker lane. Lanes 2-4: represent biological replicates of tracheal 
aspirates from uninfected controls. Lanes 5-7: biological replicates of bronchoalveolar lavages (BALs) from 
patients with TB. Lanes 8-10: biological replicates of sputa for patients with TB; Lanes 11: sputum from a 
patient with multi-drug resistant (MDR) TB. 
 
7.2.2. LC-MS analysis of O-glycans 
 
In order to analyse the O-glycans, the glycoprotein bands were excised from the blot 
generated in Figure 7.1. The O-glycans were then released from the blot by reductive 




coupled to electrospray tandem mass spectrometry (LC-ESI-MS/MS) and their LC 
chromatograms are illustrated in Figure 7.2.  
 
Five core types of O-glycans were detected, namely; core 1, core 2, core 3, core 4 and core 
5. High amounts of cores 1, 2, 3 and 4 were detected in uninfected controls (Figure 7.1 and 
Table 7.1). Sialyl-Tn angtigens were also detected at lower amounts of an average of 5.2%. 
Small amounts of core 5 glycans (˂ 1%) were detected in uninfected controls.  
 
High amounts of cores 1 and 2 glycans were detected in BALs. The BAL 1 and 2 were co-
infected with HIV. No core 3 glycans were detected in sample 1, while 0.5% was detected in 
sample 2 and 35.8% detected in sample 3. No core 4 and core 5 glycans were detected in 
BAL 1 and 2. Compared to BAL 1 and 2, 35.8%, 7.4% and 1.3% of core 3, core 4 and core 5 
glycans were detected in BAL 3 (Table 7.1).  
 
A similar pattern observed in uninfected controls was noticed in sputa. High amounts of 
cores 1, 2, 3 and 4 were detected in sputa with Sialyl-Tn antigens detected in samples 2 and 
3. High amounts of core 1 and core 2 were detected in the MDR sample. Lower amounts of 
core 3 and the Tn antigens were detected in MDR at 7.3% and 5.4% respectively.  
 
More sulfation of the core 1 structures was observed when compared to sialylation and 
fucosylation in uninfected controls. Core 2 structures consisted mainly of fucosylated and 
α2,3-linked sialic acid as compared to sulfated glycans. Core 3 structures consisted of both 
α2,3-linked sialic acid and α2,6-linked sialic acid. However, more α2,6-linked sialic acid were 
observed from the structures. Fucosylation and sulphation of core 3 structures was also 
observed. However, more structures were sialylated and fucoslylated than sulfated. Core 4 
structures were sialylated, fucosylated and sulfated. No significant differences were noticed 
with the distribution of the modifications among samples. More α2,3-linked sialic acids were 
noted.  
 
In general, the majority of the O-glycans were sialylated. The majority of fucosylated O-
glycans were associated to blood type and Lewis type. Sulphation of the glycans were found 






Figure 7.2: LC-MS chromatograms of respiratory mucus in uninfected controls and in TB. 
Mass spectra from liquid chromatography-mass spectrometry (LC-MS) of O-glycans released from respiratory mucus separated by SDS-AgPAGE and blotted to PVDF. A: 
Tracheal aspirate from uninfected controls. B: Bronchoalveolar lavage (BAL) from patient with TB. C: Sputum from patient with TB. D: Sputum from patient with multi-drug 




Table 7.1: Percentages of the relative amounts of the different putative O-glycan structures detected using LC-MS 









1 2 3 1 2 3 1 2 3 MDR 
384 Hex1HexNAc1 Galβ1-3GalNAcol 1 – – 4.7 6.1 2.8 6.9 2.9 1.8 0.6 1.6 2.5 3.3 
425 HexNAc2 GlcNAcβ1-3GalNAcol 3 – – – – 1.2 – – 1.2 0.2 1.8 0.8 – 
464 Hex1HexNAc1Sul1 S-Galβ1-3GalNAcol 1 – – – – – – – – – – 1.1 – 
513 NeuAc1HexNAc1 NeuAcα2-6GalNAcol 0 – – 1.9 5.2 3.2 6.5 3.8 2.9 – 3.9 3.0 5.4 
530 Hex1HexNAc1dHex1 Fucα1-2Galβ1-3GalNAcol 1 H – – 4.9 3.5 8.4 3.2 2.6 5.4 5.2 2.3 3.2 
587-1 Hex1HexNAc2 Galβ1-3(GlcNAcβ1-6)GalNAcol 2 – – 0.7 1.0 0.7 – – – 0.2 0.8 1.1 – 
587-2 Hex1HexNAc2 GlcNAcβ1-3Galβ1-3GalNAcol 1 – – – 1.0 0.8 – – – – – – – 
587-3 Hex1HexNAc2 Galβ1-4GlcNAcβ1-3GalNAcol 3 – – 0.4 0.9 1.0 – 0.5 1.9 2.1 2.1 1.3 1.4 
587-4 Hex1HexNAc2 Galβ1-3GlcNAcβ1-3GalNAcol 3 – – 2.5 2.3 1.1 – – – 3.5 0.2 1.5 – 
628 HexNAc3 GlcNAcβ1-3(GlcNAcβ1-6)GalNAcol 4 – – – – 0.4 – – – – 0.7 0.4 – 
667-1 Hex1HexNAc2Sul1 Galβ1-3(6SGlcNAcβ1-6)GalNAcol 2 – – – – – – – – 0.4 – 0.3 – 
667-2 Hex1HexNAc2Sul1 Gal-(S)GlcNAcβ1-3GalNAcol 3 – – – – – – – – – – 0.6 – 
667-3 Hex1HexNAc2Sul1 Gal-(S)GlcNAcβ1-3GalNAcol 3 – – 0.9 – 0.2 – – 0.4 – – 0.5 – 
675-1 NeuAc1Hex1HexNAc1 Galβ1-3(NeuAcα2-6)GalNAcol 1 – – 2.0 7.4 3.5 6.6 5.9 3.7 3.3 3.8 4.2 4.9 
675-2 NeuAc1Hex1HexNAc1 NeuAcαα2-3Galβ1-3GalNAcol 1 – – 1.7 3.8 1.4 3.6 3.7 2.1 1.2 1.9 2.0 2.1 
716-1 NeuAc1HexNAc2 GlcNAcβ1-3(NeuAcα2-6)GalNAcol 3 – – 1.0 1.3 0.9 – – 4.3 1.4 1.2 0.9 1.2 
716-2 NeuAc1HexNAc2 GalNAcα1-3(NeuAcα2-6)GalNAcol 5 – – – 0.7 0.4 – – 0.6 0.6 0.6 0.6 1.3 
733-1 Hex1HexNAc2dHex1 Galβ1-3(Fucα1-4)GlcNAcβ1-3GalNAcol 3 – a/x 1.3 – 0.6 – – 1.0 – 0.6 – – 
733-2 Hex1HexNAc2dHex1 Galβ1-4(Fucα1-3)GlcNAcβ1-3GalNAcol 3 – a/x 0.2 – – – – – – – – – 
733-3 Hex1HexNAc2dHex1 Fucα1-2Galβ1-3GlcNAcβ1-3GalNAcol 3 H – – – 1.5 – – 0.5 – 1.2 1.9 1.4 
733-4 Hex1HexNAc2dHex1 Fucα1-2(GalNAcα1-3)Galβ1-3GalNAcol 1 A – – – – – 2.6 – – – – – 
733-5 Hex1HexNAc2dHex1 Fucα1-2Galβ1-4GlcNAcβ1-3GalNAcol 3 H – – – 0.3 – – 0.4 – 1.6 0.5 1.0 
733-6 Hex1HexNAc2dHex1 Fucα1-2Galβ1-3(GlcNAcβ1-6)GalNAcol 2 H – – – 0.4 – – – – 0.3 0.2 1.1 
749-1 Hex2HexNAc2 Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcol 2 – – 1.7 3.8 3.3 4.6 2.1 0.9 3.3 1.5 3.1 0.5 








1 2 3 1 2 3 1 2 3 MDR 
790-1 Hex1HexNAc3 GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcol 4 – – 0.6 – 0.9 – – – 1.2 1.0 0.5 0.3 
790-2 Hex1HexNAc3 Galβ1-4GlcNAcβ1-3(GlcNAcβ1-6)GalNAcol 4 – – 0.1 – 0.4 – – – – – 0.1 – 
813-1 Hex1HexNAc2dHex1Sul1 Gal(Fuc)(6S)GlcNAcβ1-3GalNAcol 3 – – 1.9 – – – – – – – – – 
813-2 Hex1HexNAc2dHex1Sul1 Fucα1-2Gal-(S)GlcNAcβ1-3GalNAcol 3 H – 0.0 – – – – 0.2 – 0.1 0.3 – 
813-3 Hex1HexNAc2dHex1Sul1 S-Gal(Fuc)GlcNAcβ1-3GalNAcol 3 – a/x 1.8 – – – – – – – – – 
813-4 Hex1HexNAc2dHex1Sul1 Fucα1-2Gal-(S)GlcNAcβ1-3GalNAcol 3 H – – – – – – – – 0.2 0.2 – 
813-5 Hex1HexNAc2dHex1Sul1 Fucα1-2Galβ1,3(6S-GlcNAcβ1,6)GalNAcol 2 H – – – – 3.6 – – – 0.3 0.4 – 
821 NeuAc1Hex1HexNAc1dHex
1 
Fucα1-2Galβ1-3(NeuAcα2-6)GalNAcol 1 H – – 7.5 3.5 5.0 4.7 0.4 – 2.8 0.8 3.2 
829-1 Hex2HexNAc2Sul1 Galβ1-3[Galβ1-4(6S)GlcNAcβ1-6]GalNAcol 2 – – – – 0.2 – – – 0.5 0.0 0.6 – 
829-2 Hex2HexNAc2Sul1 Gal(S)GlcNAc-Galβ1-3GalNAcol 1 – – – – 0.3 – – – – – – – 
829-3 Hex2HexNAc2Sul1 Gal-GlcNAc-(S)Galβ1-3GalNAcol 1 – – 1.2 5.5 0.9 – 2.3 0.4 2.4 0.4 3.1 – 
829-4 Hex2HexNAc2Sul1 Gal-GlcNAc-(S)Galβ1-3GalNAcol 1 – – – – 0.8 – – – – 0.4 – – 
870 Hex1HexNAc3Sul1 S+GlcNAcβ1-3(Gal-GlcNAcβ1-6)GalNAcol 4 – – – – – – – – –  0.7 – 
878-1 NeuAc1Hex1HexNAc2 Gal-GlcNAcβ1-3(NeuAcα2-6)GalNAcol 3 – – 0.5 6.2 0.8 – – 2.7 0.9 1.0 1.1 – 
878-2 NeuAc1Hex1HexNAc2 GlcNAcβ1-4Galβ1-3(NeuAcα2-6)GalNAcol 1 – – 3.9 2.8 0.8 – – – 2.7 – 0.3 – 
878-3 NeuAc1Hex1HexNAc2 NeuAcα2-6Galβ1-4GlcNAcβ1-3GalNAcol 3 – – – – – – – 0.5 – – – – 
878-4 NeuAc1Hex1HexNAc2 NeuAcα2-3Galβ1-3(GlcNAcβ1-6)GalNAcol 1 – – – – 0.4 – – – 0.3 0.3 0.3 1.2 
878-5 NeuAc1Hex1HexNAc2 NeuAcα2-3Galβ1-4GlcNAcβ1-3GalNAcol 3 – – – – 0.2 – – 6.7 2.8 1.3 0.5 – 
879 Hex1HexNAc2dHex2 Fucα1-2Gal(Fuc)GlcNAcβ1-3GalNAcol 3 H b/y – – – – – – – – – 0.7 
895-1 Hex2HexNAc2dHex1 Galβ1-3[Gal(Fuc)GlcNAcβ1-6]GalNAcol 2 – a/x 1.7 1.4 0.9 – – 0.9 – 0.6 1.3 – 
895-2 Hex2HexNAc2dHex1 Galβ1-3[Gal(Fuc)GlcNAcβ1-6]GalNAcol 2 – a/x 0.3 – – – – – – – – – 
895-3 Hex2HexNAc2dHex1 Gal(Fuc)GlcNAc-Galβ1-3GalNAcol 1 – a/x – 1.5 0.4 – – – – – 0.2 0.7 
895-4 Hex2HexNAc2dHex1 Gal(Fuc)GlcNAc-Galβ1-3GalNAcol 1 – a/x – 1.7 0.7 – – – – – 0.1 0.0 
895-5 Hex2HexNAc2dHex1 Galβ1-3(Fucα1-2Galβ1-4GlcNAcβ1-6)GalNAcol 2 H – – 0.8 0.6 5.2 – – – 1.0 0.9 1.9 
895-6 Hex2HexNAc2dHex1 Fucα1-2Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcol 2 H – – 6.0 1.8 6.8 1.4 0.2 – 1.0 1.2 1.5 
936-1 Hex1HexNAc3dHex1 Fucα1-2Gal-GlcNAcβ1-3(GlcNAcβ1-6)GalNAcol 4 H – – – 0.2 – – – – – – – 
936-2 Hex1HexNAc3dHex1 GlcNAcβ1-3(Fucα1-2Galβ1-4GlcNAcβ1-6)GalNAcol 4 H – – – 0.8 – – – – 2.9 0.6 1.7 
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959 Hex1HexNAc2dHex2Sul1 Fucα1-2Gal-(Fuc)(S)GlcNAcβ1-3GalNAcol 3 H b/y – – – – – – – 0.6 – – 
966 NeuAc2Hex1HexNAc1 NeuAcα2-3Galβ1-3(NeuAcα2-6)GalNAcol 1 – – – – 1.0 1.9 10.8 1.5  1.6 0.7 4.2 
975-1 Hex2HexNAc2dHex1Sul1 Gal(Fuc)(6S)GlcNAc-Galβ1-3GalNAcol 1 – a/x 3.0 – 1.4 – – – 0.7 0.2 0.2 – 
975-2 Hex2HexNAc2dHex1Sul1 Gal(Fuc)(6S)GlcNAc-Galβ1-3GalNAcol 1 – a/x – – – – – – 1.6 – 0.7 – 
975-3 Hex2HexNAc2dHex1Sul1 S+Galβ1-3(Fucα1-2Galβ1-4GlcNAcβ1-6)GalNAcol 2 H – – – – – – – – – 0.5 – 
975-4 Hex2HexNAc2dHex1Sul1 Galβ1-3[Gal(Fuc)(S)GlcNAcβ1-6]GalNAcol 2 – a/x – – 0.3 – – – – – – – 
975-5 Hex2HexNAc2dHex1Sul1 Fucα1-2Galβ1-3[Galβ1-4(6S)GlcNAcβ1-6]GalNAcol 2 H – – – 1.0 7.0 – 0.5 – 1.1 3.6 – 
1024-1 NeuAc1Hex1HexNAc2dHex
1 
Fuc(Gal)GlcNAcβ1-3(NeuAcα2-6)GalNAcol 3 – a/x 2.6 – 1.2 – – 2.4 – – – – 
1024-2 NeuAc1Hex1HexNAc2dHex
1 
Fuc(Gal)GlcNAcβ1-3(NeuAcα2-6)GalNAcol 3 – a/x 0.9 – – – – – – – – – 
1024-3 NeuAc1Hex1HexNAc2dHex
1 
NeuAcα2-3Gal(Fuc)GlcNAcβ1-3GalNAcol 3 – a/x – – – – – 2.8 0.4 0.3 0.3 – 
1024-4 NeuAc1Hex1HexNAc2dHex
1 
Fucα1-2Galβ-GlcNAcβ1-3(NeuAcα2-6)GalNAcol 3 H – – – 0.5 – – – –  0.6 – 
1024-5 NeuAc1Hex1HexNAc2dHex
1 
Fucα1-2Galβ-GlcNAcβ1-3(NeuAcα2-6)GalNAcol 3 H – – – 0.4 – – 0.4 – 1.0 0.5 – 
1032-1 Hex2HexNAc3Sul1 S + GlcNAcβ1-3Galβ1-3Gal(Galβ1-4GlcNAcβ1-6)GalNAcol 2 – – 0.6 – 0.5 – – – 0.5 – 0.4 – 
1032-2 Hex2HexNAc3Sul1 Gal-GlcNAcβ1--3[Gal-(S)GlcNAcβ1-6]GalNAcol 4 – – 1.0 – 1.1 – – – 2.3 – 1.8 – 
1040-1 NeuAc1Hex2HexNAc2 Galβ1-4GlcNAcβ1-3Galβ1-3(NeuAcα2-6)GalNAcol 1 – – – 8.7 1.8 4.0 4.1 2.0 0.8 1.1 0.9 2.3 
1040-2 NeuAc1Hex2HexNAc2 NeuAcα2-3Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcol 2 – – 0.8 7.9 1.1 6.3 4.1 0.3 1.4 0.8 0.8 2.1 
1040-3 NeuAc1Hex2HexNAc2 Galβ1-3(NeuAcα2-3Galβ1-4GlcNAcβ1-6)GalNAcol 2 – – 1.0 6.8 0.5 5.3 5.1 3.6 4.4 3.5 3.0 0.7 
1041-1 Hex2HexNAc2dHex2 Fucα1-2Gal(Fuc)GlcNAcβ1-3Galβ1-3GalNAcol 1 H b/y – – – – – – – 0.4 – 1.5 
1041-2 Hex2HexNAc2dHex2 Gal(Fuc)GlcNAc-(Fuc)Galβ1-3GalNAcol 1  a/x – – 0.2 – – – – 0.3 – – 
1041-3 Hex2HexNAc2dHex2 Fucα1-2Gal(Fuc)GlcNAcβ1-3Galβ1-3GalNAcol 1 H b/y – – 0.4 – – – – 0.2 – – 
1041-4 Hex2HexNAc2dHex2 Fucα1-2Galβ1-3(Fucα1-2Galβ1-4GlcNAcβ1-6)GalNAcol 2 H – – – 1.1 5.4 – – – 3.2 – 1.0 
1081 NeuAc1Hex1HexNAc3 GlcNAcβ1-3(NeuAcα2-3Galβ1-4GlcNAcβ1-6)GalNAcol 4 – – – – 0.9 – – 1.1 2.9 2.8 1.2 3.3 
1098-1 Hex2HexNAc3dHex1 Galβ1-3[Fucα1-2(GalNAcα1-3)Galβ1-4GlcNAcβ1-6]GalNAcol 2 A – – – 1.0 – 2.5 – – – – – 
1098-2 Hex2HexNAc3dHex1 Gal(Fuc)GlcNAc-Galβ1-3(GlcNAcβ1-6)GalNAcol 2 – a/x – – 0.4 – – – – – – – 
1098-3 Hex2HexNAc3dHex1 Gal(Fuc)GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcol 4 – a/x – – 1.0 – – – – 0.6 0.5 0.9 
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1098-5 Hex2HexNAc3dHex1 Fucα1-2Galβ1-4GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcol 4 H – – – 0.4 – – – – 0.7 0.4 – 
1104-1 NeuAc1Hex1HexNAc2dHex
1Sul1 
NeuAcα2-3(S)Gal(Fuc)GlcNAcβ1-3GalNAcol 3 – a/x 2.0 – – – – – – – – – 
1104-2 NeuAc1Hex1HexNAc2dHex
1Sul1 
NeuAcα2-3Gal(Fuc)(6S)GlcNAcβ1-3GalNAcol 3 – a/x 2.3 – – – – – – – – – 
1112 Hex2HexNAc3Sul2 2S+Gal-GlcNAcβ1-3(GalGlcNAcβ1-6)GalNAcol 4 – – – – – – – – – – – – 
1114-1 Hex3HexNAc3 Gal-GlcNAcb1-3Galb1-3(Galb1-4GlcNAcb1-6)GalNAcol 2 – – 0.7 – 0.7 – – – 0.6 – – – 
1114-2 Hex3HexNAc3 Galβ1-3(Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-6)GalNAcol 2 – – – – 0.1 – – – – – – – 
1120 NeuAc1Hex2HexNAc2Sul1 S + Galβ1-4GlcNAcβ1-3Galβ1-3(NeuAcα2-6)GalNAcol 1 – – – – 3.3 – – – – – 0.4 – 
1121-1 Hex2HexNAc2dHex2Sul1 Fucα1-2Galβ1-3[Fucα1-2Gal(S)GlcNAcβ1-6]GalNAcol 2 – – – – – – – – – 0.8 1.5 – 
1121-2 Hex2HexNAc2dHex2Sul1 Fucα1-2Galβ1-3[Fucα1-2Galβ1-4(6S)GlcNAcβ1-6]GalNAcol 2 – – – – 1.0 – – 0.9 – 0.8 1.5 – 
1169 NeuAc2Hex1HexNAc2 NeuAcα2-3Galβ1-4GlcNAcβ1-3(NeuAcα2-6)GalNAcol 3 – – – –  – – 4.6 – – – – 
1170 NeuAc1Hex1HexNAc2dHex
2 
Fucα1-2Gal(Fuc)GlcNAcβ1-3(NeuAcα2-6)GalNAcol 3 – b/y – – 0.4 – – 1.1 – 0.6 – 1.5 
1178-1 Hex2HexNAc3dHex1Sul1 Gal-GlcNAcβ1-3[Gal(Fuc)(6S)GlcNAcβ1-6]GalNAcol 4 – a/x 0.8 – – – – – – – – – 
1178-2 Hex2HexNAc3dHex1Sul1 Gal-GlcNAc-(Fuc)Gal-(S)GlcNAcβ1-3GalNAcol 3 – – 3.4 – 1.1 – – – 1.0 – 0.1 – 
1178-3 Hex2HexNAc3dHex1Sul1 Fucα1-2Gal-GlcNAcβ1-3(S-Gal-GlcNAcβ1-6)GalNAcol 4 H – – –  – – – – – 0.4 – 
1178-4 Hex2HexNAc3dHex1Sul1 Fucα1-2Gal-GlcNAcβ1-3(S-Gal-GlcNAcβ1-6)GalNAcol 4 H – – – 0.6 – – 0.8 – 1.0 3.6 – 
1178-5 Hex2HexNAc3dHex1Sul1 Fucα1-2Gal-GlcNAcβ1-3(S-Gal-GlcNAcβ1-6)GalNAcol 4 H – – – – – – – – 0.7 0.8 – 
1186-1 NeuAc1Hex2HexNAc2dHex
1 
Gal(Fuc)GlcNAc-Galβ1-3(NeuAcα2-6)GalNAcol 1 – a/x – – 0.1 – – – – – – – 
1186-2 NeuAc1Hex2HexNAc2dHex
1 
Galβ1-3[NeuAcα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-6]GalNAcol 2 – a/x 1.4 – 0.9  1.4 2.3 1.5 0.7 0.8 1.3 
1186-3 NeuAc1Hex2HexNAc2dHex
1 
Galβ1-3[NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-6]GalNAcol 2 – a/x 1.5 – – – – – 0.8 – – – 
1186-4 NeuAc1Hex2HexNAc2dHex
1 
NeuAcα2-3Galβ1-3(Fucα1-2Galβ1-4GlcNAcβ1-6)GalNAcol 2 H – – – 0.6 – – – – 1.2 0.6 1.8 
1186-5 NeuAc1Hex2HexNAc2dHex
1 
NeuAcα2-3Galβ1-3[Gal(Fuc)GlcNAcβ1-6]GalNAcol 2 – a/x – – 0.5 – – 0.7 – 0.6 – – 
1186-6 NeuAc1Hex2HexNAc2dHex
1 
Fucα1-2Galβ1-3(NeuAcα2-3Galβ1-4GlcNAcβ1-6)GalNAcol 2 H  – – 1.5 4.1 – 2.1 – 2.6 1.4 3.3 
1187 Hex2HexNAc2dHex3 Fucα1-2Galβ1-3[Fucα1-2Gal(Fuc)GlcNAcβ1-6]GalNAcol 2 H b/y – – 0.8 – – – – – – 1.0 
1194-1 Hex3HexNAc3Sul1 S + Galβ1-3(Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-
6)GalNAcol 
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1194-2 Hex3HexNAc3Sul1 S + Gal-GlcNAc-Gal-GlcNAc-Galβ1-3GalNAcol 1 – – – – 0.5 – – – – – – – 
1227 NeuAc1Hex1HexNAc3dHex
1 
GlcNAcβ1-3[NeuAcα2-3Gal(Fuc)GlcNAcβ1-6]GalNAcol 4 – a/x – – – – – 0.7 0.6 – – – 
1243-1 NeuAc1Hex2HexNAc3 NeuAcα2-6Galβ1-4GlcNAcβ1-3(Galβ1-4GlcNAcβ1-
6)GalNAcol 
4 – – 6.6 – 1.4 – – 0.8 7.1 1.7 0.7 – 
1243-2 NeuAc1Hex2HexNAc3 NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3GalNAcol 3 – – – – – – – 0.6 – – – – 
1244-1 Hex2HexNAc3dHex2 Gal(Fuc)GlcNAcβ1-3[Gal(Fuc)GlcNAcβ1-6]GalNAcol 4 – a/x – – 0.2 – – – – – – – 
1244-2 Hex2HexNAc3dHex2 Fucα1-2Galβ1-4GlcNAcβ1-3(Fucα1-2Galβ1-3GlcNAcβ1-
6)GalNAcol 
4 H – – – 0.9 – – – – 1.4 0.7 1.6 
1244-3 Hex2HexNAc3dHex2 Fucα1-2Galβ1-4GlcNAcβ1-3(Fucα1-2Galβ1-4GlcNAcβ1-
6)GalNAcol 
4 H – – – 0.4 – – – – 2.0 0.4 2.5 
1258 Hex2HexNAc3dHex1Sul2 S-Gal-GlcNAcβ1-3[Gal(Fuc)(6S)GlcNAcβ1-6]GalNAcol 4 – a/x 4.0 –  – – – – – 0.9 – 
1266-1 NeuAc1Hex2HexNAc2dHex
1Sul1 
S + NeuAcα2-3Galβ1-3[Gal(Fuc)GlcNAcβ1-6]GalNAcol 2 – a/x – – 0.9 – – – – – – – 
1266-2 NeuAc1Hex2HexNAc2dHex
1Sul1 
NeuAc+Fuc+Galβ1-3[Galβ1-4(6S)GlcNAcβ1-6]GalNAcol 2 – – – – 1.8 – – – – – – – 
1266-3 NeuAc1Hex2HexNAc2dHex
1Sul1 
NeuAc+Fuc+Galβ1-3[Galβ1-4(6S)GlcNAcβ1-6]GalNAcol 2 – – – – – – – – – – 0.9 – 
1267 Hex2HexNAc2dHex3Sul1 Fucα1-2Galβ1-3[Fucα1-2Gal(Fuc)(S)GlcNAcβ1-6]GalNAcol 2 H a/x – – – – – – – –  – 
1274 Hex3HexNAc3Sul2 2S + Galβ1-3(Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-
6)GalNAcol 
2 – – – – 3.7 – – – – – 2.7 – 
1301 Hex2HexNAc4dHex1 GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3(Galβ1-4GlcNAcβ1-
6)GalNAcol 
4 A – – – – – – – – – – – 
1315 NeuAc2Hex1HexNAc2dHex
1 
NeuAcα2-3Gal(Fuc)GlcNAcβ1-3(NeuAcα2-6)GalNAcol 3 – a/x – – – – – 3.3 – – – – 
1324-1 Hex2HexNAc3dHex2Sul1 S-Gal(Fuc)GlcNAc-Gal(Fuc)GlcNAcβ1-3GalNAcol 3 – a/x – – – – – – – – – – 
1324-2 Hex2HexNAc3dHex2Sul1 Fucα1-2Gal-GlcNAc-(Fuc)Gal-(S)GlcNAcβ1-3GalNAcol 3 H – – – 0.5 – – 0.3 – 0.4 – – 
1324-3 Hex2HexNAc3dHex2Sul1 S+Fucα1-2Gal-GlcNAcβ1-3(Fucα1-2Gal-GlcNAcβ1-
6)GalNAcol 
4 H – – – – – – – – 0.4 1.1 – 
1324-4 Hex2HexNAc3dHex2Sul1 S+Fucα1-2Gal-GlcNAcβ1-3(Fucα1-2Gal-GlcNAcβ1-
6)GalNAcol 
4 H – – – – – – – – 0.3 0.1 – 
1331-1 NeuAc2Hex2HexNAc2 NeuAcα2-3Galβ1-3(NeuAcα2-6Galβ1-4GlcNAcβ1-
6)GalNAcol 
2 – – – – – – 12.1 2.0  1.6 0.3 9.1 
1331-2 NeuAc2Hex2HexNAc2 NeuAcα2-3Galβ1-3(NeuAcα2-3Galβ1-4GlcNAcβ1-
6)GalNAcol 
2 – – – – – 1.6 26.3 5.7 5.4 5.7 1.5 10.0 
1332-1 NeuAc1Hex2HexNAc2dHex
2 
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1332-2 NeuAc1Hex2HexNAc2dHex
2 
Fucα1-2Galβ1-3[NeuAcα2-3Gal(Fuc)GlcNAcβ1-6]GalNAcol 2 H a/x – – 0.5 – – – – – – 2.5 
1332-3 NeuAc1Hex2HexNAc2dHex
2 
NeuAcα2-3Gaβ1-3[Fucα1-2Gal(Fuc)GlcNAcβ1-6]GalNAcol 2 H a/x – – 0.8 – – – – – 0.3 – 
1332-4 NeuAc1Hex2HexNAc2dHex
2 
Fucα1-2Galβ1-3[NeuAcα2-3Gal(Fuc)GlcNAcβ1-6]GalNAcol 2 H a/x – – 0.6 – – – – – 0.4 – 
1340-1 Hex3HexNAc3dHex1Sul1 S+Gal(Fuc)GlcNAc-Gal-GlcNAc-Galβ1-3GalNAcol 1 – a/x – – – – – – – – 0.1 – 





4 H – 3.0 – – – – – 2.3 – – – 
1389-2 NeuAc1Hex2HexNAc3dHex
1 





4 H – – – 1.6 – – – – 2.8 0.9 3.7 
1389-4 NeuAc1Hex2HexNAc3dHex
1 
NeuAcα2-3Gal(Fuc)GlcNAcβ1-3(Gal-GlcNAcβ1-6)GalNAcol 4 – a/x – – – – – – – 1.6 0.5 – 
1390-1 Hex2HexNAc3dHex3 Fucα1-2Gal-GlcNAcβ1-3[Fucα1-2Gal(Fuc)GlcNAcβ1-
6]GalNAcol 
4 H b/y – – 0.6 – – – – 0.3 – – 
1390-2 Hex2HexNAc3dHex3 Fucα1-2Gal-(Fuc)GlcNAcβ1-3(Fucα1-2Gal-GlcNAcβ1-
6)GalNAcol 
4 H b/y – – – – – – – 0.5 – – 
1404-1 Hex2HexNAc3dHex2Sul2 2S + Fucα1-2Galβ1-4GlcNAcβ1-3[Gal(Fuc)GlcNAcβ1-
6]GalNAcol 
4 H a/x – – – – – – – – – – 
1404-2 Hex2HexNAc3dHex2Sul2 2S + Fucα1-2Galβ1-4GlcNAcβ1-3(Fucα1-2Galβ1-4GlcNAcβ1-
6)GalNAcol 
4 H – 1.5 – 0.3 – – – – – – – 
1405 NeuAc1Hex3HexNAc3 NeuAc+Galβ1-3(Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-
6)GalNAcol 
2 – – – – – – – – – – – – 
1406 Hex3HexNAc3dHex2 Fucα1-2Gal-GlcNAc(Fucα1-2)Galβ1-3(Galβ1-4GlcNAcβ1-
6)GalNAcol 
2 H b/y – – 0.4 – – – – – – – 
1411 NeuAc2Hex2HexNAc2Sul1 NeuAcα2-3Galβ1-3[NeuAcα2-3Galβ1-3(6S)GlcNAcβ1-
6]GalNAcol 
2 – – – –  – – – – 1.2 – – 
1420-1 Hex3HexNAc3dHex1Sul2 2S + Fucα1-2Galβ1-3(Gal-GlcNAc-Gal-GlcNAcβ1-6)GalNAcol 2 H – 7.2  1.7 – – – 1.5 – 0.6 – 
1420-2 Hex3HexNAc3dHex1Sul2 2S+Gal(Fuc)GlcNAc-Gal-GlcNAc-Galβ1-3GalNAcol 1 – a/x – – – – – – – – 0.9 – 
1420-3 Hex3HexNAc3dHex1Sul2 2S+Gal(Fuc)GlcNAc-Gal-GlcNAc-Galβ1-3GalNAcol 1 – a/x – – – – – – – – 1.1 – 
1463 Hex3HexNAc4dHex1 Galβ1-3[GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-
4GlcNAcβ1-6]GalNAcol 























2 – a/x 1.2 – – – – 1.6 1.2  1.3 – 
1479 Hex4HexNAc4 Galβ1-4GlcNAcβ1-3Galβ1-3(Galβ1-4GlcNAcβ1-3Galβ1-
4GlcNAcβ1-6)GalNAcol 
2 – – – – 0.1 – – – – – – – 
1485 NeuAc1Hex3HexNAc3Sul1 NeuAc+S+Galβ1-3(Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-
6)GalNAcol 
2 – – – – – – – – – – – – 
1486 Hex3HexNAc3dHex2Sul1 Galβ1-3[Fucα1-2Gal-GlcNAc(S)Gal(Fuc)GlcNAcβ1-
6]GalNAcol 
2 H – – – – – – – – – – – 
1527 Hex2HexNAc4dHex2Sul1 GalNAcα1-3(Fucα1-2)Galβ1-3[GalNAcα1-3(Fucα1-2)Gal-
(S)GlcNAcβ1-6]GalNAcol 
2 A – – – – – – – – – – – 
1534-1 NeuAc2Hex2HexNAc3 NeuAcα-3Gal-GlcNAcβ1-3(NeuAcα2-3Gal-GlcNAcβ1-
6)GalNAcol 
4 – – – – – – – – 1.0 – – – 
1534-1 NeuAc2Hex2HexNAc3 NeuAcα-3Gal-GlcNAcβ1-3(NeuAcα2-3Gal-GlcNAcβ1-
6)GalNAcol 
4 – – – – – – – – – – – – 
1535-1 NeuAc1Hex2HexNAc3dHex
2 

























2 – a/x – – – – – – – – – – 
1566-1 Hex3HexNAc3dHex2Sul2 2S + Fuc + Fucα1-2Galβ1-3(Gal-GlcNAc-Gal-GlcNAcβ1-
6)GalNAcol 
2 H a/x 6.2 – 0.9 – – – 2.2 – – – 





4 A – – – – – – – – – – – 
1609 Hex3HexNAc4dHex2 Gal-GlcNAcβ1-3[Fucα1-2Gal(Fuc)GlcNAc-Gal-GlcNAcβ1-
6]GalNAcol 
4 H b/y – – 0.3 – – – – – – – 
1614 NeuAc2Hex2HexNAc3Sul1 S+NeuAcα-3Gal-GlcNAcβ1-3(NeuAcα2-3Gal-GlcNAcβ1-
6)GalNAcol 










4 – a/x – – – – – – – – – – 








1 2 3 1 2 3 1 2 3 MDR 
1625 Hex4HexNAc4dHex1 Gal-GlcNAc-Galβ1-3[Gal(Fuc)GlcNAc-Gal-GlcNAcβ1-
6]GalNAcol 




















2 – a/x – – – – – – – – – – 
1650 Hex2HexNAc5dHex2 GalNAcα1-3(Fucα1-2)Gal-GlcNAcβ1-3[GalNAcα1-3(Fucα1-
2)Gal-GlcNAcβ1-6]GalNAcol 










4 – – – – – – – 1.3 2.3 0.8 – – 
1689 Hex3HexNAc3dHex2Sul1 Galβ1-4GlcNAcβ1-3[Gal(Fuc)(6S)GlcNAcGal(Fuc)GlcNAcβ1-
6]GalNAcol 
4 – a/x – – – – – – – – – – 
1696-1 NeuAc2Hex3HexNAc3 NeuAcα2-3Galβ1-3(NeuAcα2-6Galβ1-4GlcNAcβ1-3Galβ1-
4GlcNAcβ1-6)GalNAcol 
2 – – – – – – – 1.1 – – – – 
1696-2 NeuAc2Hex3HexNAc3 NeuAcα2-3Galβ1-3(NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-
4GlcNAcβ1-6)GalNAcol 




















2 H b/y – – – – – – – – – – 
1712 Hex3HexNAc3dHex3Sul2 Fucα1-2Galβ1-3[Gal(Fuc)(S)GlcNAc-Gal(Fuc)(S)GlcNAcβ1-
6]GalNAcol 










4 – – – – – – – – – – – – 
1769-1 Hex3HexNAc4dHex2Sul2 Gal(Fuc)(6S)GlcNAc-Gal-GlcNAcβ1-3[Gal(Fuc)(6S)GlcNAcβ1-
6]GalNAcol 
4 – a/x – – – – – – – – – – 
1769-2 Hex3HexNAc4dHex2Sul2 Gal(Fuc)(6S)GlcNAc-Gal-GlcNAcβ1-3[Gal(Fuc)(6S)GlcNAcβ1-
6]GalNAcol 








1 2 3 1 2 3 1 2 3 MDR 
1770 NeuAc1Hex4HexNAc4 Galβ1-3(NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-
3Galβ1-4GlcNAcβ1-6)GalNAcol 
2 – – – – – – – – 0.9 – – – 
1771-1 Hex4HexNAc4dHex2 Gal(Fuc)GlcNAc-Galβ1-3[Gal(Fuc)GlcNAc-GalGlcNAcβ1-
6]GalNAcol 
2  a/x 1.3 – – – – – – – – – 
1771-2 Hex4HexNAc4dHex2 Fucα1-2Galβ1-4GlcNAcβ1-3(Fucα1-2)Galβ1-3(Galβ1-
4GlcNAcβ1-3Galβ1-4GlcNAcβ1-6)GalNAcol 
2 H – – – 0.2 – – – – – – – 
1771-3 Hex4HexNAc4dHex2 Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-2Galβ1-
4GlcNAcβ1-3Galβ1-4GlcNAcβ1-6)GalNAcol 





2 – a/x – – – – – – 1.2 – – – 
1785-1 Hex4HexNAc4dHex1Sul2 Fuc+ 2S +Galβ1-4GlcNAcβ1-3Galβ1-3(Galβ1-4GlcNAcβ1-
3Galβ1-4GlcNAcβ1-6)GalNAcol 
2 – – – – 3.9 – – – – – 1.3 – 
1785-2 Hex4HexNAc4dHex1Sul2 Fuc+ 2S +Galβ1-4GlcNAcβ1-3Galβ1-3(Galβ1-4GlcNAcβ1-
3Galβ1-4GlcNAcβ1-6)GalNAcol 
2 – – – – – – – – – – 2.0 – 
1796 Hex2HexNAc4dHex3 GalNAcα1-3(Fucα1-2)Gal-GlcNAcβ1-3[GalNAcα1-3(Fucα1-
2)Gal-(Fuc)GlcNAcβ1-6]GalNAcol 
4 A a/x – – – – – – – – – – 
1812 Hex3HexNAc5dHex2 GalNAcα1-3(Fucα1-2)Galβ1-3[GalNAcα1-3(Fucα1-2)Galβ1-
4GlcNAcβ1-3Galβ1-4GlcNAcβ1-6]GalNAcol 








































2 – a/x – – – – – – – – – – 
1915 Hex3HexNAc4dHex3Sul2 Gal(Fuc)(6S)GlcNAc-Gal-(Fuc)GlcNAcβ1-
3[Gal(Fuc)(6S)GlcNAcβ1-6]GalNAcol 
4 – a/x – – – – – – 0.9 – 1.2 – 
1917 Hex4HexNAc4dHex3 Fucα1-2Galβ1-4GlcNAcβ1-3(Fucα1-2Galβ1-4GlcNAcβ1-
6)Galβ1-3[Fucα1-2Galβ1-4GlcNAcβ1-6]GalNAcol 













1 2 3 1 2 3 1 2 3 MDR 
1931 Hex4HexNAc4dHex2Sul2 2Fuc+ 2S +Galβ1-4GlcNAcβ1-3Galβ1-3(Galβ1-4GlcNAcβ1-
3Galβ1-4GlcNAcβ1-6)GalNAcol 










2 – a/x – – – – – – – – – – 
2061 NeuAc2Hex4HexNAc4 NeuAcα2-3Galβ1-3(NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-
4GlcNAcβ1-3Galβ1-4GlcNAcβ1-6)GalNAcol 
2 – – – – – – – – 5.1 – – – 
2063 Hex4HexNAc4dHex4 Fuc + Fucα1-2Galβ1-4GlcNAcβ1-3(Fucα1-2Galβ1-
4GlcNAcβ1-6)Galβ1-3[Fucα1-2Galβ1-4GlcNAcβ1-6]GalNAcol 
2 H – – – – – – – – 0.5 – – 
2068-1 NeuAc2Hex3HexNAc3dHex
2Sul1 
_S + 2Fuc + NeuAcα2-3Galβ1-3(NeuAcα2-3Galβ1-
4GlcNAcβ1-3Galβ1-4GlcNAcβ1-6)GalNAcol 





2 – a/x – – – – – – –  – – 









Initially, this part of the study was aimed at identifying specific secreted mucin 
oligosaccharides following Western blotting. However, followingthe release of O-glycans by 
β-elimination, a white salt residue (BH4) was visible at the bottom of the tube of the eluted 
glycans. Several attempts to remove these salt residues failed. This was an enormous 
challenge as the eluted glycans could not be identified using the LC mass spectrometry. Drs. 
Niclas Karlsson and Chunsheng Jin offered their experience and assistance with determining 
the putative structures of the O-glycans from respiratory mucus. 
 
Higher amounts of core 1–4 O-glycan structures were found in uninfected controls and 
sputa than in BALs. It is hypothesised that the mucus samples from uninfected controls 
(tracheal aspirates) and sputa might have been contaminated with salivary mucins. 
Furthermore, core 3 and core 4 structures diminished in BALs in the presence of HIV. Mucins 
with core 5 structures have been reported in human meconium and intestinal carcinoma 
tissue (Brockhausen et al., 2009). However, this study found small amounts of core 5 O-
glycan structures in the respiratory mucus (tracheal aspirates, BALs and sputa). Some core 
structures contained sialic acids, fucoses and sulfates respectively and as mixtures. 
 
Sialic acids are negatively charged and hydrophobic (Varki, 2008). These properties are 
important in structural and modulatory roles. The O-glycan profiles showed more sialylated 
O-glycans. Specifically α2,3-linked terminal sialic acid and α2,6-linked terminal sialic acid. It 
has been reported that α2,3-linked terminal sialic acids and α2,6-linked terminal sialic acids 
play a crucial role in the initial process of infection; an observation that was demonstrated  
in a study where sialic acids from influenza viruses bound to airway epithelium (Varki, 2008). 
Additionally, α2,3-linked terminal sialic acids are present in the lower airways. Sialylation 
has also been described in inflammation in acute phase reaction (Varki, 2008). However, its 
role in altering the immune response remains unknown. Therefore, the presence of 
sialylation might also indicate inflammation as a result of TB. Sialylation has also been found 




important to note as this opportunistic pathogen can use mucins as a nutrient source in the 
progression of an infection (Aristoteli and Willcox, 2003). 
  
Another modification that is negatively charged sulfations. Sulfated glycans are known to 
confer ion exchange and viscosity (Lo-Guidice et al., 2007). Sulfated glycans have also been 
associated with cell adhesion and recognition on microbes.  
 
Reports have indicated that fucosylation has been widely found in ABO blood groups and 
that it is important in blood transfusion (Becker and Lowe, 2003). The study found blood 
type H antigens from blood group O with terminal Fucα1-2Gal-, and A antigens from blood 
group A with terminal Fucα1-2(GalNAcα1-3)Gal-. Fucosylation has also been seen in microbe 
interaction. The best known interaction in the intestinal tract is with Helicobacter pylori 
where the microbe attached through Lewis b antigen (Becker and Lowe, 2003; Sonawane et 
al., 2012). The majority of fucosylated O-glycans detected were associated to blood type 
and Lewis type (a/b/x/y). The significance of this in TB is not yet known. However, 
fucosylation has been extensively studied in cancer and has led tor sialyl Lewis A antigen as 
a biomarker in pancreatic cancer (Wantanabe et al., 2016). 
 
This chapter shows preliminary data in studying respiratory mucus in TB. It was found that 









CHAPTER 8 : IMMUNOHISTOCHEMICAL ANALYSIS OF RESPIRATORY 




Mucins are complex glycoproteins that are high in carbohydrate content. They are divided 
into neutral and acidic forms. Immunohistochemistry is a very valuable tool widely used in 
the localisation of proteins in tissue sections. Thornton and colleagues have reported that 
tissue distribution of mucins was determined through reactivity to the carbohydrates using 
classical and special histological stains for glycoproteins (Thornton et al., 1997)).  
 
Classical histological stains such as Haematoxylin and Eosin (H & E) are normally employed 
to determine histological diagnoses (Ali et al., 2012). Special stains are used to determine 
the localisation and types of mucins expressed in tissue. The Periodic-Acid Schiff (PAS) and 
Alcian Blue (AB) stain combination is used to differentiate between neutral and acidic 
mucins in tissue sections. The PAS technique not only differentiates the mucins but also 
widely identifies glycoproteins and carbohydrates. Additionally, the AB stain is used to stain 
the mucopolysaccharides found in the goblet cells (Ali et al., 2012). The acidic mucins are 
further subdivided into sulfated mucins (sulfomucins) and sialylated mucins (sialomucins). 
Histochemically, the usage of High Iron Diamine (HID)/AB stain in tissue separates 
sulfomucins and sialomucins (Ali et al., 2012; Thornton et al., 1997).  
 
The aims of this chapter were to confirm the expressed mucins identified in the previous 
chapter using Western blotting and to describe the expression and location of respiratory 
mucins in TB lung tissue. The specialised stains, PAS/AB and HID/AB together with anti 
(-MUC2, -MUC5AC, -MUC5B, -MUC7 and -MUC16) antibodies were used to determine the 
mucins expressed in TB and to locate where the mucins are expressed. 
 
Serial sections (2 µm) were cut from formalin fixed paraffin wax embedded lung tissue 
blocks prepared from tissue obtained at post mortem from fifteen TB infected lungs. In 
addition, 2 µm serial sections were cut from other tissues to serve as experimental controls. 




salivary gland tissue served as control for both MUC5B and MUC7, and ovarian teratoma 






All tissue blocks selected for the study were prepared from post mortem lung specimens 
with a known TB diagnosis.  Black pigment was observed in the bronchi of two patients. This 
black pigment is normally associated with environmental carbon. However the increased 
black pigmentation in these patients suggested that they were smokers. 
 
The PAS/AB blue stain located the mucins in the lung tissue. Out of 15 tissue samples, 7 
cases showed PAS/AB positivity. The PAS stain, which locates neutral mucins was considered 
positive when the cells stained magenta and the AB which stains acidic mucins was 
considered positive when cells stained blue. Lung tissues with both neutral and acidic 
mucins stained purple. Neutral mucins were observed in the bronchial epithelium, in the 
bronchial mucus glands and in the lumen of the bronchi. Acidic mucins were observed in the 
small bronchial glands and in the cartilage. Figure 8.1 illustrates the expression of mucins in 
the epithelium of the bronchus and the bronchial glands. Non-specific staining was seen in 





Figure 8.1: Identification of mucin glycoproteins in lung tissue PAS/AB. 
(A) The goblet cells of the bronchus epithelium expressing mainly acidic mucins (blue) and some neutral 




The acidic mucins were further analysed using the HID/AB stain to differentiate the 
sulfomucins and sialomucins. Sulfomucins stained black and sialomucins were observed as a 
blue colour. The sulfomucins and sialomucins were mainly observed in the goblet cells of 
the bronchi as depicted in Figure 8.2. Some goblet cells were exclusively sialomucins, some 
goblet cells were exclusively sulfated and other goblet cells contained a mixture of 
sulfomucins and sialomucins. Exclusive sialomucins and exclusive sulfomucins were also 






Figure 8.2: Expression of sulfomucins and sialomucins in lung tissue. 
(A) Expression of sulfomucins (black) and sialomucins (blue) in the goblet cells of the bronchus epithelium 
(X80). (B) Expression of sulfomucins and sialomucins in the bronchial glands (X80).  
 
8.2.3 Mucins in the lung tissue 
 
The proportions of positively stained cells were graded as follows: 1+ (5-25 %); 2+ (26-50%); 
3+ (51-75%) and 4+ (>75%).  
 
8.2.3.1 MUC2  
 
None of the lung tissue examined was positive for MUC2. 
 
8.2.3.2 MUC5AC  
 
MUC5AC expression was confined to the epithelium of the bronchi of 4 cases out of the 15 
cases (Figure 8.3).  However, MUC5AC was not expressed in all the goblet cells of all the 
patients. The proportion of positive staining was less than 50% in 3 cases. These were 







Figure 8.3: Immunohistochemical expression of the MUC5AC mucins in lung tissue. 
(A) MUC5AC expression in the goblet cells of the bronchus (X40). (B) Expression of MUC5AC in the goblet cells 




Nine cases out of 15 were positive for MUC5B. Four cases were assigned a 4+ score with 
more than 75% of goblet cells of the bronchi and bronchial luminal mucin staining positive. 
The expression of MUC5B in the bronchi is demonstrated in Figure 8.4. Inconsistent focal 
luminal mucin staining was observed in 2 of the cases where less than 5% of the cells were 
positive for MUC5B. MUC5B was also expressed in the bronchial glands as shown in Figure 
8.5. An allocation of 3+ was assigned to 3 cases, of which Type II pneumocytes were positive 
with 2+ in 2 of the cases. Focal staining in the necrotic area was observed in 7 of the cases as 
illustrated in Figure 8.5. MUC5B positive staining was also observed on the periphery of the 










Figure 8.4: Immunohistochemical expression of the MUC5B mucins in bronchi. 
(A) Expression of MUC5B in the goblet cells of the epithelium with a dark pigment from environmental carbon 
outside the bronchus (X40). (B) MUC5B expression in the goblet cells of the lining of the bronchus (x80). (C) 






Figure 8.5: Immunohistochemical expression of the MUC5B mucins in lung tissue. 
(A) MUC5B expression in the bronchial glands and the goblet cells of the bronchi (X80). (B) The expression of 








Figure 8.6: Expression of the MUC5B mucins in the tuberculous granuloma. 
(A) Positive MUC5B staining on the periphery of the cytoplasm of the giant cells (red arrow heads) and in some 
of the epithelioid histiocytes of the granuloma (black arrow) (X80). (B) A magnified giant cell showing 








8.2.3.4 MUC7   
 
The expression of MUC7 was observed in all cases. One case showed the expression of 
MUC7 in the epithelia of the bronchi. In 2 cases, MUC7 was positive in the serous cells of the 
bronchial glands. Figure 8.7 illustrates the expression of MUC7 in the epithelia of the 
bronchi and the bronchial glands. Interestingly, in all 15 cases, focal staining of MUC7 was 
noted in the endothelial cells, giant cells in the granulomas, the epithelioid histiocytes of the 
granulomas and alveolar macrophages (histiocytes). MUC7 was observed in approximately 
5% of the histiocytes in all the 15 cases. Figure 8.8 shows the expression of MUC7 in the 
granulomas. The MUC7 staining of giant cells was prominent in the centre of the cytoplasm. 
Sporadic staining was also observed in the alveolar space, and in one of the cases MUC7 was 




Figure 8.7: Expression of the MUC7 mucins in the epithelium of bronchus and bronchial 
glands. 
(A) The epithelium of a bronchus expressing MUC7 mucins (X40). (B) Positive MUC7 staining in the serous cells 











Figure 8.8: Expression of the MUC7 mucins in the tuberculous granulomas. 
(A) Positive MUC7 staining in the granulomas (X40). (B) A magnified granuloma showing MUC7 staining of the 




8.2.3.5 MUC16  
 
MUC16 positive staining was observed in 6 cases out of 15. MUC16 was expressed mainly in 
the goblet cells of the epithelia. Two cases were graded 4+, 1 case was graded 2+ and 3 
cases were graded 1+. The expression of MUC16 was also observed in the bronchial glands, 
staining more than 75% of the cells in the glands.  The expression of MUC16 in the bronchial 






Figure 8.9: Expression of MUC16 mucins in the bronchial glands and in the epithelium of 
bronchus. 
(A) Expression of MUC16 in the bronchial glands and the disrupted epithelium of the bronchus (X80). (B) 
Expression of MUC16 in the bronchial glands at a magnification of X160. (C) Goblet cells of the bronchial 







In normal tissue, mucin expression is regulated in a relatively organ- and cell-specific 
manner (Andrianifahanana et al., 2006). However, distinct expression patterns are observed 
under pathologic conditions. MUC5AC mucins are expressed in the goblet cells of the 
epithelium and MUC5B mucins are expressed in the submucosal glands. However, MUC5B 
mucins have also been shown to be expressed in the surface epithelium.  
 
The results in this study confirmed previous reports on the localisation of the expression of 
MUC5AC in the goblet cells of the respiratory epithelia in the lungs, the trachea and the 
bronchi (Lopez-Ferrer et al., 2001). This study demonstrated that MUC5AC was expressed by 
bronchial cells and some goblet cells but not in all PAS positive epithelial cells. Work by 
Buisine and colleagues have shown the expression of MUC5AC from the developmental 
phase (Buisine et al., 1999).  
 
In this chapter, MUC5B was observed in both the bronchial epithelium and the bronchial 
glands. In addition, MUC5B was expressed in the granulomas. The reactivity of giant cells 
and histiocytes of the granuloma to both MUC5B and MUC7 respectively was an interesting 
finding in TB.  The presence of M.tb in the lungs initiates an inflammatory immune response 
resulting in the recruitment of macrophages and neutrophils (Fallahi-Sichani et al., 2013). 
 
In TB, mature macrophages undergo transformation to form epithelioid histiocytes in the 
granuloma (that are characteristic of necrosis) and multinucleated giant cells 
(Ramakrishnan, 2012). Granulomas are described as aggregates of epithelioid histiocytes 
which form in an attempt to deal with bacteria that evade the immune system (Lugo-
Villarino et al., 2013; Mukhopadhyay and Gal, 2010).However, granulomas can dissociate as 
a result of increased necrosis and the accumulation of caseum in the center, ultimately 
forming cavities that disseminate and release the pathogen into the airways. The high 
expression of MUC5B and MUC7 in the giant cells of the granulomas suggests that these 






The giant cells are surrounded by lymphocytes that are primarily restricted to peripheral 
regions of granulomas, forming the lymphocytic cuff that keeps granulomas in an intact 
balanced state. This is the solid form of these pathological structures that is believed to 
control disease progression by containing or confining bacteria within the center of an intact 
granuloma. 
 
MUC5B and MUC7 were found at different positions on the giant cells of the granulomas. 
MUC5B stained the periphery of the cytoplasm while MUC7 stained the centre (cytoplasm) 
of the giant cells. The significance of the differential staining is not yet known. In addition to 
its identification in the granulomas, MUC7 was detected in the serous cells in the bronchial 
glands of the lung tissue. The expression pattern mimicked the expression noticed in the 
salivary glands. This finding was consistent with that seen in studies investigating the 
expression of MUC7 in the respiratory tract (Li et al., 2006; Sharma et al., 1998). Moreover 
this study demonstrated the expression of MUC7 in the respiratory epithelium of the 
bronchi. The expression of MUC7 has never been previously reported in the epithelium of 
the human lung tissue. However, a study by (Li et al., 2006) has shown the expression of 
MUC7 in the respiratory epithelium of the bronchioles of transgenic mice. They attributed 
this finding to the fact that their study examined MUC7 expression in transgenic mice lung 
tissue and not human lung tissue. They further found elevated MUC7 expression upon 
stimulation by the lipopolysaccharide of P. aeruginosa. 
 
MUC7 is mainly secreted in the saliva and is also reported to be expressed in the respiratory 
tract. Most of the studies on the role of MUC7 have extensively focussed on the saliva. 
However, the role of MUC7 in respiratory diseases is not fully understood. Investigations on 
the interaction between MUC7 and oral bacteria such as Streptococci and Staphylococcus 
aureus have indicated that MUC7 provides a protective role in the oral cavity. Other studies 
have also been conducted to elucidate the role of MUC7 in the respiratory tract. Genetic 
studies have shown MUC7 to play a role in the protection of the respiratory tract of 
asthmatic individuals (Kirkbride et al., 2001; Watson et al., 2003). A study by (Fan and 
Bobek, 2010) has outlined the lack of understanding of MUC7 regulation in different stages 
of the different respiratory diseases. Their study however concluded that the elevation of 




respiratory tract.  
 
This chapter of the study has demonstrated that MUC5B together with MUC7 may provide a 
protective role in TB. Both MUC5B and MUC7 were expressed in the giant cells in the 
granulomas and the epithelioid histiocytes of the granulomas. Granulomas are considered 
to be the most common abnormality in pulmonary pathology (Mukhopadhyay and Gal, 
2010). Furthermore they are reported to pose diagnostic challenges. Granulomas form in an 
attempt to contain infection by M.tb. Hence the expression of MUC5B and MUC7 in the 







CHAPTER 9 : GENERAL DISCUSSION AND CONCLUSION 
 
Pathogens can enter the human body through several portals of entry. Most pathogens 
employ mechanisms such as evasion of the host defence, penetration of the host and 
adherence to host tissue.  Many bacteria gain entry into the body by penetrating the 
mucous membranes and Mycobaterium tuberculosis (M.tb), the causative agent of 
tuberculosis (TB) is no exception (Neutra and Kozlowski, 2006). TB disease is among the top 
three leading causes of the death in the world (Cifuentes et al., 2010). The aim of the study 
was to isolate and characterise mucus glycoproteins (mucins) in order to elucidate the role 
of the dominant secreted mucins in patients with TB. 
 
Previous biochemical analyses of bronchial secretions have demonstrated that MUC5AC and 
MUC5B mucins are responsible for mucus gel formation. This study further confirmed that 
MUC5AC and MUC5B mucins are the major mucins secreted in TB. The Western blot 
analysis showed high levels of MUC5AC as compared to MUC5B in tracheal aspirates from 
uninfected controls, BALs and sputa from patients with TB. In contrast, the 
immunohistochemical analysis showed the expression of higher levels of the MUC5B mucin 
at lung tissue level.  From these results, it is clear that MUC5B is highly expressed in the lung 
however lower levels are detected in the mucus. We therefore hypothesise that MUC5B is 
more tenacious and not easily expelled as compared to MUC5AC. 
 
This study has also shown that MUC5AC mucin has similar charge densities in tracheal 
aspirates, BALs and sputa. A phenomenon supported by Thornton et al. (1996) that even 
though the level of MUC5AC mucin varies between respiratory samples, the electrophoretic 
mobility and charge density remains similar. This study further demonstrated MUC5AC and 
MUC5B mucins in BALs had similar charge densities in respiratory secretions. However the 
mobility of MUC5B varied between individuals indicative of the heterogeneous nature of 
MUC5B. MUC5B glycoforms were observed in tracheal aspirates and sputa. The existence of 
the MUC5B glycoforms in tracheal aspirates and sputa raised questions as to whether there 
are differences in the composition of MUC5B mucin in the lung, trachea and the mouth or 
saliva. Furthermore, whether saccharides are added to the MUC5B mucin produced in the 





Immunohistochemisty has shown that granulomatous response in TB is characterized by 
MUC5B staining of the periphery of the giant cells and MUC7 staining in the cytoplasm of 
giant cells. The study has thus shown that mucus plays an important role in the recruitment 
of inflammatory responses and that both MUC5B and MUC7 seem to play a protective role 
in the granulomas. This could be a way of providing protection in the lung against M.tb. 
 
In MDR-TB, mucins could not be detected from Western blot analysis. However, traces or no 
mucin was detected following dot blotting. This indicated depletion of mucins in MDR-TB. 
Further analysis of the patient indicated the presence of Pseudomonas aeruginosa. A study 
by (Aristoteli and Willcox, 2003) demonstrated that mucins were used as nutrient source in 
the progression of the infection. Therefore, the depletion of mucins in MDR-TB mucus 
suggested that there was mucin degradation by P. aeruginosa. Sialylation has also been 
found to be responsible for colonization of airways by Pseudomonas species (Varki, 2008). 
The O-glycan analysis showed high amounts of sialic acid in MDR-TB. 
 
Protein studies have been undertaken to map and identify protein expression in healthy and 
diseased states. (Issa et al., 2011) attempted to influence the migration of high molecular 
weight proteins during electrophoresis through the addition of urea to composite gels. 
However, they found that the addition of urea was beneficial in simplifying the gel casting 
procedure. In this study protein expression profiles were determined using 2D SDS PAGE. 
The 2D SDS PAGE together with AgPAGE and NuPAGE are systems used to analyse proteins. 
The different PAGES provide different stability of both protein and gel matrix and offer 
different resolutions. The study looked at tracheal aspirates from uninfected controls and 
BALs and sputa from patients with TB, in order to provide information about changes in 
protein composition in the airways in response to infection by M.tb. Cytoskeletal proteins, 
defence and immune proteins were higher in TB than in uninfected controls. These high 
cytoskeletal and structural proteins in TB may be due to lung tissue remodelling that takes 
place during disease progression. In addition, defence proteins might be higher in TB as they 





Glycosylation is one of the widely described post translational modifications. It provides 
many roles such as cell-cell interactions, protein stabilization to structural support and 
aiding in protein folding (Brockhausen et al., 2009; Schauer, 2004). Core 3 and 4 O-glycan 
structures diminished in the presence of HIV.Core 5 structures were also detected using LC-
MS. However, Core 5 structures are very rare. As this part of the work provided preliminary 
data, more investigations are required to confirm the presence of core 5 O-glycan structures 
and their differences. 
 
Higher amounts of sialic acids which have been associated with inflammation in acute phase 
reaction and cell signaling events through cell-cell interaction were observed (Schauer, 
2004; Varki, 2008). Protein analysis of respiratory secretions showed higher amounts of 
signaling molecules in TB. It is suggested that the higher signaling molecules found in TB 
may be attributed to active signaling events induced upon the recognition of the bacteria. 
Therefore, these increased signaling molecules could be related to the presence of 
increased sialic acids. 
 
Limitations of the study 
 
Sample procurement 
 Individuals without respiratory diseases did not produce mucus even after sputum 
induction.  
 Individuals without respiratory diseases do not undergo bronchoscopy as it is an 
invasive procedure.  
 With the complication of HIV, some definite TB positive patients were sputum-scarce 
as they did not have a productive cough.  
 All tissue blocks selected for the study were prepared from post mortem lung 
specimens with a known TB diagnosis. Lung tissue (from biopsies) could not be 







 To expand the study on O-glycan structures as only three samples were examined in 
uninfected controls and TB. This expanded study should also investigate O-glycans 
from specific mucins excised following Western blotting. In addition, the presence of 
core 5 structures needs to be investigated further.  
 The three bands of MUC5B found in TB samples following Western blotting need to 
be investigated further to confirm the bands identified.  
 To design a cell culture (in vitro) model to establish the presence of MUC5B and 
MUC7; and to determine the pathways leading to the presence of MUC5B and MUC7 
in the giant cells. An understanding of the pathophysiology of granulomas is critical 
for the design of new drugs and therapies. 
 
Conclusion 
This study has provided some information in understanding the behaviour of mucins in TB. 
Mucus was however weakened by opportunistic bacteria such as P. aeruginosa in MDR-TB. 
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